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1 Preface
Radiation therapy along with surgery and chemo- or target-oriented therapy (antibody and ”small
molecules”) represent the four pillars of oncological treatment of cancer patients whilst approx.
50% of all cancer patients receive some sort of radiotherapeutic treatment. Many tumour entities,
including brain and head and neck tumours require radiation as part of the existing standard-of-
care therapy schemes. Thus, the efficiency of a radiation therapy treatment represents a strong
determinant of the overall prognosis for these diseases. The efficiency of radiation therapy is de-
termined on the one hand by the intrinsic radiosensitivity of the normal tissue surrounding the
tumour which restrains the maximum tolerated and thus applicable total dose. For the other, re-
sistance of tumour cells upon irradiation in the course of radiation therapeutic treatment can limit
its overall effect. Hence, one of the uttermost important objectives in molecular radiooncological
research is to understand the mechanisms of the radiation response in normal and tumour tissue
while the knowledge of which would provide the foundation for the identification of molecular tar-
get structures to be tackled by therapeutic agents that would allow the modulation of the radiation
response in such a way radiation therapy becomes most efficient. This as a matter, of course only
would work if the modulating agent specifically increases the radiation sensitivity of the tumour
tissue and without also increasing that of the surrounding normal tissue.
The last decades of cancer research have undoubtedly shown that tumour biology is very much
characterised by inter- and intraindividual heterogeneity. Modern therapeutic approaches have to
account for this by providing individualised treatments. This requires the ability to stratify into
groups that are likely to respond to individualised treatment approaches in the first place and to a
priori identify patients being parts of these strata. This involves identification of prognostic markers
in clinical, radiomics and molecular data of patients as part of retrospectively or prospectively col-
lected cohorts. The latter can be efficiently done in high-dimensional molecular omics ”big-data”
sets that characterise the genome, transcriptome, proteome, metabolome etc. that are generated
on clinical samples from patients of such cohorts in combiniation with clinical follow-up data fol-
lowed by predictive modelling.
Through the mechanistic characterisation of the molecular radiation response and the discov-
ery of prognostic markers predicting the therapeutic success of radiation treated cancer patients,
important steps have been made forward. So, for head and neck cancer and glioblastoma prog-
nostic markers were identified and independently validated. With regard to the understanding
of the molecular radiation response both for normal and tumour tissue important insights have
been generated. Combining these two sources of knowledge is likely to result in new personalised
therapy concepts for radiation treated cancer. Another non-intended side-effect of radiotherapy
is the induction of secondary malignancies in non-tumour tissue that receives irradiation dose as a
side-effect. While epidemiologically proven, the underlying mechanisms and markers of radiation-
induced secondary malignancies are still under investigation. We have demonstrated for radiation-
induced thyroid and breast cancer that such mechanisms and markers exist.
The present cumulative habiliation thesis puts up clinical-translational scientific projects mak-
ing extensive use of computational approaches - two of which are part of the present work - that
were published in peer-reviewed papers that worked towards the understanding of the mech-
anisms of the radiation response and identified prognostic markers in radiation-therapy treated
cancer patient cohorts and cohorts of patients with radiation-induced breast cancer.
2 Scientific Background 4
2 Scientific Background
2.1 Cellular radiation response in the context of radiation therapy
The aim of primary definitive or adjuvant radio (chemo)therapy is to kill all dormant or dividing
tumour cells by introducing DNA damage. Single-strand breaks (SSB), double-strand breaks (DSB)
or base changes in the DNA of the cells are caused, whereby the biological effect of the radiation is
mainly caused by unrepaired or incorrectly repaired DSBs. There are various mechanisms of DNA
repair in affected cells. Besides single strand break repair (SSBR), base excision repair (BER) and
homologous recombination (HR), non-homologous end-joining (NHEJ) plays the leading role [1].
Defective repair of DNA damage can lead to the loss of the unlimited ability for tumour cell division,
whereby different forms of cell death (apoptosis, necrosis, autophagy, mitotic cell death) or senes-
cence can be induced. Cells with non-repaired or mismatched DNA damage often go through sev-
eral cell divisions before mitotic cell death (mitotic catastrophe) is activated. Serine protein kinase
ATM (ataxia teleangiectasia mutated) is an important sensor of DNA damage and triggers various
signalling cascades involved in the regulation of cell cycle control, cell cycle arrest, DNA repair and
cell death [2]. In sufficiently irradiated tumour cells, cell death is directly activated because the large
number of DNA damages exceeds the cell’s repair capacity. The capacity for DNA repair of each cell
type determines the specific intrinsic sensitivity of each cell type. Tumour cells bear large numbers
of genetically enhanced mutations, such as inactivating mutations of the P53 gene, in the course
of tumour evolution. Genetic alterations often affect signal molecules involved in DNA repair, as a
result of which tumour cells usually have reduced repair capacity and are therefore more severely
damaged than normal tissue cells as a result of being exposed to radiation. In addition, the normal
tissue is exposed to a lower dose than the tumour tissue in the course of a therapeutic irradiation.
This results in a survival advantage of normal cells with prior elimination of the tumor cells [3].
2.1.1 Approaches for the modulation of the radiation response
In order to modulate the sensitivity of normal and tumour tissue to radiation, targeted therapy can
be applied at different levels, which essentially include DNA repair, cell cycle control, cell division
and signalling pathways influencing cell death (e. g. NF-B or PI3K signalling pathways) and further-
more the microenvironment and a reduction of normal tissue toxicity [2]. In order to increase the
radiation sensitivity of tumour cells without influencing the radiation sensitivity of normal tissue
one strategy is the intensification of the oxygen effect by increasing the oxygen partial pressure in
the breathing air in the context of a so-called hyperbaric oxygenation to increase the oxygen con-
centration in the tissue [4, 5]. The oxygen effect describes the amplification of the effect of ionizing
radiation by the radicals and peroxides formed during radiolysis in the presence of oxygen, which
attack the DNA in a chain reaction and fixate the DNA damage. The effect occurs mainly with the
application of low-LET (linear energy transfer) radiation and is more pronounced the higher the
oxygen concentration in the tissue. Hypoxic tumour areas, on the other hand, are characterised by
increased resistance to radiation, which is why their elimination is, amongst other factors, decisive
for the success of radiation therapy [6]. In addition, some chemotherapeutic agents and targeted
substances for modulating radiation sensitivity and simultaneously damaging tumour cells have
been successfully used in clinical applications such as e. g.B. Mitomycin-C, taxanes, antifolates, cis-
platin, 5-FU, hydroxycarbamide and the EGFR inhibitor cetuximab in the radiochemotherapeutic
treatment of head and neck tumours [7, 8, 9, 10]. Another chemotherapeutic agent that is used
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in standard therapy of glioblastomas which is also radiosensitising is temozolomide [11, 12, 13].
Although the specific synergistic effects of these substances cannot be determined in detail by
means of radiochemotherapy, cooperative effects that act simultaneously and at the same loca-
tion on a tissue are differentiated from those that occur locally and possibly also at different times.
In addition to the pharmacological mechanism of action, this distribution also depends to a large
extent on the design of the therapy scheme [7, 10].
2.1.2 Therapy resistance
In the course of radiotherapeutic treatment of tumours, the occurrence of local and locoregional
recurrences can often be observed, which is a strong limiting factor for the success of the therapy.
Three factors can be blamed for the occurrence of local recurrences: the radiation resistance of
hypoxic tumour cells, the ability of tumour cells to repopulate and intrinsic or acquired resistance
towards radiation [2]. Since tumour cells exhibit a high degree of genomic instability, resistance
to radiation can also be acquired in the course of tumour evolution and the enrichment of ge-
netic alterations, e.g. mutation of P53, an important cell cycle control gene [7]. Accordingly, it is
an important research objective to identify the markers and mechanisms underlying intrinsic and
acquired radiation resistance in order to be able to use them for prognosis and targeted therapy.
2.1.3 Radiation-induced secondary malignancies
One side effect of radiotherapeutic treatment, particularly in the case of fractionated percutaneous
photon-based radiotherapy is significant deposition of dose in normal tissue surrounding the tu-
mour to be treated [14]. This problem is even more prominent the younger the patients are at
the time of the radiotherapeutic treatment [15, 16]. While from the epidemiologic point of view
there is no doubt about the inducibility of secondary cancers after radiation exposure the molecu-
lar mechanisms leading to radiation-induced carcinogenesis are not yet conclusively investigated
[15]. However, in own research projects we could identify markers of radiation-induced thyroid and
breast cancer. For thyroid cancer we identified a region on chromosomal band 7q11 which contains
the gene CLIP2. 7q11 was exclusively gained in thyroid cancers of patients who were exposed to
radiation from the Chernobyl accident fallout compared to a non-exposed control group. Further,
expression of the CLIP2 protein was significantly increased in the exposed group compared with
the unexposed group [17, 18, 19]. For breast cancer we recently demonstrated in a group of female
patients who worked as clean-up workers at the Chernobyl power plant facility and were exposed
to radiation that their breast cancer tissues showed attenuated expression of the transcription fac-
tor TRPS1 compared to a non-exposed control group. We further found miRNA hsa-miR-26b-5p
as a likely regulator of TRPS1 as its expression was increased in the exposed compared to the non-
exposed group [20]. In the same group of patients we identified a genomic copy number signature
that allows prediction of the exposure status in breast cancer [21]. The breast cancer-related works
are part of the present thesis.
2.2 Improvement of therapeutic success by the use of high-dimensional data analysis
Prior therapy of a tumour disease is the initial diagnosis, which must be followed by further diag-
nostic surveys through imaging (radiology), histology (pathology) and molecular markers (molec-
ular pathology). Based on the overall diagnosis, a decision is made as to which therapy route is
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chosen. The combination of surgical, radiotherapeutic, chemotherapeutic and new targeted treat-
ment influences the clinical course of the disease and thus the therapeutic success. The process
of individual diagnosis for the overall diagnosis, which is decisive for the therapy decision, is the
key to an optimal therapy, in which the patients are assigned to a corresponding therapy scheme
based on the diagnosis groups. The likelihood that in the course of standard treatment the cho-
sen therapy route will lead to success is high for the majority of the assigned group. However, the
clinical course at individual level is highly heterogeneous due to individual differences which can-
not be resolved by radiological and pathological diagnostics. The aim of the analysis of clinically
associated high-dimensional data sets is therefore to identify mechanisms of radiation sensitivity,
molecular target structures for personalized therapy approaches and prognostic markers for ther-
apy response.
High-dimensional data sets and analyses can be used to calculate the so-called molecular net-
work of radiation sensitivity. These networks can, for example, be calculated from microarray or
next generation sequencing derived gene expression data sets of tissues with different radiation
sensitivity and represent the interaction of genes associated with altered radiation sensitivity. By
assigning genes to signalling pathways, molecular mechanisms of radiation sensitivity can be de-
rived in the form of molecular networks. This in turn allows the most important subnetworks to be
identified, whose manipulation has the potential to modulate the radiation sensitivity [22]. Such
analyses would, in the most optimal case, result in the identification of a target structure, which
would allow specific sensitisation of the tumour tissue but not the normal tissue [23].
One promising route towards achievement of the above-mentioned goals is the analysis of
comprehensive data sets of different molecular levels from cells of normal and tumour tissue. These
data sets are generated using microarray technology, mass spectrometry and next generation se-
quencing. The molecular levels genome, transcriptome and proteome, the interaction of which is
described by the ”Central Dogma of Molecular Biology”, can be recorded and the molecular levels
of epigenetics, which have a regulatory effect on genome, transcriptome and proteome, should
be considered even importantly [24]. Such ”big data”, integrative data sets are characterised by the
fact that several molecular levels are simultaneously recorded in the measurement of clinical tissue
samples or cells of model systems and the interaction of these is taken into account in the analysis.
So, the integration of miRNA and mRNA levels can be used to identify genes that are regulated by
the miRNAs involved and thus allow drawing conclusions about the functional role of these miR-
NAs.
Biological systems can be studied on the molecular, cellular, organ, individual or population
level. Understanding, describing, quantifying and analysing these levels as systems or parts of
systems is the core of systems biology research approaches. The aim is to identify the elements
that make up a biological system as globally as possible, systematically searching for connections
between these elements and characterising the type of interaction. Like a circuit diagram of a tech-
nical device, an attempt is being made to represent the biological system as a regular and repro-
ducible network that can precisely described. This requires that the elements of the molecular
levels of cells representing normal tissue or tumour tissue are captured as completely as possible
[25, 26]. The great advantage over traditional, purely association-based, descriptive biological re-
search lies in the potential predictive power of systematically described systems. If the system is
known, then it is also possible to make a statement about how the system will change in the event
of a change (perturbation) of one or more components. These predictions are made with the help
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of mathematical models adapted to the high-dimensional systems biology data.
2.3 Statistical analysis of high-dimensional data sets
2.3.1 Association analysis of integrative high-dimensional data sets
In association analysis, which is hypothesis-driven, patients are divided into groups that differ with
respect to one parameter e.g. response to therapy. The measurement data of each data point is
then assigned to the groups to be compared and subjected to a statistical test, which allows the null
hypothesis to be checked and which is adequate for the test situation. Decisive for the selection
of the test is, among other things, the distribution of the measured values, which must correspond
to a certain distribution (e. g. normal distribution) for parametric tests, whereas this prerequisite
does not have to be fulfilled for non-parametric tests. In addition, the data type (continuous or
categorical data) plays an important role in the selection of a test. The final result of an association
test is the probability for the rejection of the null hypothesis, which is represented by the so-called
P-value. Many null hypotheses are tested in the association analysis of high-dimensional data sets
due to the large number of data points. According to the measured data points, the number ranges
from a few hundred (microRNA) to several million (Next Generation Sequencing)[27, 28].
Multiple Testing Problem
With normally distributed data and a significance level of 5%, a false positive rate (error I. type) of 5%
is to be expected by definition, i.e. 5 false positive test results on 100 tests, 50 on 1,000 and 50,000
on 1 million. This problem is described as a so-called multiple test problem, which is addressed to
reduce the number of false positives by correcting the P-values resulting from the statistical tests.
The two best-known strategies have been developed and published by Carlo Emilio Bonferroni and
the mathematicians Yoav Benjamini and Yosi Hochberg, whereas the false discovery rate (FDR) de-
veloped by Benjamini and Hochberg has established itself as a standard method in biostatistics
because it is less conservative, i.e. tends to reject less null hypotheses [29, 30].
Static and dynamic data
Cells and tissues represent biological systems and are therefore dynamic. Thus, high-dimensional
molecular measurements from tissues correspond to snapshots of dynamic processes and result
in static data sets. Most of the clinical high-dimensional datasets contain one of these snapshots
for each patient, whereby it must be left to chance as to the exact time at which this snapshot cor-
responds. However, since the molecular concentrations determined using high-throughput mea-
surement technology correspond to the average over an entire tissue segment, it is assumed that
found group differences represent general and thus also robust markers for a certain phenotype.
Numerous studies have identified prognostic and predictive markers that are used in the diagno-
sis and therapy of tumour diseases. These include in the case of glioblastoma methylation of the
promoter of the MGMT gene, in breast cancer a chromosomal rearrangement leading to the fusion
protein HER2/neu or in squamous cell carcinoma in the head and neck area mutation of the P53
gene and especially HPV virus infection and activity [31, 32, 33, 34]. In contrast to static data sets,
dynamic data sets need to be generated from living cells by performing several measurements at
different times. Dynamic data sets are often generated in the frame of perturbation experiments in
order to determine the effect of a stimulus (e. g. irradiation) on the rapidly reacting molecular lev-
els, such as transcriptome, miRNA level or proteome. The answer can be quantified and described
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over a whole period of time or, in the simplest case, a distinction can be made between answering
sooner and later after perturbation [35]. Another application of dynamic data is the computation of
gene regulatory association networks, which can be performed much more accurately from time-
dependent transcriptome data than from static transcriptome data sets [36].
2.3.2 Interpretation of primary analysis results
In association analyses of high-dimensional data sets, especially gene expression data sets (mRNA
array or RNAseq), a large number of genes correlated with the investigated groups are often found.
In order to facilitate the interpretation of these often complex results, downstream analyses are
carried out. A frequently used approach here is enrichment analysis, in which genes are grouped
together into gene sets, resembling biological processes known from the literature. Specific ac-
cumulation of genes in these gene sets is tested and it is assumed that, in the event of a positive
result, the underlying biological process is involved in the formation of the associated phenotype.
In the context of a modified radiation response of tumour or normal cells, changes in genes that
occur frequently in signalling pathways associated with DNA repair, stress response, senescence or
apoptosis would be expected.
2.3.3 Prediction analysis in high-dimensional data setting
One of the central analyses of high-dimensional data is the development of prognostic signatures
using prediction approaches. The aim of such analyses is to develop a signature consisting of sev-
eral features (i. e. genes, miRNAs, proteins) from a high-dimensional data set, whose expression
allows the calculation of a so-called ”risk score”, which in turn reflects the probability of a certain
outcome such as therapeutic success or survival. The underlying signature is calculated from a
high-dimensional data set in combination with clinical follow-up and endpoints (e. g. overall sur-
vival, tumour-specific survival, relapse-free survival). A particular challenge in the development of
prognostic signatures is to keep the complexity (i. e. the number of elements used) of the signa-
ture low in a sense that the probability of an overfitting of the underlying model is kept low as well.
Overfitting usually leads to the fact that the calculated signature cannot be validated in a differ-
ent data set than the one in which it was developed (”validation surprise”). Cross-validation and
the use of the Akaike Information Criterion (AIC) are frequently used methods for the reduction
or avoidance of model overfitting [37, 38]. A key element of each signature determination is its
validation in an independent data set. For this purpose, a training and a validation data set must
be defined before the calculations are started. Validity can also be increased by testing the model
against other independent data sets. The basis for the development of prognostic signatures is
the Cox regression model, which estimates the influence of variables on the duration of an event
(e. g. death or occurrence of a relapse). Possible variables included in the model represent the mea-
suring points of a high-dimensional data set. In order to select from these variables those which,
as part of a signature, reliably predict the occurrence of the considered endpoint, either linear re-
gression methods in combination with regularization or a so-called step-by-step regression (e. g.
forward selection, forward-selection backward-elimiation, bidirectional elimination) are generally
used [39, 40, 41, 42].
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2.3.4 Reconstruction of gene regulatory networks
The reconstruction of gene regulatory association networks is helpful for the investigation of molec-
ular mechanisms of radiation response. In the case of de novo reconstructed gene regulatory net-
works, it is advantageous to gain knowledge about the interaction of genes in the context of the
radiation response without prior knowledge. This analysis is based on the assumption that direct
or indirect interaction of genes is expressed in a high correlation of the expressions of the relevant
interaction partners. The central elements of gene regulatory association networks are the tran-
scription factors, which influence entire groups of genes in their expression behaviour. However,
since correlations reflect causalities only to a limited extent and a pure correlation-based method
leads to numerous false-positive interactions, the principle of partial correlation can be used. The
final result of the analysis is a network with all calculated direct and indirect interaction partners
[36]. The advantage of representation in the form of a network is that it can be analyzed with the
help of network graph analysis. This includes, for example, the analysis using centrality measures,
which allow the identification of the most important and central genes. Such genes could, in con-
nection with the research of the molecular mechanisms of radiation response, be candidates for
target structures that are suitable for the modulation of radiation sensitivity. In addition, so-called
network modules can be used to identify which groups of genes are the most likely to interact. The
detailed analysis of network modules can allow conclusions to be drawn on previously unknown
mechanisms of action of genes [43]. In order to be able to use transcriptome data sets for the
purpose of reconstructing gene regulatory association networks, they must meet certain require-
ments, so the number of replicates used should be as large as possible and the sample should be
as uniform as possible [44].
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3 Own research
The research projects being part of this thesis are from three different areas: Identification and
characterisation of prognostic markers in head and neck squamous cell carcinoma (HNSCC) and
glioblastoma, identification of markers predicting radiation exposure in radiation-induced breast
cancer and bioinformatic/biostatistic tools for the time-resolved analysis of transcriptome data and
the determination of genomic copy number data from widely used Affymetrix SNP 6.0 data. In the
following all papers included are shortly described, summarised and potential implications for the
field are discussed.
3.1 A 5-MicroRNA signature predicts Survival and Disease Control of Patients with
Head and Neck Cancer negative for HPV-infection
Hess J*, Unger K*, Maihoefer C, Schüttrumpf L, Schneider L, Heider T, Weber P, Marschner S,
Braselmann K, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M,
Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Rödel C, Stuschke
M, Zips D, Zitzelsberger H, Ganswindt U, Henke M, Belka C A 5-MicroRNA signature predicts
Survival andDisease Control of Patients with Head andNeck Cancer negative for HPV-infection.
Clin Canc Res. 2018 Aug 31. (IF: 10.2, *co-first authorship)
3.1.1 Background
The 5-year survival rate of patients with locally advanced head and neck squamous carcinoma (HN-
SCC) is approx. 50%. Standard-of-care comprises surgery in combination with radio(chemo)therapy
(adjuvant treatment) or definitive radio(chemo)therapy treatment. The success of therapy is ex-
pressed by local and distant control of the tumour while in cases where radiotherapy is involved,
tumour control is reduced by resistance to radiation. A lot of discussion about the mechanism of
the development of recurrences is ongoing and alternative and complementary treatment con-
cepts including immunotherapy have been proposed [45]. However, this requires knowledge of
the strata that are likely to profit or not to profit from new therapy concepts. This, in turn, requires
prognostic biomarkers that allow, either alone or, more likely, in combination with the established
molecular and clinical prognostic markers, to classify patients in order to assort them into specific
treatment strata. As for most cancer entities established molecular clinical parameters that would
allow specific stratification are also missing for HNSCC. The only established molecular factor for
HNSCC is HPV16 infection. Although, its predictive significance remains subject of discussion, HPV-
associated HNSCC now is also considered being a distinct cancer entity [46, 47, 48]. Moreover, a
number of other candidate prognostic markers have been proposed for HNSCC, however there is
none that made it into clinical practice so far [49].
3.1.2 Summary
We set out to search for a prognostic signature predicting the risk for local and distant recurrence
in the course of HNSCC therapy. In a discovery cohort of 85 HPV-negative HNSCC patients estab-
lished by the German Consortium for Translational Cancer Research Radiation Oncology Group
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(DKTK-ROG) we identified a 5-miRNA signature predicting recurrence of the disease and survival
endpoints. We were able to validate our results in an independent cohort of HPV-negative pa-
tients who were recruited at the Department of Radiation Oncology at the LMU University Clinics.
Using recursive partitioning analysis (RPA) we were further able to build a decision tree integrating
the prognostic miRNA signature with established clinical parameters and identified four prognosti-
cally distinct groups as a potential aid in therapy guidance. In addition a transcriptome-supported
miRNA-mRNA target prediction network provides putative insights into the molecular networks
the miRNA signature is embedded in.
3.1.3 Methods, Results and Discussion
3.1.3.1 Patients The two cohorts exclusively contained HPV-negative HNSCC patients who had
undergone surgical resection of the tumour followed by radio(chemo)therapy. All patients were
diagnosed with histologically proven HNSCC of the hypopharynx, oropharynx, or the oral cavity.
The DKTK-ROG discovery cohort contained patients who were treated from 2005-2011 at one of
the eight DKTK partner sites [50]. The monocentric validation cohort comprised 85 patients treated
between 2008 and 2013 at the LMU Department of Radiation Oncology.
3.1.3.2 miRNA microarray expression profiling Total RNA with preserved small RNA fraction
was used for global miRNA expression profiling using Agilent microarrays. After quality assessment
and filtering the data set comprised the profiles of 1.046 miRNAs across 161 patients.
3.1.3.3 Prognostic model A robust likelihood-based survival modelling forward-selection ap-
proach was used for the selection of features i.e. miRNAs in the discovery set to be included in a
prognostic cox-proportion hazard model predicting freedom from recurrence [51]. The maximum
number of miRNAs allowed in the model was 20 and iterative random assignment of 4 folds for
cross-validation was 10 times repeated. The best model was chosen according to the Akaike Infor-
rmation Criterion (AIC) and contained the following five miRNAs: hsa-let-7g-3p, hsa-miR-6508-5p,
hsa-miR-210-5p, hsa-miR-4306, and hsa-miR-7161-3p. Risk scores were calculated for each patient
after linear combination of signature miRNA expressions and prediction model cox-proportional
hazard coefficients. The median risk score of the discovery set was used as a threshold for the defi-
nition of high- and low-risk patients in the validation set. Fig 1 shows the performance of the model
in the discovery and validation sets (although not meaningful the log-rank test p-value for the dis-
covery set was included for demonstration purposes). In addition to the endpoint freedom from
recurrence which was used to build and train the model the signature also predicted other end-
points such as recurrence-free survival, overall survival and disease-specific survival.
In order to assess performance of the model with regard to sensitivity and specificity of the risk fac-
tor, receiver-operator characteristics (ROC) analysis was conducted. The analysis was performed
in comparison to other clinical parameters that also showed association with freedom from re-
currence in univariate cox-proportional hazard analysis. After five years follow-up (freedom from
recurrence) the risk factor showed a better AUC compared with T-stage, lymphovascular invasion
(LVI) and extracapsular extension (ECE, Figure 2).
In order to test for independence of the miRNA risk factor from the other clinical parameters, mul-
tivariate cox analysis was performed in which T-stage, LVI and ECE were included as covariates.
Overall the model significantly predicted freedom from recurrence for DKTK-ROG with a hazard-
ratio of 5.55 (95% CI 2.09-14.79, P=0.0006) and for LMU-KKG with a hazard-ratio of 3.94 (95% CI
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1.23-12.59, P=0.02082).
These data and results demonstrate the independent prognostic relevance of the 5-miRNA sig-
nature and a superior prognostic value compared with established clinical parameters. However,
prognostic relevance alone does not mean clinical relevance which requires that the prognostic
marker aids in therapeutic decision making in concert with established clinical parameters. An ap-
proach to define prognostic groups considered for different treatment is the generation of decision
trees using recursive partitioning analysis (RPA). We applied RPA in a pooled analysis on a dataset
combining DKTK-ROG and LMU-KKG on the parameters 5-miRNA signature risk factor, T-stage, N-
stage and ECE. The analysis revealed four distinct groups that significantly differed in prognosis.
The groups identified by RPA could build the basis for the conception of personalised treatment
approaches while in a first step the group with the best prognosis could be considered for thera-
peutic deintensification- and that with the worst prognosis for intensification strategies.
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Figure 1: Freedom from recurrence stratified by risk according to the five-miRNA-signature:
miRNA expression and Kaplan-Meier curves in the training and validation set. Heat map col-
ors indicate scaled miRNA log2 expression values multiplied by the Cox proportional hazard coef-
ficients (coxph) from low (blue) to high (red) on a scale from -3 to 3 for each of the five signature
miRNAs in the training (left panel) and validation set (right panel). Kaplan-Meier curves for the end-
point freedom from recurrence for HNSCC patients of the training (DKTK-ROG sample; left panel)
and validation set (LMU-KKG sample; right panel) stratified into low- and high-risk patients accord-
ing to the five-miRNA-signature. P-values are derived by log-rank test.
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Figure 2: Time-dependent ROC curve analysis for the prediction of freedom from recurrence.
(A) Time-dependent receiver operating characteristics (ROC) curves for the prediction of freedom
from recurrence in the training (left panel) and validation set (right panel) at five follow-up years.
The area under the curve (AUC) and the 95% CI of the five-miRNA-signature derived risk factor, TNM
T stage, lymphovascular invasion (LVI), and extracapsular extension (ECE) are shown. (B) ROC curve
analysis was performed for freedom from recurrence in the training (left panel) and validation set
(right panel) at follow-up years 1-5. The area under the curve (AUC) of the five-miRNA-signature
derived risk factor, TNM T stage, lymphovascular invasion (LVI), and extracapsular extension (ECE)
are shown over time (at years 1-5).
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Figure 3: Risk groups for recurrence identified by recursive partitioning analysis (RPA). RPA tree
and risk groups for recurrence combining the parameters five-miRNA-signature (high-risk, low-
risk), ECE (negative, positive), T stage (T1/T2, T3/T4), and N stage (N0/N1, N2/N3) in the pooled
HNSCC data set (n=162). Each node shows the predicted probability of recurrence (locoregional
or distant failure; color code low to high: blue-red), the number of events for the total number of
patients, and the percentage of observations in the node. Kaplan-Meier curves for the endpoint
freedom from recurrence for the four identified risk groups “low-risk”, “low-intermediate risk”, “high-
intermediate risk”, and “high-risk”. Multivariate and pairwise comparisons are shown. P-values are
derived by log-rank test.
3.1.4 Conclusion
In the study we identified a prognostic 5-miRNA signature in a multicentric cohort followed by
validation in a monocentric cohort. The signature was independent of established clinical prog-
nosticators. Moreover, integration with established clinical prognostic parameters resulted in four
prognostically distinct groups that could be considered for personalised therapeutic concepts.
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3.1.5 Outlook
In a next step thorough exploration of the mechanistic molecular impact of the signature will be
carried out in order to investigate the possibilities of specifically molecularly targeting the revealed
prognostic groups. This involves in vitro and in vivo characterisation of cells with regulated expres-
sion of the signature miRNAs on the one hand. On the other hand transcriptome analysis of tumour
specimens followed by correlation with the 5-miRNA signature risk score will be carried out. An-
other ongoing project investigates the intra-tumour heterogeneity of tissue sections of patients
from the LMU-KKG cohort for whom the 5-miRNA signature risk score is known.
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3.2 Prediction of the therapy response in glioblastoma
Niyazi M, Pitea A, Mittelbronn M, Steinbach J, Sticht C, Zehentmayr F, Piehlmaier D, Zitzels-
berger H, Ganswindt U, Rödel C, Lauber K, Belka C, Unger K A 4-miRNA signature predicts the
therapeutic outcome of glioblastoma. Oncotarget. 2016 Jul 19;7(29):45764-45775. (IF: 5.2)
3.2.1 Background
Glioblastoma (GBM) represent the most aggressive form of gliomas and in the standard setting
including patients younger than 70 years with a Karnofsky performance score (KPS) greater 60 are
treated by surgical resection and adjuvant radiochemotherapy followed by maintenance chemother-
apy with temozolomide [12, 11]. However, high rate of recurrence is mostly responsible for the
5-year overall survival rate of 10% [52, 53]. Beside the established clinical prognostic markers in-
cluding age, sex and KPS the only relevant molecular prognosticator is methylation of the promoter
region of the MGMT gene. MGMT promoter methylation as such, however, lacks sufficient prog-
nostic power for changing therapeutic decisions.
In an explorative study we set out to identify a molecular signature that enables stratification of
GBM patients into prognostically significant groups for tailored GBM treatment approaches. We
decided for miRNA as the molecular level of interest as it is known that miRNAs with a high de-
gree of promiscuity target and regulate several mRNA species encoding for proteins involved in
various signaling pathways [54]. Further, miRNA expression profiles can be easily accessed from
formalin-fixed paraffin-embedded (FFPE) tissue which are gathered in the frame of clinical routine
diagnostics carried out on stereotactic biopsies or surgically resected tumour tissues [55].
3.2.2 Summary
We profiled global miRNA expression patterns using microarray technology in a standard-treated
retrospective cohort of 36 GBM patients. A prognostic cox-proportional hazard model was gen-
erated after applying iterative forward-selection feature selection in combination with overall sur-
vival as clinical outcome endpoint. A signature consisting of four miRNAs was identified that sig-
nificantly predicted overall survival in a retrospective validation cohort (n = 58) that was matched
for age, sex and MGMT promoter methylation status. The signature was independent from age,
sex and MGMT methylation status and identified a high- and low-risk group that differed in the
risk for death in the discovery and validation cohorts. The signature was technically validated in
the discovery cohort by qRT-PCR. At the functional level matched miRNA and trancriptome data
were used for correlation analyses in order to identify genes that are likely to be regulated by the
signature miRNAs.
3.2.3 Methods, Results and Discussion
The FFPE sections of resected tumour tissues from 36 GBM patients were subjected to total RNA
isolation followed by miRNA expression profiling using Febit human miRNA microarrays. The re-
sulting data were quality filtered and quantile normalised. In conjunction with overall survival time
and censoring status the data were subjected to iterative forward-selection for feature selection
using the R package rbsurv [56]. Based on the Akaike Information Criterion (AIC) which provides a
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trade-off between complexity and model deviance four miRNAs were selected: hsa-let-7a-5p, hsa-
let-7b-5p, hsa-miR-125a-5p and hsa-miR-615-5p. A risk score was built using linear combination
and high- and low-risk groups were defined using its median. Although not meaningful, in the dis-
covery cohort, the high-risk and low risk groups showed a hazard-ratio of 3.8 (95%-CI 2.03-12.85,
log-rank test p-value: 0.0001, Fig. 4). In the validation cohort this finding could be replicated af-
ter calculating the risk scores using linear combination of the model coefficients and expression of
signature miRNAs and defining high- and low-risk groups using the median threshold as defined
in the discovery cohort. In the validation cohort, the risk for death in the high-risk group was 2.1
times higher compared to the low-risk group (95%-CI 1.13-3.91, log-rank test p-value: 0.02, Fig. 5).
Moreover, in both cohorts the signature was independent of sex, age and MGMT promoter methy-
lation status. The latter is important with regard to a potential integration of the signature and
MGMT promoter methylation which has the potential to identify strata with even more extreme
differences in prognosis.
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Figure 4: 4-miRNA signature as prognostic marker in the retrospective GBM cohort. A. Kaplan-
Meier overall survival analysis of high-risk and low-risk GBM patients. High-risk and low-risk pa-
tients were stratified based on the risk factors calculated from the cox-proportional hazard coeffi-
cients and the miRNA expression levels as measured in the microarray (left panel, 36 patients) or
by qRT-PCR analyses (bottom panel, 19 patients). Hazard ratios and p-values were calculated by
log-rank test. B. Overall survival (top panel), hierarchical cluster heat map of miRNA array expres-
sion levels (middle panel), and risk factors calculated on the basis of miRNA expression values and
cox-proportional hazard coefficients (bottom panel) for all patients. miRNAs hsa-let-7a-5p, hsa-let-
7b-5p and hsa-miR-125a-5p in patients of the higher-risk group show a tendency towards lower
expression and that of hsa-miR-615-5p a tendency towards higher expression. The median risk
factor value was used to classify high-risk and low-risk patients. C. Distribution of age (left panel)
and sex (middle and right panels) in high-risk and low-risk GBM patients. Statistical comparison
was performed by Student’s t-test or Fisher’s exact test. The patients of the lower-risk group were
statistically significant older compared with that of the lower-risk group. The differences in the
numbers of male and female patients of the lower- and higher-risk groups were not statistically
significant.
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Figure 5: Validation of 4-miRNA GBM signature in retrospective validation set. A. Age distribu-
tion in the exploratory cohort and the TCGA GBM cohort before and after age matching. B. Overall
survival (top panel), hierarchical cluster heat map of miRNA expression levels (middle panel), and
risk factors for patients of the age- and sex-matched TCGA GBM cohort. The median risk factor
value was used to classify high-risk and low-risk patients. miRNAs hsa-let-7a-5p, hsa-let-7b-5p and
hsa-miR-125a-5p in the high-risk group show a slight tendency towards lower expression and that
of hsa-miR-615-5p a slight tendency towards higher expression. C. Kaplan-Meier overall survival
analyses of high- and low-risk patients of the matched TCGA GBM cohort. Classification was per-
formed on the basis of the risk factors calculated from the cox-proportional hazard coefficientsand
the miRNA expression levels. Hazard ratios and p-values were calculated by log-rank test. D. Dis-
tribution of age (left panel) and sex (right panel) in high-risk and low-risk patients of the age- and
sex-matched TCGA GBM cohort. Student’s t-test and Fisher’s exact test were employed for statistical
comparison as depicted.
3.2.4 Conclusion
In the study we were able to identify a prognostic 4-miRNA signature that allows to identify high-
and low-risk GBM patients. This signature has the potential to identify patients which would profit
from therapy options different from the current standard-of-care setting.
3.2.5 Outlook
In order to prove validity of the miRNA signature the level of independent validation has to be
increased by testing in further miRNA data sets from standard-treated GBM patients. Further, vali-
dation in a prospective setting is required. Another aspect is the evaluation of signature expression
in blood plasma samples in order to test potential prognostic significance as liquid biopsy marker.
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3.3 Agenomic copy number signature predicts radiation exposure in post-Chernobyl
breast cancer.
Wilke CM, Braselmann H, Hess J, Klymenko SV, Chumak VV, Zakhartseva LM, Bakhanova EV,
Walch AK, Selmansberger M, Samaga D, Weber P, Schneider L, Fend F, Bösmüller HC, Zitzels-
berger H, Unger K A genomic copy number signature predicts radiation exposure in post-
Chernobyl breast cancer. Int J Cancer. 2018 Sep 15;143(6):1505-1515. (IF: 7.3)
3.3.1 Background
Breast cancer is known to be a heterogeneous disease which is associated with a number of risk
factors such as life style, smoking, age. In addition, incidence of the disease has been associated
with exposure to ionising radiation at the epidemiology level [57, 58, 59]. However, at the molecular
level no radiation-specific mechanisms of radiation-associated breast cancer tumourigenesis have
been identified so far. In the course of the clean-up activities after the Chernobyl reactor accident
on the 26th April 1986 so-called ”liquidators” were employed to remove nuclear waste from the
reactor facilities. These clean-up workers were exposed to significant doses of ionising radiation in
the range of only a few to hundreds of milligrays. Amongst these, also female workers have been
employed and exposed and increased breast cancer incidence rates have been reported for most
regions that were contaminated with radioactive fallout in the aftermath of the Chernobyl accident
including oblasts in Russia, Belarus and the Ukraine [60, 61, 62].
3.3.2 Summary
We set up a comparative study on a cohort of female breast cancer patients from women who
were exposed to ionising radiation in the course of Chernobyl clean-up activities and a case-by-
case matched control cohort of sporadic female breast cancer patients who were not exposed and
who were from the same regions of residence. We selected genomic copy number as the molecu-
lar level of interest since the DNA double strand break is the primary relevant molecular lesion in
cells caused by ionising irradiation. A signature comprising nine different genomic copy number
regions was established in a randomly selected training subset of the data which was subsequently
validated in the remaining data.
3.3.3 Methods, Results and Discussion
FFPE sections from 68 patients were used for the generation of the training data set and that from
the remaining 68 patients for the validation data set. All sections were reviewed by a pathologist
for the purpose of diagnosis and typing of the estrogen- and progesteron-receptor expression and
HER2 after immunohistochemistry staining. Further, the cellularity was determined and tumour
regions marked prior macrodissection.
Macrodissected tumour tissues were subjected to DNA extraction using the Qiagen AllPrep kit. The
genomic DNA of the tumours was labelled with Cy3-dCTP and that of pooled male reference DNA
(Promega) with Cy5-dCTP using random-prime labelling prior hybridisation on Agilent 8x60k hu-
man aCGH arrays. After washing the slides were scanned using an Agilent array scanner.
The resulting spot intensities were imported into the R statistical platform. Log2 ratios were built
after correction for spatial artefacts and median normalisation [63]. The copy number profiles were
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subjected to circular binary segmentation, copy number calling and copy number regions calcu-
lation using the R packages CGHcall and CGHregions [64, 65]. In order to build a mathematical
model predicting exposure status a multivariate logistic regression approach was used while ex-
posure status was used as response variable and genomic copy number status (-1 loss, 0 normal
and 1 gain) of the signature regions were used as independent variables. The signature regions
were identified by a stepwise-forward-selection/backward-elimination feature selection approach.
Akaike information criterion (AIC) was used for selection of the best performing model. A signature
consisting of nine genomic copy regions on chromosomal bands on chromosomal bands 7q11.22–
11.23, 7q21.3, 16q24.3, 17q21.31, 20p11.23–11.21, 1p21.1, 2q35, 2q35 and 6p22.2 was identified.
The performance of the signature is illustrated in Figure 6. From the 68 patients (34 exposed and
34 non-exposed) in the validationset 45 were predicted as exposed and 23 as non-exposed. This
results in a true-positive rate of 0.794 and a false-positive rate of 0.529. The ROC area under the
curve (AUC) was 0.617 and thereby greater than an area of 50% as it would be expected just by
chance (Figure 7).
The signature is, therefore, with some statistical uncertainties able to predict breast cancer that is
likely of having developed in the course of exposure to ionising radiation. The uncertainties in pre-
diction can be explained by the fact that the range of radiation doses the exposed patients have
received was wide and real ground truth with regard to known radiation-induced and spontaneous
breast cancer cases cannot be formulated. However, the results suggest that a molecular signature
of genomic copy number changes differentiates radiation-exposed and non-exposed breast can-
cers.
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Figure 6: Performanceof 9-CNAsignature in validation set. Copy number gains (green) and losses
(red) are shown in the top panel. The risk score on the probability scale is indicated in the middle
panel while data are sorted according to the ascending order of the risk score per patient. Patients
with probabilities greater than 0.5 are predicted as exposed, otherwise as non‐exposed (middle
panel, right and left side, respectively). The exposure status of each patient is indicated in the low
panel, thus on the right yellow cases mark true positives, blue cases mark false positives. On the
left side yellow cases mark false negatives, blue cases mark true negatives.
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Figure 7: Receiver Operator Characteristics (ROC) analysis. ROC analysis of the logistic regression
model using the 9-CNA signature fitted on the training set and evaluated on the validation set.
Each point (circles) corresponds to a probability cutoff level decreasing from left to right, given by
the steps visualized in Figure 6. Points are connected by straight lines.
3.3.4 Conclusion
We identified a genomic copy number signature that allows the differentiation of breast cancers
from patients who were exposed and those who were not exposed to ionising radiation. It bears
the potential to study radiation-specific molecular features of radiation-induced breast cancer such
as secondary breast cancer that develops in the course of medical radiation.
3.3.5 Outlook
In order to translate the results of the study into the clinical setting, verification of the signature in
a clinically derived cohort of secondary breast cancers that developed the disease after exposure
to therapeutic radiation of preceding malignant diseases such as tumours of the lung.
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3.4 Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation ex-
posure in post-Chernobyl breast cancer
Wilke CM, Hess J, Klymenko SV, Chumak VV, Zakhartseva LM, Bakhanova EV, Feuchtinger
A, Walch AK, Selmansberger M, Braselmann H, Schneider L, Pitea A, Steinhilber J, Fend F,
Bösmüller HC, Zitzelsberger H, Unger K Expression of miRNA-26b-5p and its target TRPS1 is
associated with radiation exposure in post-Chernobyl breast cancer. Int J Cancer. 2018 Feb
1;142(3):573-583. (IF: 7.3)
3.4.1 Background
Long-term data on the survivors of the Japan atomic bombings have shown, amongst other can-
cer entities, an increase in breast cancer that was associated with the exposure to ionising radiation
[57]. Moreover, breast cancer also is amongst the diseases that have been shown to be increased
in incidence after the Chernobyl accident in 1986 [60]. The important role of epigenetics and post-
transcriptional regulation via miRNAs has been increasingly acknowledged in the last decades and
a number of miRNAs have been shown to be associated with breast cancer carcinogenesis. We
took up this knowledge and conducted a study in which we studied the role of these miRNAs in
radiation-associated breast cancer that has developed in patients who were exposed to ionising
radiation in the course of their role as female clean-up workers aka ”liquidators” after the Cher-
nobyl reactor accident in 1986 in comparison to spontaneous breast cancer cases from residence-
matched non-exposed controls. The main aim of our study was to determine a potential radiation-
specific role of the miRNAs and even importantly of proteins these miRNAs are likely to regulate.
3.4.2 Summary
We identified breast cancer associated miRNAs by literature research and tested these for differ-
ential expression in a cohort of 77 exposed and 77 non-exposed breast cancer patients from the
Ukraine. The patient cohort was randomly split into a discovery (n=76) and validation (n=78) set.
From the tested miRNAs only hsa-miR-26b-5p was significantly higher expressed in the exposed
compared to the unexposed patients. The protein TRPS1, which is one of the transcriptional tar-
gets of hsa-miR-26b-5p was significantly lower expressed in the exposed compared to unexposed
cases. TRPS1, which is a transcription factor, would be particularly suitable as a radiation marker
in breast cancer since it would be technically feasible to detect from diagnostic routine samples.
After siRNA knowdown of the TRPS1 gene in a breast cancer cell culture model we identified genes
playing a role in DNA-repair, cell cycle, mitosis, cell migration, angiogenesis and EMT pathways.
3.4.3 Methods, Results and Discussion
From the 77 breast cancer patients who were exposed and from the 77 patients who were no ex-
posed to radiation formalin-fixed paraffin-embedded tissue sections were available. The tissue
sections were assessed by a pathologist for diagnosis and the definition of tumour regions prior
macrodissection and isolation of DNA and total RNA including small RNAs using the Qiagen All-
Prep kit. Further, the pathologist provided estrogen, progesteron, HER2, c-kit, cytokeratin 5/6, P53,
Ki-67 and BRCA1/2 status. Further, for all exposed cases the doses the patients received was re-
constructed using the RADRUE method [66]. The majority of tumours was diagnosed as invasive
3 Own research 25
carcinoma of no special type (NST). Further types diagnosed were invasive lobular carcinoma (ILC),
intracystic papillary breast carcinoma and breast carcinomas with medullary features.
In order to find miRNAs repeatedly reported to play a role in breast cancer carcinogenesis in the
context of radiation a PubMed research was conducted which resulted the miRNAs hsa-miR-26b-
5p, hsa-miR-99b-5p, hsa-miR-221-3p and hsa-miR-222-3p for which the expression was subsequently
determined using qRT-PCR. Only hsa-miR-26b-5p could be shown to be overexpressed in the ex-
posed cases compared with the unexposed (Fig. 8).
The expression of TRPS1 which is a transcriptional target of hsa-miR-26b-5p was determined by
immunohistochemistry on FFPE slides and was significantly reduced in exposed compared to un-
exposed cases. This finding suggests a regulatory effect of hsa-miR-26b-5p on TRPS1 protein ex-
pression (Fig. 9 and Fig. 10).
Since expression of the transcription factor TRPS1 was specifically down-regulated in exposed cases
we strove for investigating the mechanistic impact of TRPS1 on the transcriptional level by siRNA
knock-down in a radiation-transformed breast cancer cell culture model B42-16 and by correlation
analyses using the TCGA breast cancer data set [67]. The transcriptome was characterised using Ag-
ilent human gene expression array analysis comparing B42-16 cells after TRPS1 siRNA knockdown
with scrambled controls. Pathway enrichment of differentially upregulated genes revealed DNA-
repair, cell cycle and mitosis and that of down-regulated genes cell migration, angiogenesis and
EMT. Using the TCGA breast cancer data set we generated a TRPS1-centered correlation network
(Fig. 11). Pathway enrichment analysis of the network revealed mostly apoptosis related pathways.
The transcriptome analysis results suggest involvement of TRPS1 important cancer hallmarks. Thus,
TRPS1 could be a early radiation-induced event in the carcinogenesis of the breast after exposure
to ionising radiation.
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Figure 8: Expression of breast cancer associated miRNAs. Violin plots displaying the expressions
of hsa‐miR‐26b‐5p, hsa‐miR‐221‐3p and hsa‐miR‐222‐3p in the Chernobyl discovery cohort and
hsa‐miR‐26b‐5p in the Chernobyl validation cohort measured by qRT‐PCR (−ΔCT values) are shown
(right panel). The nonexposed control group is labeled in light blue and the exposed group in
purple. The middle dark line represents the median of expression values. The vertical black line
represents the interquartile.
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Figure 9: TRPS1 immunohistochemistry staining Digital image analysis of immunohistochemi-
cally stained FFPE tumour sections from non‐exposed and exposed breast cancer samples using
an antibody against TRPS1. (A/B) Two representative immunohistochemically stained breast car-
cinoma cases are shown for nonexposed (A) and exposed (B) cases. Image details of Aa and Ba
(black frames) are shown in Ab and Bb. Detection and quantification of TRPS1‐stained nuclei was
performed using the digital image software Definiens. Nuclei of tumour cells, for which the staining
intensities were calculated based on the algorithm, are labeled in yellow (Ac, Bc).
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Figure 10: Differential TRPS1 protein expression in exposed and unexposed cases. Significantly
increased TRPS1 protein expression represented by the marker staining intensity was observed in
breast cancer tissues from the nonexposed groups (light blue) compared to the exposed groups
(purple) in the discovery (a, p = 0.028) and validation cohorts (b, p = 0.027). p values were calcu-
lated using the partial differential test considering intertumour heterogeneity.
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Figure 11: TRPS1‐centered correlation networks. Top 100 correlating genes with an FDR <0.05.
The expression of genes labeled with dark grey circles showed negative correlation with TRPS1 ex-
pression and that of genes labeled with light grey circles showed positive correlation with TRPS1
expression. (a) TRPS1‐centered correlation network based on global mRNA expression data from
matched sporadic breast cancers of the publicly available TCGA dataset. (b) TRPS1‐centered corre-
lation network based on microarray gene expression data from B42‐11 and B42‐16 untransfected,
scrambled‐siRNA transfected and TRPS1‐downregulated cells.
3.4.4 Conclusion
We were able to identify the radiation markers miRNA hsa-miR-26-5p and the protein TRPS1 which
have the potential to serve as a marker for radiation-induced secondary breast cancer in the clinical
setting.
3.4.5 Outlook
In order to study a potential role as markers for secondary, radiation-induced breast cancer prospec-
tive validation in clinically derived cohorts is required. Moreover, further in vitro and in vivo exper-
iments are necessary to further investigate the mechanistic role of TRPS1 and hsa-miR-26b-5p in
radiation-associated breast carcinogenesis.
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3.5 Natural Cubic Spline RegressionModeling Followed by Dynamic Network Recon-
struction for the IdentificationofRadiation-SensitivityGeneAssociationNetworks
from Time-Course Transcriptome Data
Michna A, Braselmann H, Selmansberger M, Dietz A, Hess J, Gomolka M, Hornhardt S, Blüth-
gen N, Zitzelsberger H, Unger K. Natural Cubic Spline Regression Modeling Followed by Dy-
namic Network Reconstruction for the Identification of Radiation-Sensitivity Gene Association
Networks from Time-Course Transcriptome Data. PLoS One. 2016 Aug 9;11(8). (IF: 2.8)
3.5.1 Background
The characterisation of the transcriptome and its analysis plays an important role in modern molec-
ular biology while the majority of data sets still is conducted on steady-state static datasets that
simply work out differential expression based on t-testing approaches. However, time-resolved
dynamic transcriptomic analyses are likely to be much more informative but require tailored ap-
proaches to analyse differential expression over time. One major approach to extract and analyse
the information from time-resolved transcriptome data from another angle is the reconstruction of
gene regulatory networks (GRN) that allow gathering insights into the interplay of genes expressed
by network modules. And in addition, the resulting networks and network modules can be anal-
ysed towards the involvement of molecular pathways. In this study we developed the R package
SplineTimeR which provides a workflow for the conduction of the afore described computational
tasks.
The analysis workflow of the study was established using time-resolved transcriptome data from
lymphoblastoid cells lines that were generated in the frame of the LUCY (Lung Cancer in the Young)
study and which differed in radiation sensitivity. Results on differential expression over time after
gamma irradiation with 1 Gy and 10 Gy, as well as pathway analysis of the reconstructed GRN is
presented in the study.
3.5.2 Summary
We developed the R package SplineTimeR which provides functions required for an analysis work-
flow for time-resolved transcriptome data and apply this workflow in order to work out the tran-
scriptome response of a radiation-normal and -hypersensitive lymphoblastoid cell line. The devel-
oped natural cubic spline regression modelling (NCSRM) approach for time-resolved differential
transcriptomics showed superior performance in comparison with existing approaches.
3.5.3 Methods, Results and Discussion
A graphical outline of the study is shown in Fig. 12.
3 Own research 31
Figure 12: Graphical outline of the study.
The transcriptome profiles of biological replicates of the normal and the hypersensitive cell lines
were generated 15 min, 30 min, 1 h, 2 h, 4 h, 8 h and 24 h after irradiation or sham irradiation. For
this Agilent human gene expression microarrays were used. The profiles of the duplicates were
averaged and then analysed for differential gene expression between irradiated and sham con-
trol. We applied the NCSRM approach on the data sets and revealed a sparse response at the gene
expression level of the normal sensitive cells after 1 Gy (7 genes) compared to that of the hypersen-
3 Own research 32
sitive cells (2335 genes). An example for NCRSM differential expression of the gene BBC3 is shown
in Fig. 13. After 10 Gy irradiation both cell lines showed a massive transcriptomic response: 3892
genes for the normal and 6019 genes for the hypersensitive cells. For assessing plausibility of the
results pathway enrichment analysis was conducted for the differentially expressed genes. This re-
sulted in no pathway for the normal sensitive cell line after 1 Gy and in hundreds of pathways for
the other comparisons which all showed cell cycle and cell division related pathways at the top of
the lists.
Figure 13: NCRSM fit for gene BBC3 in the hypersensitive cells The blue line represents the fitted
model for the control (0 Gy) and read line that for the irradiated group (1 Gy). Blue and red dots
represent the measured expression levels of the biological replicates. Vertical lines represent the
endpoints and interior knots correspond to the 0.33- and 0.66-quantiles.
The expression profiles of these genes were then subjected to GRN reconstruction using the GeneNet
approach which resulted in networks that in size (number of nodes/edges) were proportional to
the number of underlying differentially expressed genes: normal sensitive 1 Gy no network, hyper-
sensitive 1 Gy 1140/12198 (nodes/edges), normal sensitive 10 Gy 2735/84695 (nodes/edges) and
hypersensitive 10 Gy 3483/114629 (nodes/edges). We identified the top most important genes (i.e.
nodes) from the networks using a combined network analysis metric and subjected these genes to
pathway enrichment analysis. Normal sensitive cells after 10 Gy and hypersensitive cells after 1 Gy
showed strong association with cellular senescence while hypersensitive cells after 10 Gy showed
enrichment of apoptosis related pathways.
We also evaluated the differential expression results and reconstructed GRNs that were received
after NCSRM and another established method for the analysis of time-course transcriptome data
BETR (Bayesian Estimation of Temporal Regulation)[68]. Overall, NCSRM detected more genes as
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differentially expressed compared to BETR but there was a great overlap between NCRSM and BETR
results. Also when comparing the top hub genes of the GRNs there was a good overlap between
enriched pathways. In line with the literature BETR seems to underestimate the number of truly
differentially expressed genes and thereby is likely to miss potentially important information. Also,
in contrast to BETR NCSRM is more flexible and tolerant when it comes to selection of time-points
and missing data. This is an important feature since it is not a rare scenario that the design of tran-
scriptomic data analysis is not optimised for the purpose of differential expression analysis. In a
further comparison where we compared the overlap of GRNs reconstructed from NCRSM and BETR
identified differentially expressed genes with the interactions as known from the Reactome Inter-
action Network database. Except one network we saw significantly better overlap between NCRSM
derived GRNs with Reactome than with that of the BETR derived ones [69].
3.5.4 Conclusion
We established a workflow for the differential gene expression, GRN reconstruction and functional
interpretation of the GRNs of time-resolved transcriptome data. Our approach is flexible and tol-
erant against frequently occurring experimental uncertainties such as suboptimal study design or
missing data points. Analysis of the biological data set revealed differences and common proper-
ties in the molecular radiation response. We provide the workflow as a Bioconductor R package
and thereby allow public and free access to it for the scientific community.
3.5.5 Outlook
Since GRNs are derived from transcriptome data the identified interactions between genes could
reflect direct or indirect relationships of the expressed proteins. Thus, the physical interaction be-
tween nodes identified in the GRNs and their biological meaning will will be subject of future stud-
ies.
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3.6 Copy number aberrations from Affymetrix SNP 6.0 genotyping data - how accu-
rate are the commonly used prediction approaches?
Pitea A, Kondofersky I, Sass S, Theis FJ, Mueller NS, Unger K. Copy number aberrations
from Affymetrix SNP 6.0 genotyping data—how accurate are commonly used prediction
approaches? Briefings in Bioinformatics. 2018:doi:10.1093/bib/bby096, (IF: 6.3)
3.6.1 Background
Genomic copy number changes (CNA) are frequently occurring in most cancer entities and different
approaches are available for typing CNAs while the method of choice is array comparative genomic
hybridisation (aCGH). However, also other sources of data which are not primarily for this purpose
can be used for typing CNAs including DNA methylation array data, exome and whole genome
sequencing data and SNP (short nucleotide polymorphism) array data. In our study we focussed
on Affymetrix SNP 6.0 data generated from clinical tumour specimen. Since we are working in the
field we used the Affymetrix SNP 6.0 data on the TCGA (The Cancer Genome Atlas) head and neck
squamous cell carcinoma (HNSSC) data set [70]. In addition and in order to be able to assess the
performance of different approaches we used a simulated Affymetrix SNP 6.0 like dataset. The main
aim of the study was, to compare the performance of established analysis approaches including
OncoSNP, ASCAT, CGHcall, genoCNA and GISTIC with each other. Further, we improved the tumour-
derived data tailored approach CGHcall for the purpose which we called CGHcall*. Moreover, we
compared the CNA results of the assessed analysis approaches on the TCGA HNSCC data set with
published CNA data on HNSCC.
3.6.2 Summary
In our study we comprehensively compared the performance of the copy number calling algo-
rithms OncoSNP, ASCAT, CGHcall, genoCNA and GISTIC and considered confounding or biasing
parameters tumour purity, length of CNA and CNA burden. Amongst the tested algorithms CGHcall
provided the best performance with regard to prediction call accuracy. However, we observed that
the accuracy of CGHcall drops once the CNA burden exceeds 50% of the genome. CGHcall*, an ad-
justed version of CGHcall was implemented and we could demonstrate its improved performance.
The scripts of the workflow and conducted analyses is provided to the community in GitHub.
3.6.3 Methods, Results and Discussion
For performance assessment two data sets were used: A synthetic Affymetrix SNP 6.0 data set that
was generated using the jointseg R package and the HapMap dataset on naturally occurring CNAs
in the human populations for which comprehensive experimental validation data exist [71, 72].
For the evaluation of the performance on a realistic tumour sample derived data set the raw data
of the TCGA HNSCC data were used. All SNP 6.0 data were preprocessed using Affymetrix Power
Tools (APT) in order to receive LRR (probewise LogR-ratio) values and B-allele frequencies which
were already available for the simulated data. All data were then subjected to analysis with the
genomic copy number analysis tools OncoSNP, ASCAT, CGHcall, genoCNA and GISTIC.
Performance for the simulated data was assessed using F score statistics which integrates precision
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(positive predicted value) and recall (sensitivity). Good prediction is reflected by F-score values to-
wards 1 and bad prediction by values towards 0. Differences between F-score distributions were
assessed using Wilcoxon Cox test and resulting p-values were Bonferroni corrected.
When manually inspecting the copy number calling profiles we observed that in case of profiles
with more than half of the genome changed in copy number reflected by the segmentation pro-
files, prediction of the CGHcall algorithm fails. This problem was caused by estimating the baseline
copy number for which the median of all LRR values per profile is used and which fails in case of
more than 50% of the profile being altered. We solved this by only considering LRRs which are cov-
ered by the interval [-0.1, 0.1]]. This correction was implemented in the CGHall workflow which we
then called CGHcall*.
CGHcall* included, the prediction F-scores were determined for the 100 simulated genomic copy
number data. When comparing the performance of the algorithms for profiles with different simu-
lated tumour purity (i.e. cellularity) huge differences were obvious. GISTIC was not able to correctly
predict CNAs in profiles with less then 100% tumour purity. The ability to correctly call losses was
poor for all algorithms while CGHcall* and GenoCNA improved with higher tumour purity. The
overall performance of the algorithms to call the normal state was not good for all algorithms but
improved with higher purities. With purities greater than 70% CGHcall* and GenoCNA performed
best. Prediction F-scores also for gains were not good for tumour purities below 70% for all algo-
rithms but significantly improved for CGHcall* and GenoCNA for 70% purity and greater. For 100%
purity CGHcall* and OncoSNP performed best. The results are summarised in Fig. 14
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Figure 14: Performance of CNA calling algorithms on synthetic data. The y-axis represents the
F-score and x-axis represents the tumour purity level in %. The three facets represent the different
classes: loss, normal and gain. Each boxplot consists of F-scores for 100 synthetic samples. The
total number of genetic markers covered by the synthetic signal was approximately 8 bp.
Another important factor in CNA analysis is the length of the underlying chromosomal seg-
ments. Optimally an algorithm performs equally well for short, medium and long segment lengths.
We could show that for 100% tumour purity OncoSNP and CGHcall* perform best across different
copy number segment lengths as outlined in Fig. 15 A. Finally, when comparing the performance
of the algorithms dependent from the CNA burden OncoSNP and CGHcall* most accurately pre-
dicted the true copy number states when the CNA burden was greater 50% (Fig. 15 A).
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Figure 15: Heatmap of meanF-scores for different lengths of copynumber regions (A) and for
CNA burdens smaller and greater 50%.
Further we tested performance of the algorithms on the non-tumour HapMap SNP 6.0 data (n
= 81) for which comprehensive validation data were generated using array CGH and fluorescence
in situ hybridisation and which we used as true state. Again, GenoCNA and CGHcall* performed
almost similarly and best amongst all algorithms while the performance of GenoCNA was slighly
better than that of CGHcall* (Fig. 16).
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Figure 16: Heatmap of mean F-scores for different lengths of copynumber regions (A) and for
CNA burdens smaller and greater 50%.
Finally, we typed the genomic copy number changes in the TCGA HNSCC data set. We com-
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pared the frequencies of gene copy number alterations of genes CDKN2A and CCND1 which are
frequently altered in HNSCC as reported by Gollin et al. (2014) with that determined in the TCGA
data [73]. In this comparison CGHcall* and GISTIC showed the best comparable results while most
profiles were from tumours with tumour purities greater 60%.
3.6.4 Conclusion
We evaluated the prediction performance of commonly used SNP 6.0 data genomic copy number
calling algorithms and provide a pipeline for this purpose. Further, we could improve overall per-
formance of CGHcall implemented in CGHcall*. Our study provides the basis for informed selection
of the best suitable genomic copy number calling algorithm when using Affymetrix SNP 6.0 data.
3.6.5 Outlook
The provided pipeline could be used as blueprint for the performance assessment for copy number
typing for other data types allowing for copy number typing such as genomic number from DNA
methylation array data, whole exome or whole genome sequencing data.
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Statement of translational relevance (word count: 150 words) 
 
HPV-negative HNSCC cancer is currently treated with a set of standard-of-care therapeutic 
approaches which in total result in approx. 50% overall survival for locally advanced HNSCC 
demonstrating that substantial subgroups are not likely to profit from state-of-the-art therapy. The 
most relevant clinical event limiting success of HNSCC therapy is recurrence of the disease after 
surgical tumor resection followed by radio(chemo)therapeutic treatment. The presented HNSCC 
HPV-negative five-miRNA-signature predicts the risk for recurrence in HNSCC and allows, in 
combination with the clinically established risk factors, the definition of four prognostically 
distinct groups. This provides the first prerequisite for the consideration of personalized treatment 
approaches in HPV-negative HNSCC. Possible personalized treatment options include 
consideration of adjusting therapy intensity according to the overall risk for therapy failure in the 
first line. Further, and most importantly, it represents the basis for a more focused search for 
molecular therapeutic targets improving therapy success for appropriate patients.  
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Abstract (word count: 249 words) 
Purpose: 
HPV-negative head and neck squamous cell carcinoma (HNSCC) associates with unfavorable 
prognosis while independent prognostic markers remain to be defined. 
Experimental Design: 
We retrospectively performed miRNA expression profiling. Patients were operated for locally 
advanced HPV-negative HNSCC and had received radiochemotherapy in eight different hospitals 
(DKTK-ROG; n=85). Selection fulfilled comparable demographic, treatment and follow-up 
characteristics. Findings were validated in an independent single-center patient sample (LMU-
KKG; n=77). A prognostic miRNA-signature was developed for freedom from recurrence and 
tested for other endpoints. Recursive-partitioning analysis was performed on the miRNA-
signature, tumor and nodal stage, and extracapsular nodal spread. Technical validation used qRT-
PCR. A miRNA-mRNA target network was generated and analyzed. 
Results: 
For DKTK-ROG and LMU-KKG patients, the median follow-up was 5.1 and 5.3 years, the 5-
year freedom from recurrence rate was 63.5% and 75.3%, respectively. A five-miRNA-signature 
(hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306 and hsa-miR-7161-3p) 
predicted freedom from recurrence in DKTK-ROG (HR 4.42, 95% CI 1.98−9.88, P<0.001), 
which was confirmed in LMU-KKG (HR 4.24, 95% CI 1.40−12.81, P=0.005). The signature also 
predicted overall survival (HR 3.03, 95% CI 1.50−6.12, P=0.001), recurrence-free survival (HR 
3.16, 95% CI 1.65−6.04, P<0.001) and disease-specific survival (HR 5.12, 95% CI 1.88−13.92, 
P<0.001), all confirmed in LMU-KKG data. Adjustment for relevant covariates maintained the 
miRNA-signature predicting all endpoints. Recursive-partitioning analysis of both samples 
combined classified patients into low (n=17), low-intermediate (n=80), high-intermediate (n=48) 
or high risk (n=17) for recurrence (P<0.001). 
Conclusions: 
The five-miRNA-signature is a strong and independent prognostic factor for disease recurrence 
and survival of patients with HPV-negative HNSCC.  
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Introduction 
 
Prognosis of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) 
generally remains poor. Whereas patients with high-risk human papillomavirus (HPV) associated 
HNSCC have a considerably more favorable outcome, HPV-negative patients still have to expect 
limited disease control and survival (1,2). From the biologic perspective, intrinsic resistance of 
tumor cells to radiochemotherapy or therapy failure caused by metastatic spread are possible 
underlying factors. Consequently, research aims at altering radiation dose and fractionation or - 
more recently - at the additional administration of targeted drugs and/or immune checkpoint 
inhibitors (3,4). However, biomarkers to predict which patients potentially would profit from 
these approaches are missing. 
Complex and heterogeneous genomic aberrations and mutation patterns molecularly control 
initiation and progression of HNSCC (5-7). MicroRNAs (miRNAs), involved in 
posttranscriptional regulation, have been shown to be highly deregulated in most cancers and 
might well be of prognostic relevance (8,9). In HNSCC aberrantly expressed miRNAs were 
described (10-12). However, so far no study has investigated the prognostic role of miRNAs by 
comprehensive miRNA-profiling in well-characterized HPV-negative HNSCC cohorts. 
Here we analyzed miRNA expression profiles in cancer tissue of locally advanced HNSCC 
(n=162). We hypothesized that we can develop a miRNA-based molecular signature, which 
allows to stratify HPV-negative HNSCC patients according to risk of recurrence following 
adjuvant radio(chemo)therapy.  
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 7 
Materials and Methods 
 
Patient specimens and study design 
In the present study, we analyzed two independent samples of HNSCC patients who had 
undergone surgical resection followed by adjuvant radio(chemo)therapy: the DKTK-ROG 
(German Consortium for Translational Cancer Research, Radiation Oncology Group) and the 
LMU-KKG (Ludwig-Maximilians-University of Munich, Clinical Cooperation Group 
“Personalized Radiotherapy in Head and Neck Cancer“) samples. For both of which, clinical data 
and treatment-naive patient tissue specimens were collected retrospectively. All patients were 
diagnosed with histologically proven HNSCC of the hypopharynx, oropharynx or the oral cavity. 
Only HPV-negative HNSCC were included (Supplementary Methods). Ethical approval (EA) for 
this retrospective study, carried out in accordance with the Declaration of Helsinki, was obtained 
by the ethics committees of all DKTK-ROG partners including the LMU (EA 312-12, 448-13, 
17-116). Tumor stage was assessed using the UICC TNM Classification of Malignant Tumors, 
7th edition. 
The multicentric study sample DKTK-ROG originally included 221 HNSCC patients treated at 
one of the eight different DKTK partner sites (13). This study reports on 85 out of 143 patients 
with HPV-negative tumors who were treated between 2005 and 2011. 58 patients had to be 
omitted due to insufficient tumor material. All patients received postoperative radiotherapy 
covering the previous tumor region and regional lymph nodes with concurrent cisplatin(CDDP)-
based chemotherapy according to standard protocols. Inclusion criteria were positive microscopic 
resection margins and/or extracapsular extension (ECE) of lymph nodes and/or tumor stage pT4 
and/or or more than three positive lymph nodes. The median overall treatment time was 44 days 
(interquartile range IQR 43-46 days). Adjuvant radiotherapy including elective irradiation of 
cervical lymph nodes was applied with a median dose of 50 Gy (median dose 2 Gy/fraction) and 
a boost to the former tumor region and to microscopic disease (if any) to a median dose of 66 Gy 
(median dose 2 Gy/fraction). Cisplatin was applied weekly with a median cumulative dose of 200 
mg/m² body surface area (BSA) (range 100-300 mg/m² BSA). 
The monocentric study sample LMU-KKG included originally all HNSCC patients with at least 
UICC TNM stage III or close/positive microscopic resection margins (resection margins were 
considered “close margin” when declared R0, but less than 5 mm by the local pathologist) who 
were treated with adjuvant radiotherapy between 06/2008 and 01/2013 at the LMU Department 
of Radiation Oncology (14). The median overall treatment time was 45 days (IQR 43-47 days) 
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with five fractions per week. A median radiation dose of 64 Gy (median dose 2 Gy/fraction) was 
applied to the former tumor bed or regions of ECE, elective lymph node regions have been 
covered according to tumor stage and localization with a median dose of 50 Gy (median dose 2 
Gy/fraction), 56 Gy (median dose 2 Gy/fraction) were applied to involved lymph node regions. 
In the case of close/positive microscopic resection margins and/or ECE, patients received 
concurrent chemotherapy. The majority (76 %) of the patients received CDDP/5-fluorouracil (5-
FU) (CDDP: 20 mg/m² BSA day 1–5/29–33; 5-FU: 600 mg/m² BSA day 1–5/29–33). In selected 
cases, Mitomycin C (MMC) or 5-FU/MMC replaced platin-based chemotherapy. This study 
reports on the HPV-negative tumor subset (n=77) of all patients with available tumor tissue 
specimens (n=115). 
After histopathological review of haematoxylin and eosin stained tissue sections from available 
blocks with formalin-fixed and paraffin-embedded (FFPE) tumor tissue by a pathologist (DKTK-
ROG: KW; LMU-KKG: CW/AW), the tumor area was annotated. If necessary, microdissection 
was performed prior nucleic acids extraction in order to ensure a tumor cellularity (i.e., the 
percentage of tumor cells in analyzed tissue) of at least 60% (DKTK-ROG: median 60%, IQR 
60-70%; LMU-KKG: median 70%, IQR 70-80%).  
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 9 
Procedures 
Total RNA, including the small RNA fraction, was extracted using the Qiagen miRNeasy FFPE- 
(DKTK-ROG) or the AllPrep DNA/RNA FFPE-Kit (LMU-KKG) according to the 
manufacturer’s protocols (Qiagen, Hilden, Germany). Isolated RNA was quantified with the 
Qubit-Fluorometer and integrity of small RNAs was assessed (Supplementary Methods). 
miRNA expression was profiled using SurePrint G3 8x60K Human miRNA Microarrays 
(AMADID 70156; Agilent Technologies, Santa Clara, CA, USA) representing 2,549 human 
miRNAs (content sourced from miRBase database, Release 21.0; Supplementary Methods). 
Microarray raw data were uploaded to the publicly available database ArrayExpress (accession 
no. E-MTAB-5793). miRNA expression microarray profiling resulted in a data set of 162 
HNSCC samples (DKTK-ROG: n=85; LMU-KKG: n=77). 
Data analysis was performed using the R statistical software (version 3.3.1) in combination with 
R-Bioconductor/CRAN packages (Supplementary Methods)(15). 
For the purpose of building a Cox proportional hazards model predicting disease recurrence in 
combination with miRNA expression, we used a robust likelihood-based survival modelling 
approach deploying an iterative forward-selection algorithm implemented in the R package 
rbsurv (16). We recently built a miRNA-signature predicting outcome in glioblastoma using the 
same approach (Supplementary Methods)(17). 
Experimentally validated miRNA-target genes of the signature miRNAs were obtained from the 
miRTarBase database (Release 6.0). The Cytoscape software (version 3.2.1) with the Reactome 
FI plugin (version 4.0.0) was used to generate a miRNA-mRNA target regulatory network and to 
conduct pathway enrichment analysis of the target genes. Pathways with P-values < 0.05 were 
considered as significantly enriched with target genes (18). 
For technical validation of microarray data quantitative real-time RT-PCR (qRT-PCR) analysis 
was performed (Supplementary Methods). 
Clinical endpoints and statistical analysis 
As the main objective of the study was the identification of a miRNA-signature that allows 
separation of patients according to risk of recurrence, the primary endpoint was freedom from 
recurrence. Freedom from recurrence was defined as the time (days) from the start of 
radiotherapy treatment to the time of the first observation of confirmed locoregional or distant 
recurrence. Data for recurrence-free patients were right-censored either at the date of death or last 
follow-up visit. Additional endpoints included were recurrence-free survival, overall survival, 
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 10 
disease-specific survival, disease-unspecific survival, distant control, and locoregional control. 
We calculated recurrence-free survival (days) from the date of radiotherapy treatment start to the 
first observation of locoregional/distant recurrence or death due to any cause; overall survival 
from the date of radiotherapy treatment start to the date of death from any cause; disease-specific 
survival from the date of radiotherapy treatment start to the date of tumor related death; non-
tumor related survival from the date of radiotherapy treatment start to the date of non-tumor 
related death; distant control from the date of radiotherapy treatment start to the date of distant 
recurrence; locoregional control from the date of radiotherapy treatment start to the date of local 
recurrence. In the absence of an event, patients were censored at the date of the last follow-up 
visit (or the date of death). 
 
Kaplan-Meier curves were compared for statistical difference using the log-rank test using the R-
package survival. Median time-to-event estimates and Hazard ratios (HR) with 95% confidence 
intervals (CI) were determined. Univariate Cox proportional hazard analysis was performed to 
evaluate the association of clinicopathological variables with outcome (Supplementary Methods). 
We used multivariate Cox proportional hazards analysis to assess the prognostic value of the 
identified miRNA-signature after adjustment for other prognostic clinical parameters as 
covariates. 
The clinical endpoint prediction performance of the five-miRNA-signature and 
clinicopathological variables in terms of sensitivity and specificity, represented by the 
corresponding areas under the curve (AUCs), was determined for follow-up times from 1 to 5 
years (Supplementary Methods). 
Recursive partitioning analysis (RPA) for the generation of a decision tree considering the 
clinical parameters ECE status, TNM T stage, TNM N stage and resection margin status with or 
without the five-miRNA-signature defined risk groups was conducted using the R-package rpart 
(Supplementary Methods). 
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Results 
The clinicopathological characteristics of the HNSCC patients included in our study (median 
follow-up: DKTK-ROG 5.1 years, IQR 3.7-5.6; LMU-KKG 5.3 years, IQR 4.4-6.4) are listed in 
Table 1. Compared to the DKTK-ROG sample, which exclusively contained patients treated by 
postoperative radiotherapy with concurrent cisplatin-based chemotherapy, only 63.6% of the 
LMU-KKG sample received concurrent radiochemotherapy. Accordingly, the LMU-KKG 
sample contained fewer patients with UICC TNM stage IV, advanced nodal stage, ECE or 
positive microscopic resection margins. 31.5% of all patients (51/162) developed disease 
recurrence within the observed follow-up time while the two samples did not differ with regard to 
the endpoints freedom from recurrence and recurrence-free survival (Figure S1). The 5-year 
freedom from recurrence rate was 63.5% and 75.3% for DKTK-ROG and LMU-KKG patients, 
respectively. 
The miRNA expression profiling of 162 tumor specimens identified 1,031 expressed miRNAs. 
After univariate preselection 524 miRNAs remained for feature selection using a robust 
likelihood-based survival modeling forward-selection approach (Table S1). The best model 
according to the Akaike Information Criterion (AIC) contained the five miRNAs hsa-let-7g-3p, 
hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306 and hsa-miR-7161-3p with the following Cox 
proportional hazard coefficients: -0.5214183, -0.5254865, 0.6461524, -0.3678727 and -
0.8165854, respectively. The coefficients were subsequently used for individual risk score 
calculation after linear combination with appropriate expressions of the signature miRNAs. Using 
the median risk score as a cut-off, 43 patients of the DKTK-ROG sample (training set) were 
assigned to the low-risk group (median time to event not reached (NR), 95% CI 2047−not 
estimable (NE); eight events) and 42 to the high-risk group (median time to event 748 days, 95% 
CI 459–NE; 24 events). As expected, the groups differed significantly in their risk of recurrence 
(HR 4.42, 95% CI 1.98−9.88; log-rank P<0.001; Figures 1A, S2). 
We applied the five-miRNA-based signature prediction model to the miRNA expression data set 
of the LMU-KKG sample (validation set) using the cut-off as calculated from the training sample 
data (0.03629712) and assigned 38 patients to the low-risk (median NR, 95% CI NE−NE; four 
events) and 39 patients to the high-risk group (median NR, 95% CI 708−NE; 15 events). The risk 
for recurrence of the high-risk patients was significantly increased compared to that of the low-
risk patients (HR 4.24, 95% CI 1.40−12.81; P=0.005) confirming the prognostic value of the 
five-miRNA-signature (Figures 1A, S2). miRNA-based risk group classification was not 
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associated with simultaneous chemotherapy treatment (Table 1), which was further supported 
after stratification to LMU-KKG patients treated by concurrent radiochemotherapy (n=49; HR 
3.85, 95% CI 1.09-13.58, P=0.024; Figure S3). 
Moreover, high-risk patients of both samples showed significantly reduced recurrence-free 
survival, overall survival and disease-specific survival rates (Figure 1B). We could also 
demonstrate an impact of both failure sites (locoregional and distant) on the risk stratification, 
while low- and high-risk patients did not differ in non-tumor related death (Figure S4). 
In order to assess whether the five-miRNA-signature was an independent prognosticator, 
associations of known clinicopathological factors with the miRNA-defined risk groups were 
tested. TNM T stage, ECE and tumor localization were associated with the miRNA risk groups 
(Table 1). In the subsequent univariate Cox proportional hazard analysis, TNM T stage and 
lymphovascular invasion (LVI) were significantly associated with freedom from recurrence in 
both samples, ECE was identified as a significant parameter in the DKTK-ROG sample only, 
whereas no differences between the three tumor localizations were observed (Table S2; Figures 
S5-S7). After adjustment for these parameters in multivariate Cox regression analysis, the five-
miRNA-signature retained its independent and exclusive prognostic role in both samples (training 
set: HR 5.55, 95% CI 2.09-14.79, P<0.001; validation set: HR 3.94, 95% CI 1.23-12.59, 
P=0.021; Table 2). 
We analyzed the sensitivity and specificity of the five-miRNA-signature in the prediction of 
different clinical endpoints in comparison to the clinical prognostic parameters TNM T stage, 
LVI and ECE. At 5 years follow-up, the five-miRNA-signature demonstrated a superior 
prediction of all endpoints analyzed (Figures 2A, S8). Furthermore, in time-dependent analysis 
(follow-up years 1 to 5), the five-miRNA-signature superiorly predicted all endpoints from 2 to 5 
years compared to the clinicopathological parameters. After one year follow-up, higher AUCs for 
the miRNA-signature compared with the analyzed endpoints were only observed in the training 
set for the endpoints disease-specific survival and overall survival (Figures 2B, S9, S10). After 
combining the five-miRNA-signature with the clinicopathological parameters (TNM T stage, 
LVI, ECE) an even better prediction of all endpoints from 2 to 5 years was achieved for both 
HNSCC samples, also when compared to combinations of the clinicopathological risk factors 
(Figures 2C, S11). This was also the case after one year follow-up in the DKTK-ROG sample. 
In order to obtain deeper insights into the biological regulatory function of the signature 
miRNAs, we generated a miRNA-mRNA target regulatory network comprising experimentally 
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validated miRNA-target interactions, whereby twelve target genes were found to be shared by the 
signature miRNAs (Table S3, Figure S12). Pathway enrichment analysis of the target genes 
revealed 36 pathways including p53, ATM, and FoxO signalling, DNA double-strand break 
response, pre-NOTCH expression and processing, mitosis and senescence associated pathways 
(Table S4). 
For technical validation of the five-miRNA-signature and potential clinical diagnostic 
application, we measured the expression of the signature miRNAs in the validation set (n=71) by 
qRT-PCR confirming the microarray-derived results as the miRNA-classified risk groups 
significantly differed in freedom of recurrence (HR 5.07, 95% CI 1.17−21.94, P=0.016; Figure 
S13) 
In a Kaplan-Meier analysis in which the samples were pooled (n=162) and stratified according to 
resection margin status, TNM T stage, TNM N stage, ECE and tumor localization the resulting 
five-miRNA-signature risk groups significantly differed in clinical outcome (Figures S14, S15). 
This motivated us to further combine the five-miRNA-signature with clinically relevant 
parameters. RPA identified four different risk groups for recurrence (“low-risk”, “low-
intermediate-risk”, “high-intermediate-risk” and “high-risk”) including the five-miRNA-signature 
as strongest parameter together with TNM T stage, ECE and TNM N stage (Figure 3 and 
extended Figure version S16). The worst prognostic group included miRNA-signature-high-risk 
patients with ECE-positive T3/T4 tumors (median freedom from recurrence 438 days), while 
miRNA-signature-low-risk patients with T1/T2 N0/N1 HNSCC had the best prognosis (no 
event). The four risk groups also significantly differed with regard to locoregional and distant 
control, recurrence-free survival, overall survival and disease-specific survival (Figures S17, 
S18). RPA considering only the clinical parameters identified three risk groups for recurrence 
with T stage as the strongest parameter together with ECE and N stage (Figure S19A). 
Combining the three RPA derived risk groups with the risk factor of our five-miRNA-signature 
revealed patient subgroups significantly differing in clinical outcome (“RPA intermediate-risk”: 
HR 2.71, 95% CI 1.21-6.06, P=0.012; “RPA high-risk”: HR 12.20, 95% CI 1.54-96.90, P=0.004; 
Figure S19B). 
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Discussion 
 
Here we report, for the first time a five-miRNA-signature in HPV-negative patients that predicts 
decreased cancer control following adjuvant radiochemotherapy. Freedom from recurrence was 
the chosen primary endpoint to better estimate treatment effects, as HNSCC patients often suffer 
from multiple comorbidities that affect overall survival (19). Overall, baseline and treatment 
characteristics of our patients were balanced and compare well to reports on HPV-negative 
HNSCC. Remarkably our identified five-miRNA-signature predicts survival as well. Of note: its 
prognostic significance is independent from known clinical parameters 
 
A potential limitation of the study is the fact that clinical data for both samples were obtained 
retrospectively. We thus cannot fully exclude certain selection bias. Heterogeneity due to 
inclusion of a multicenter HNSCC patient sample minimized and potentially excluded selection 
bias. In addition, the signature’s robustness and potential clinical applicability was underlined by 
identification in a multicenter sample and validation in an independent monocentric sample. Most 
other studies introducing prognostic miRNA-signatures (e.g. ovarian, nasopharyngeal and colon 
cancer) followed a comparable strategy (8,20,21). 
The fact that the DKTK-ROG sample exclusively included HNSCC patients treated by post-
operative radiochemotherapy, whereas the LMU-KKG sample comprised both adjuvant treatment 
groups – radiotherapy with simultaneous chemotherapy and radiotherapy alone – might be seen 
as another limitation of our study. However, from our point of view, the independence of the 
five-miRNA-signature from the addition of simultaneous chemotherapy even strengthens the 
potential of our five-miRNA-signature. 
A further potential shortcoming of our study is that the final RPA was limited by small numbers 
of patients. In order to achieve the highest possible number of cases and the maximum statistical 
power, we pooled both HNSCC samples for this analysis (n=162). In all clinical endpoints a 
significant separation of risk groups defined by clinical risk factors combined with the five-
miRNA-signature was achieved. 
To substantiate our findings on patient stratification into risk groups, further validation of our 
five-miRNA-signature in independent retrospective and in particular prospective patient 
populations with fully annotated clinical data will be important future steps. 
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Previous studies have identified multiple deregulated miRNAs in HNSCC partly with prognostic 
relevance for patients (10-12,22-26). A meta-analysis revealed that in particular overexpression 
of miR-21, one of the most frequently studied cancer-related miRNAs, predicts poor prognosis in 
HNSCC (10). However, in general, the overlap of prognostic miRNAs across different HNSCC 
studies is small. This can be potentially explained by differences in demography, treatment 
parameters, composition of patient subgroups (e.g. subsite and HPV-status) as well as by 
methodological issues like the lack of independent validation, limitations due to small sample 
size, the analysis of different endpoints, the number of miRNAs screened and the non-availability 
of thorough clinical information including HPV-status (27). Our comprehensive miRNA profiling 
approach deliberately and exclusively focused on HPV-negative patients based on the fact that all 
current data indicate a completely distinct molecular pathogenesis of HPV-associated cancer, 
which, meanwhile, is regarded a distinct clinical entity (2,6). 
Nevertheless, in our study we were able to confirm previously reported prognostic miRNAs in 
HNSCC such as hsa-miR-21-3p, hsa-let-7g-3p, hsa-miR-210-5p and hsa-miR-210-3p (Figure 
S20) underlining the validity of our miRNA analysis (10,22,26,28,29). In addition, hsa-mir-210-
5p and hsa-let-7g-3p form part of our five-miRNA-signature. hsa-let-7g was shown to predict 
prognosis in oral cavity squamous cell carcinoma (29) and breast cancer patients (30) via 
inhibition of cell invasion and metastasis. Besides head and neck cancer (28), hsa-mir-210 was 
already reported as prognostic factor in breast cancer (31-34), soft-tissue sarcoma (35), 
osteosarcoma (36), pancreatic cancer (37), non-small cell lung cancer (38), renal cancer (39) and 
glioblastoma (40). Multiple functions of hsa-miR-210 are described including hypoxic response, 
regulation of mitochondrial metabolism, cell cycle, cell survival, differentiation DNA repair and 
immune response (41). To the best of our knowledge, the remaining three signature miRNAs 
(hsa-miR-6508-5p, hsa-miR-4306 and hsa-miR-7161-3p) have not yet been associated with 
HNSCC or cancer in general. 
miRNAs are integrative regulator molecules with a highly promiscuous nature thereby interfering 
with multiple pathways. Thus, it is not possible to deduce a definitive functional role of a given 
miRNA within a signaling network. Nevertheless, studying the miRNA-mRNA-target network 
our five-miRNA-signature suggests enrichment of specific signaling pathways: p53, ATM, FoxO 
signaling, and DNA double strand break response, pre-NOTCH expression and processing, as 
well as mitosis and senescence associated pathways. Several of the pathways and miRNA target 
genes were already shown to be relevant for the pathogenesis and radiation response of HNSCC 
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(5-7,42-47). Mutations of IGF1R and ARID1A and the involvement of CADM1 and SOD2 in 
HNSCC have been reported (6,43,46,47). 
Gene expression relates to prognosis of HNSCC (48) as does a seven-gene signature, recently 
also described in our patients (49); this signature, however, predicts freedom from recurrence 
independently from the above mentioned five-miRNA-signature (unpublished). Analogous to 
their prognostic independence the molecular impact of the Schmidt et al. seven-gene signature 
shows no obvious overlap with that of our five-miRNA-signature (49). However, to pin down 
mechanisms and pathogenic relevance of the five-miRNA-signature further studies are required. 
 
At present, treatment decisions for patients with HNSCC are guided predominantly by clinical 
findings. The only relevant biological marker with yet limited influence on treatment decisions is 
HPV-status (1). A key prerequisite for the potential clinical application of a molecular signature 
is a robust, fast and easy to perform laboratory assay. Our qRT-PCR validation of the high-
throughput omics data is a first step in this direction. 
The five-miRNA-signature’s potential is particularly exemplified by the fact that, when 
combined with the clinically relevant prognostic parameters TNM T stage, ECE and TNM N 
stage, it allowed the significant stratification of patients into four risk groups for recurrence. 
Strikingly, in this context, the five-miRNA-signature was the strongest factor for patient 
stratification. Furthermore, the integration of the molecular signature with clinical factors not 
only improved the prediction of outcome but also allowed a more detailed, clinically meaningful 
stratification of patients, which, in turn, could be used as a clinical patient stratification tool. 
Possible personalized treatment options include consideration of adjusting therapy intensity 
according to the overall risk for therapy failure. In particular patients with the highest risk of 
recurrence, for whom the standard treatment is not sufficient, might be candidates for more 
personalized treatment options such as the addition of targeted drugs or immune checkpoint 
inhibitors to radio(chemo)therapy, dose escalation or further (neo)adjuvant chemotherapy. On the 
other hand, for patients with the lowest risk of recurrence de-escalation strategies for the 
reduction of therapy-associated toxicity could be considered. Here dose de-escalation and the 
omission of chemotherapy would be options, as the long-term benefit from the addition of 
simultaneous chemotherapy to radiotherapy is not given for all patients (50). Further, the five-
miRNA-signature represents the basis for a more focused search for molecular therapeutic targets 
improving therapy success for appropriate patients. 
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In order to evaluate the predictive value of the five-miRNA-signature for the guidance of 
treatment decisions, prospective validation studies and clinical trials considering treatment 
stratification are required in future. 
In summary, the herein identified prognostic five-miRNA-signature independently predicts 
disease control and survival of HPV-negative patients. The target gene network of the signature 
miRNAs is well in line with known mechanisms driving HNSCC pathogenesis. In combination 
with established prognostic clinical parameters the ability of the signature to predict disease 
control and survival even improves and allows the definition of four prognostically distinct 
groups. These may provide an important step towards personalized HNSCC treatment.  
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 18 
Acknowledgements 
 
The study was supported by the DKTK-ROG and the Clinical Cooperation Group “Personalized 
Radiotherapy in Head and Neck Cancer”, Helmholtz Zentrum München. 
The authors want to thank L. Dajka, S. Heuer, C. Innerlohinger, U Buchholz, and C.-M. Pflüger 
for their excellent technical assistance, R. Caldwell for editorial assistance, all co-workers of the 
Clinical Cooperation Group “Personalized Radiotherapy in Head and Neck Cancer” for scientific 
support, and all members of the DKTK-ROG for their valuable contribution to the DKTK-ROG 
data set.  
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 19 
References 
 
1. O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, et al. 
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal 
cancer according to minimal risk of distant metastasis. J Clin Oncol 2013;31:543-50 
2. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development 
and validation of a staging system for HPV-related oropharyngeal cancer by the 
International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a 
multicentre cohort study. Lancet Oncol 2016;17:440-51 
3. Bossi P, Alfieri S. Investigational drugs for head and neck cancer. Expert Opin Investig 
Drugs 2016;25:797-810 
4. Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A, et al. 
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell 
Carcinoma of the Head and Neck. Front Oncol 2017;7:72 
5. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome 
sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in 
NOTCH1. Science 2011;333:1154-7 
6. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck 
squamous cell carcinomas. Nature 2015;517:576-82 
7. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The 
mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-
60 
8. Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, et al. 
Development and validation of a microRNA-based signature (MiROvaR) to predict early 
relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol 
2016;17:1137-46 
9. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and 
therapeutics. A comprehensive review. EMBO Mol Med 2012;4:143-59 
10. Jamali Z, Asl Aminabadi N, Attaran R, Pournagiazar F, Ghertasi Oskouei S, Ahmadpour 
F. MicroRNAs as prognostic molecular signatures in human head and neck squamous cell 
carcinoma: a systematic review and meta-analysis. Oral Oncol 2015;51:321-31 
11. Koshizuka K, Hanazawa T, Fukumoto I, Kikkawa N, Okamoto Y, Seki N. The 
microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell 
carcinoma. J Hum Genet 2017;62:3-13 
12. Sethi N, Wright A, Wood H, Rabbitts P. MicroRNAs and head and neck cancer: 
reviewing the first decade of research. Eur J Cancer 2014;50:2619-35 
13. Lohaus F, Linge A, Tinhofer I, Budach V, Gkika E, Stuschke M, et al. HPV16 DNA 
status is a strong prognosticator of loco-regional control after postoperative 
radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a 
multicentre explorative study of the German Cancer Consortium Radiation Oncology 
Group (DKTK-ROG). Radiother Oncol 2014;113:317-23 
14. Maihoefer C, Schüttrumpf L, Macht C, Pflugradt U, Hess J, Schneider L, et al. 
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and 
neck – clinical results from the cohort of the clinical cooperation group “Personalized 
Radiotherapy in Head and Neck Cancer”. Radiation Oncology 2018;13:123 
15. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation 
for Statistical Computing; 2016. 
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 20 
16. Cho H, Yu A, Kim S, Kang J, Hong S-M. Robust Likelihood-Based Survival Modeling 
with Microarray Data. 2009 2009;29:16 
17. Niyazi M, Pitea A, Mittelbronn M, Steinbach J, Sticht C, Zehentmayr F, et al. A 4-
miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget 2016 
18. Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The 
Reactome pathway Knowledgebase. Nucleic Acids Res 2016;44:D481-7 
19. Piccirillo JF, Vlahiotis A. Comorbidity in patients with cancer of the head and neck: 
prevalence and impact on treatment and prognosis. Curr Oncol Rep 2006;8:123-9 
20. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, et al. Prognostic and predictive 
value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. 
Lancet Oncol 2013;14:1295-306 
21. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, et al. Prognostic value of a microRNA 
signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 
2012;13:633-41 
22. Ganci F, Sacconi A, Manciocco V, Sperduti I, Battaglia P, Covello R, et al. MicroRNA 
expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head 
Neck 2016;38 Suppl 1:E189-97 
23. Gao G, Gay HA, Chernock RD, Zhang TR, Luo J, Thorstad WL, et al. A microRNA 
expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer 
2013;119:72-80 
24. Hess AK, Muer A, Mairinger FD, Weichert W, Stenzinger A, Hummel M, et al. MiR-
200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally 
advanced head and neck squamous cell carcinoma. Eur J Cancer 2017;77:3-12 
25. Shi H, Chen J, Li Y, Li G, Zhong R, Du D, et al. Identification of a six microRNA 
signature as a novel potential prognostic biomarker in patients with head and neck 
squamous cell carcinoma. Oncotarget 2016;7:21579-90 
26. Wong N, Khwaja SS, Baker CM, Gay HA, Thorstad WL, Daly MD, et al. Prognostic 
microRNA signatures derived from The Cancer Genome Atlas for head and neck 
squamous cell carcinomas. Cancer Med 2016;5:1619-28 
27. Shi X, Yi H, Ma S. Measures for the degree of overlap of gene signatures and applications 
to TCGA. Brief Bioinform 2015;16:735-44 
28. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, et al. hsa-mir-210 is a marker 
of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 
2010;116:2148-58 
29. Peng SC, Liao CT, Peng CH, Cheng AJ, Chen SJ, Huang CG, et al. MicroRNAs MiR-
218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell 
carcinoma. PLoS One 2014;9:e102403 
30. Qian P, Zuo Z, Wu Z, Meng X, Li G, Wu Z, et al. Pivotal role of reduced let-7g 
expression in breast cancer invasion and metastasis. Cancer Res 2011;71:6463-74 
31. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsa-miR-210 Is 
induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer 
Res 2008;14:1340-8 
32. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, et al. 
Global microRNA expression profiling identifies MiR-210 associated with tumor 
proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 
2011;6:e20980 
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 21 
33. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, et al. Breast cancer 
signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc 
Natl Acad Sci U S A 2012;109:3024-9 
34. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, et al. microRNA-
associated progression pathways and potential therapeutic targets identified by integrated 
mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011;71:5635-
45 
35. Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, et al. Expression of 
microRNA 210 associates with poor survival and age of tumor onset of soft-tissue 
sarcoma patients. Int J Cancer 2012;130:1230-5 
36. Cai H, Lin L, Cai H, Tang M, Wang Z. Prognostic evaluation of microRNA-210 
expression in pediatric osteosarcoma. Med Oncol 2013;30:499 
37. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated 
expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with 
poorer survival. Int J Cancer 2010;126:73-80 
38. Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, et al. Positive 
prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer 2014;83:272-8 
39. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, et al. miR-210 is 
a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and 
correlates with good prognosis. Br J Cancer 2013;108:1133-42 
40. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-326/miR-329 
and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of 
glioblastoma patients. J Transl Med 2013;11:10 
41. Qin Q, Furong W, Baosheng L. Multiple functions of hypoxia-regulated miR-210 in 
cancer. J Exp Clin Cancer Res 2014;33:50 
42. Hess J, Unger K, Orth M, Schotz U, Schuttrumpf L, Zangen V, et al. Genomic 
amplification of Fanconi anemia complementation group A (FancA) in head and neck 
squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical 
relevance. Cancer Lett 2017;386:87-99 
43. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation 
of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer 
Discov 2013;3:761-9 
44. Michna A, Schotz U, Selmansberger M, Zitzelsberger H, Lauber K, Unger K, et al. 
Transcriptomic analyses of the radiation response in head and neck squamous cell 
carcinoma subclones with different radiation sensitivity: time-course gene expression 
profiles and gene association networks. Radiat Oncol 2016;11:94 
45. Summerer I, Hess J, Pitea A, Unger K, Hieber L, Selmansberger M, et al. Integrative 
analysis of the microRNA-mRNA response to radiochemotherapy in primary head and 
neck squamous cell carcinoma cells. BMC Genomics 2015;16:654 
46. Vallath S, Sage EK, Kolluri KK, Lourenco SN, Teixeira VS, Chimalapati S, et al. 
CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity. Sci 
Rep 2016;6:24006 
47. Ye H, Wang A, Lee BS, Yu T, Sheng S, Peng T, et al. Proteomic based identification of 
manganese superoxide dismutase 2 (SOD2) as a metastasis marker for oral squamous cell 
carcinoma. Cancer Genomics Proteomics 2008;5:85-94 
48. Tonella L, Giannoccaro M, Alfieri S, Canevari S, De Cecco L. Gene Expression 
Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for 
Clinical Application? Curr Treat Options Oncol 2017;18:32 
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 22 
49. Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, et al. Development and 
Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by 
Postoperative Radio(chemo)therapy. Clin Cancer Res 2018 
50. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term 
follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation 
therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int 
J Radiat Oncol Biol Phys 2012;84:1198-205 
  
Research. 
on October 21, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 31, 2018; DOI: 10.1158/1078-0432.CCR-18-0776 
 23 
Tables 
Table 1: Clinical and pathological characteristics of HNSCC patients included in the DKTK-ROG 
and the LMU-KKG sample and stratified according to the five-miRNA-signature 
 Training set DKTK-ROG (n=85) Validation set LMU-KKG (n=77) 
 Number of all 
patients 
low-risk 
(n=43) 
high-risk 
(n=42) 
p-value* Number of all 
patients 
low-risk 
(n=38) 
high-risk 
(n=39) 
p-value* 
Age (years)    0.77    0.86 
<45 7 (8%) 2 (5%) 5 (12%)  3 (4%) 1 (3%) 2 (5%)  
45-54 26 (31%) 13 (30%) 13 (31%)  17 (22%) 7 (18%) 10 (26%)  
55-64 35 (41%) 18 (42%) 17 (40%)  28 (36%) 15 (39%) 13 (33%)  
65-74 17 (20%) 10 (23%) 7 (17%)  26 (34%) 13 (34%) 13 (33%)  
>75 0 0 0  3 (4%) 2 (5%) 1 (3%)  
Sex    1.0     1.0 
Male 67 (79%) 34 (79%) 33 (79%)  52 (68%) 26 (68%) 26 (67%)  
Female 18 (21%) 9 (21%) 9 (21%)  25 (32%) 12 (32%) 13 (33%)  
Tumor Localization     0.12     0.022 
Hypopharynx 13 (15%) 9 (21%) 4 (10%)  15 (19%) 4 (11%) 11 (28%)  
Oral cavity 32 (38%) 12 (28%) 20 (48%)  27 (35%) 11 (29%) 16 (41%)  
Oropharynx 40 (47%) 22 (51%) 18 (43%)  35 (45%) 23 (61%) 12 (31%)  
UICC TNM Stage    0.56     0.79 
I 0 0 0  2 (3%) 1 (3%) 1 (3%)  
II 3 (4%) 2 (5%) 1 (2%)  6 (8%) 4 (11%) 2 (5%)  
III 13 (15%) 5 (12%) 8 (19%)  23 (30%) 12 (32%) 11 (28%)  
IV 69 (81%) 36 (84%) 33 (79%)  46 (60%) 21 (55%) 25 (64%)  
T stage    0.33     0.042 
T1 12 (14%) 9 (21%) 3 (7%)  17 (22%) 9 (24%) 8 (21%)  
T2 35 (41%) 17 (40%) 18 (43%)  29 (38%) 18 (47%) 11 (28%)  
T3 22 (26%) 10 (23%) 12 (29%)  21 (27%) 10 (26%) 11 (28%)  
T4 16 (19%) 7 (16%) 9 (21%)  10 (13%) 1 (3%) 9 (23%)  
N stage    0.14     0.41 
N0 10 (12%) 5 (12%) 5 (12%)  19 (25%) 8 (21%) 11 (28%)  
N1 10 (12%) 2 (5%) 8 (19%)  20 (26%) 10 (26%) 10 (26%)  
N2 57 (67%) 33 (77%) 24 (57%)  36 (47%) 20 (53%) 16 (41%)  
N3 8 (9%) 3 (7%) 5 (12%)  2 (3%) 0 2 (5%)  
Lymphovascular invasion (LVI)   0.46     1.0 
0 42 (49%) 25 (58%) 17 (40%)  50 (65%) 26 (68%) 24 (62%)  
1 27 (32%) 13 (30%) 14 (33%)  17 (22%) 9 (24%) 8 (21%)  
Missing information 16 (19%) 5 (12%) 11 (26%)  10 (13%) 3 (8%) 7 (18%)  
Venous tumor invasion (VTI)   1.0     1.0 
0 62 (73%) 33 (77%) 29 (69%)  66 (86%) 34 (89%) 32 (82%)  
1 7 (8%) 4 (9%) 3 (7%)  3 (4%) 2 (5%) 1 (3%)  
Missing information 16 (19%) 6 (14%) 10 (24%)  8 (10%) 0 6 (15%)  
Perineural invasion (PNI)    1.0     0.55 
0 0 0 0  37 (48%) 19 (50%) 18 (46%)  
1 0 0 0  15 (19%) 6 (16%) 9 (23%)  
Missing information 85 (100%) 43 (100%) 42 (100%)  25 (32%) 13 (34%) 12 (31%)  
Resection margin status    0.52     0.49 
0 45 (53%) 21 (49%) 24 (57%)  57 (74%) 28 (74%) 29 (74%)  
1 40 (47%) 22 (51%) 18 (43%)  17 (22%) 7 (18%) 10 (26%)  
2 0 0 0  1 (1%) 1 (3%) 0  
Missing information 0 0 0  2 (3%) 2 (5%) 0  
Extracapsular extension (ECE)   0.007     0.38 
yes 41 (48%) 14 (33%) 27 (64%)  25 (32%) 11 (29%) 14 (36%)  
no 34 (40%) 24 (56%) 10 (24%)  32 (42%) 19 (50%) 13 (33%)  
not applicable (N0) 10 (12%) 5 (12%) 5 (12%)  19 (25%) 8 (21%) 11 (28%)  
Missing information 0 0 0  1 (1%) 0 1 (3%)  
Grading    0.56     0.29 
1 (well differentiated) 3 (4%) 2 (5%) 1 (2%)  2 (3%) 2 (5%) 0  
2 (moderately differentiated) 50 (59%) 23 (53%) 27 (64%)  34 (44%) 15 (39%) 19 (49%)  
3 (poorly differentiated) 32 (38%) 18 (42%) 14 (33%)  41 (53%) 21 (55%) 20 (51%)  
ECOG performance status    0.64    0.20 
0 18 (21%) 8 (19%) 10 (24%)  13 (17%) 4 (11%) 9 (23%)  
1 33 (39%) 17 (40%) 16 (38%)  40 (52%) 21 (55%) 19 (49%)  
2 6 (7%) 4 (9%) 2 (5%)  5 (6%) 1 (3%) 4 (10%)  
Missing information 28 (33%) 14 (33%) 14 (33%)  19 (25%) 12 (32%) 7 (18%)  
Smoking status    0.18     0.68 
Non-smoker 5 (6%) 4 (9%) 1 (2%)  6 (8%) 2 (5%) 4 (10%)  
Smoker 52 (61%) 23 (53%) 29 (69%)  52 (68%) 25 (66%) 27 (69%)  
Missing information 28 (33%) 16 (37%) 12 (29%)  19 (25%) 11 (29%) 8 (21%)  
Smoking history – pack-years    0.20    0.67 
≤10 (including non-smokers) 7 (8%) 5 (12%) 2 (5%)  6 (8%) 2 (5%) 4 (10%)  
>10 23 (27%) 9 (21%) 14 (33%)  48 (62%) 25 (66%) 23 (59%)  
Missing information 55 (65%) 29 (67%) 26 (62%)  23 (30%) 11 (29%) 12 (31%)  
Simultaneous Chemotherapy    1.0     0.16 
Yes 85 (100%) 43 (100%) 42 (100%)  49 (64%) 21 (55%) 28 (72%)  
No 0 0 0  28 (36%) 17 (45%) 11 (28%)  
Data are numbers (%). *Chi-square test or Fisher’s exact test.  
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Table 2: Multivariate Cox regression analysis of the five-miRNA-signature and clinicopathological 
parameters with freedom from recurrence (training and validation set) 
 
 Training set DKTK-ROG Validation set LMU-KKG 
Parameter HR (95% CI) p-value HR (95% CI) p-value 
Five-miRNA-signature (high-risk vs low-risk) 5.55 (2.09-14.79) <0.001 3.94 (1.23-12.59) 0.021 
TNM T stage (T3/T4 vs T1/T2) 2.19 (0.96-5.02) 0.064 2.71 (0.99-7.44) 0.052 
Lymphovascular invasion (yes vs no) 2.22 (0.99-4.97) 0.053 2.50 (0.84-7.45) 0.099 
Extracapsular extension (yes vs no*) 1.45 (0.61-3.48) 0.40 2.29 (0.77-6.78) 0.13 
 
*N0 tumors were included in the group of extracapsular extension negative tumors 
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Figure Legends 
 
Figure 1: Freedom from recurrence stratified by risk according to the five-miRNA-
signature: miRNA expression and Kaplan-Meier curves in the DKTK-ROG (training set) 
and the LMU-KKG (validation set) sample 
(A) Upper panel: Heat map colors indicate scaled miRNA log2 expression values multiplied by 
the Cox proportional hazard coefficients (coxph) from low (blue) to high (red) on a scale from -3 
to 3 for each of the five signature miRNAs in the DKTK-ROG (left panel) and the LMU-KKG 
sample (right panel). Lower panel: Kaplan-Meier curves for the endpoint freedom from 
recurrence for HNSCC patients of the training (DKTK-ROG sample; left panel) and validation 
set (LMU-KKG sample; right panel) stratified into low- and high-risk patients according to the 
five-miRNA-signature. P-values are derived by log-rank test. (B) Kaplan-Meier curves for 
recurrence-free survival (upper panel), overall survival (middle panel) and disease-specific 
survival (lower panel) in patients of the training (DKTK-ROG sample; left) and validation set 
(LMU-KKG sample; right) stratified according to their risk (low- and high-risk group) by the 
five-miRNA-signature. 
 
Figure 2: Performance of the prediction of freedom from recurrence comparing the five-
miRNA-signature with clinicopathological risk factors 
(A) Sensitivity and specificity derived areas under the curve (AUCs) for the prediction of 
freedom from recurrence in the DKTK-ROG (training set; left panel) and the LMU-KKG sample 
(validation set; right panel) at five follow-up years. The AUCs and the 95% CI of the five-
miRNA-signature derived risk factor (black dashed curve), TNM T stage, lymphovascular 
invasion (LVI) and extracapsular extension (ECE) are shown. 
Time-dependent sensitivity and specificity derived AUCs for the prediction of freedom from 
recurrence in the DKTK-ROG t (left panel) and the LMU-KKG sample (right panel) at follow-up 
years 1-5: (B) AUCs of the five-miRNA-signature derived risk factor (black dashed curve), TNM 
T stage, LVI and ECE. (C) AUCs for the five-miRNA-signature derived risk factor alone (black 
dashed curve), the five-miRNA-signature combined with TNM T stage, LVI and ECE (purple 
and greenish curves) and combinations of the clinicopathological risk factors TNM T stage, LVI 
and ECE (bluish curves). 
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Figure 3: Risk groups for recurrence identified by recursive partitioning analysis (RPA) 
RPA tree and risk groups for recurrence combining the parameters five-miRNA-signature (high-
risk, low-risk), ECE (negative - including N0 tumors, positive), T stage (T1/T2, T3/T4) and N 
stage (N0/N1, N2/N3) in the pooled HNSCC data set (n=162). Each node shows the predicted 
probability of recurrence (locoregional or distant failure; color code low to high: blue-red), the 
number of events for the total number of patients and the percentage of observations in the node. 
Kaplan-Meier curves for the endpoint freedom from recurrence for the four identified risk groups 
“low-risk”, “low-intermediate-risk”, “high-intermediate-risk” and “high-risk”. Multivariate and 
pairwise comparisons are shown. P-values are derived by log-rank test. See extended Figure 
version Supplementary Figure S16. 
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ABSTRACT
Multimodal therapy of glioblastoma (GBM) reveals inter-individual variability 
in terms of treatment outcome. Here, we examined whether a miRNA signature 
can be defined for the a priori identification of patients with particularly poor 
prognosis.
FFPE sections from 36 GBM patients along with overall survival follow-up were 
collected retrospectively and subjected to miRNA signature identification from 
microarray data. A risk score based on the expression of the signature miRNAs and 
cox-proportional hazard coefficients was calculated for each patient followed by 
validation in a matched GBM subset of TCGA. Genes potentially regulated by the 
signature miRNAs were identified by a correlation approach followed by pathway 
analysis.
A prognostic 4-miRNA signature, independent of MGMT promoter methylation, 
age, and sex, was identified and a risk score was assigned to each patient that 
allowed defining two groups significantly differing in prognosis (p-value: 0.0001, 
median survival: 10.6 months and 15.1 months, hazard ratio = 3.8). The signature 
was technically validated by qRT-PCR and independently validated in an age- and 
sex-matched subset of standard-of-care treated patients of the TCGA GBM cohort 
(n=58). Pathway analysis suggested tumorigenesis-associated processes such as 
immune response, extracellular matrix organization, axon guidance, signalling by 
NGF, GPCR and Wnt. Here, we describe the identification and independent validation 
of a 4-miRNA signature that allows stratification of GBM patients into different 
prognostic groups in combination with one defined threshold and set of coefficients 
that could be utilized as diagnostic tool to identify GBM patients for improved and/
or alternative treatment approaches.
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INTRODUCTION
Malignant gliomas account for approximately 70% 
of primary brain tumors diagnosed in adults. Median age 
at diagnosis is 64 years with men being more frequently 
affected than women [1].
Amongst all gliomas, glioblastoma (GBM) is the 
most common and aggressive form [2]. State-of-the-
art treatment of GBM comprises surgical resection and 
adjuvant radiochemotherapy followed by maintenance 
chemotherapy. Implementation of temozolomide (TMZ) 
into the radiochemotherapeutic regime improved 2-year 
survival rates of patients with newly diagnosed malignant 
glioma (mainly GBM) from 11% to 27%, 3-year survival 
rates from 4% to 16%, and 5-year survival rates from 2% 
to 10% [3]. Unfortunately several phase III trials employing 
targeted agents such as bevacizumab (AVAglio & RTOG 
0825) or cilengitide failed to show an improvement in 
overall survival [4, 5]. Thus, TMZ-based radiochemotherapy 
remains standard treatment for GBM. However, prognosis 
of most GBM patients still remains dismal with a high rate 
of local recurrence, emphasizing the clear need for further 
optimization [6]. At present, several strategies are being 
followed in this regard: Firstly, more elaborate imaging 
techniques as well as improved image-guidance during 
radiotherapy are being tested [7, 8]. Secondly, various 
molecularly designed substances are undergoing pre-
clinical and clinical testing for their therapeutic efficacy 
in combination with radio(chemo)therapy [9, 10]. These 
targeted treatment approaches require molecular stratification 
of patients in order to identify the subgroups that can benefit 
most from a given strategy. Classical radiochemotherapy 
also displays wide inter-individual differences in terms of 
response and survival rates [11]. Accordingly, numerous 
efforts are undertaken in order to characterize the molecular 
mechanisms orchestrating therapy sensitivity and resistance 
and to identify prognostic and predictive markers.
So far, only few prognostic factors have been defined 
for GBM, including age and Eastern Cooperative Oncology 
Group (ECOG) score. In addition, involvement of the 
subventricular zone and extent of resection are known to be of 
prognostic importance [12]. More recently, the first molecular 
markers have been established. In this regard, methylation 
of the O6-methylguanine DNA-methyltransferase (MGMT) 
promoter region was recognized to be of positive predictive 
value for the efficacy of TMZ-based radiochemotherapy, 
and molecular profiling of long-term survivors disclosed 
the positive prognostic value of a proneural-like expression 
pattern linked to mutations in the genes encoding for iso-
citrate dehydrogenases 1/2 (IDH1/2) [13].
During the last years, microRNAs (miRNAs) have 
increasingly received attention. With a high degree of 
promiscuity miRNAs target and regulate several mRNA 
species encoding for proteins involved in various signaling 
pathways [14]. Accumulating evidence indicates that miRNA 
expression signatures can serve as biomarkers for diagnosis 
and risk assessment of diverse malignancies, including GBM 
[15–20]. Given that the available prognostic markers can 
segregate GBM patients only to a limited extent, additional 
markers and/or signatures have to be defined. We focused on 
miRNA profiles, because the characterization of epigenetic 
alterations in the field of GBM research has hitherto been 
underrepresented and miRNA expression is well accessible 
from clinical routine diagnostic tissue specimen such as 
formalin-fixed paraffin-embedded (FFPE) tissue sections [21].
We sought to delineate a miRNA expression signature 
that is of predictive/prognostic value for overall survival 
in a retrospective cohort of 36 primary GBM patients who 
underwent adjuvant radiochemotherapy. Applying an iterative 
forward selection approach on miRNA microarray expression 
data, we identified a distinct signature comprising 4 miRNAs 
that was technically confirmed by quantitative real-time 
PCR (qRT-PCR) and independently validated in an age- 
and sex-matched data subset of a cohort of GBM patients 
who received standard-of-care treatment, obtained from The 
Cancer Genome Atlas (https://tcga-data.nci.nih.gov) project 
[22, 23, 3, 24]. Multivariate analysis revealed this signature 
to be independent of the MGMT promoter methylation status 
and of any other prognostic parameters that were available 
for our dataset.
RESULTS
Characterization of the patient cohort: survival 
data and univariate analysis
The MGMT promoter methylation status had no 
statistically significant influence on overall survival 
(p-value=0.763), although in Kaplan-Meier analysis a 
trend towards better survival could be observed in MGMT 
methylated patients. (Supplementary Figure S1) We also 
did not find statistically significant associations of overall 
survival with age (p-value=0.053) and sex (p-value=0.222).
Extraction of a low complexity miRNA signature 
and evaluation of its prognostic significance for 
overall survival
We analyzed miRNA expression profiles in FFPE 
samples of our patient cohort and extracted a signature 
that consisted of the four miRNAs hsa-let-7a-5p, hsa-let-
7b-5p, hsa-miR-125a-5p and hsa-miR-615-5p which was 
statistically significantly associated with overall survival 
(p-value=0.0048). The median risk score calculated from 
the expression levels of the signature miRNAs and the 
corresponding cox-proportional hazard coefficients (Table 
1) separated the patients into a high- and a low-risk group. 
Cox regression analysis of the high- and the low-risk groups 
revealed a 3.79 fold increased risk of death (95% CI: 2.03-
12.85) for the high-risk group compared to the low-risk group 
(p-value=0.000112). The median survival time was 13.5 
months for patients of the high- risk group and 18.4 months 
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for patients of the low-risk group, respectively. These results 
were visualized by Kaplan-Meier overall survival curves 
(Figure 1B). Univariate testing of the individual miRNAs 
within the signature revealed p-values in the range between 
0.0015 and 0.016, indicating that each single miRNA was 
able to statistically significantly predict overall survival. 
Expressions of miRNAs hsa-let-7a-5p, hsa-let-7b-5p and 
hsa-miR-125a-5p positively correlated with overall survival 
and and that of hsa-miR-615-5p negatively correlated 
with overall survival. Figure 1A summarizes the survival 
data of the patients in relation to the calculated risk scores 
and expression levels. When including MGMT promoter 
methylation status in a multivariate cox-proportional hazard 
model, its contribution to the model was not statistically 
significant, thereby suggesting that the identified miRNA 
signature performs independently of the MGMT promoter 
methylation status. Moreover, the other available clinical 
parameters, such as sex and age were not associated with the 
calculated risk-score and also did not statistically significantly 
contribute to the multivariate model when included. A 
detailed representation of the results can be found in Table 1. 
Further, patients in the high-risk group were older compared 
to that in the low-risk group. Concerning distribution of sex 
there were no differences between the high- and the low-risk 
groups (Figure 1C).
Independent in silico validation of the detected 
miRNA signature
For the purpose of independent validation the miRNA 
signature was tested in an age-matched miRNA data subset 
of standard-of-care treated patients (see Supplementary 
Table 1: Results of multivariate cox-proportional hazard analysis of 4-miRNA risk score, age, sex and MGMT 
promoter methylation status
Cohort Model Hazard 
ratios of 
parameters
Confidence 
intervals of 
hazard ratios
p-values of contributions of 
parameters to model
p-value 
of 
model
Discovery
4-miRNA risk-score 3.8 1.47-9.75 0.00574 0.00434
MGMTmeth 0.9 0.39-2 0.7637 0.76298
4-miRNA risk-
score+MGMTmeth 3.8,0.9 1.48-9.81/0.38-1.93 0.00558,0.70124 0.0159
Sex 1.7 0.72-3.86 0.22874 0.22151
4-miRNA risk-score+Sex 3.6,1.3 1.36-9.32/0.57-3.16 0.00982,0.50574 0.01367
Age 1 1-1.07 0.05469 0.05267
4-miRNA risk-score+Age 3.5,1 1.35-9.12/0.99-1.07 0.00979,0.10002 0.00439
4-miRNA risk-
score+MGMTmeth+Sex+Age 3.3,0.9,1,1.4
1.23-8.62/0.38-
2.15/0.99-
1.07/0.59-3.44
0.01765,0.82414,
0.11408,0.43099 0.02158
Validation
4-miRNA risk-score 2.4 1.03-5.69 0.04207 0.04247
MGMTmeth_1 0.5 0.18-1.27 0.13798 0.12236
MGMTmeth_2 0.5 0.21-1.32 0.16924 0.15812
4-miRNA risk-
score+MGMTmeth_1 3.1,0.4 1.24-7.73/0.12-1.01 0.0156,0.05204 0.01532
4-miRNA risk-
score+MGMTmeth_2 2.2,0.6 0.93-5.28/0.24-1.55 0.07096,0.29498 0.07214
Sex 1.5 0.57-3.8 0.41996 0.41121
4-miRNA risk-score+Sex 1 1.36-0.9-9.31-7.64 0.00947,0.07811 0.02402
Age 1 0.94-1.04 0.63117 0.63333
4-miRNA risk-score+Age 0 1.09-0.93-6.25-1.03 0.03098,0.37596 0.08763
4-miRNA risk-
score+MGMTmeth_1+Sex+Age 4.1,0.5,2.1,1
1.44-11.49/0.16-
1.79
0.008,0.30791, 
0.24802,0.37623 0.03941
4-miRNA risk-
score+MGMTmeth_2+Sex+Age 4.5,1,3,1
1.41-14.67/0.34-
3.09
0.01139,0.95454,
0.08428,0.22869 0.06184
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Table S1) of an independent GBM cohort downloaded from 
the TCGA database [25]. The high- and the low-risk groups 
were defined by using the median risk score of the discovery 
set (0.07811832) to dichotomize the patients of the validation 
set. The resulting cox-proportional hazard model revealed a 
hazard ratio of 2.11 (95% CI 1.13-3.91) and a p-value of 0.02 
(Figure 2C). Figure 2B summarizes the survival data of the 
patients of the validation cohort in relation to calculated risk 
scores and expression levels. Also for the validation cohort 
no statistically significant association was found between 
high- and low-risk groups and the parameters age and sex 
(Figure 2D). Univariate testing of the MGMT promoter 
methylation status derived from two DNA methylation array 
probes that have been shown previously to reliably measure 
MGMT promoter methylation status for association with 
overall survival was conducted. No statistically significant 
association was observed (cg12434587: p.value: 0.122/
hazard-ratio: 0.48, cg12981137: p-value: 0.16/hazard-ratio: 
0.48) although in Kaplan-Meier analysis a trend towards 
better survival in MGMT promoter methylation positive 
was also observable here (Supplementary Figure S2). No 
differences in the distribution of age and sex were observed 
in the high- and low-risk groups identified in the validation 
cohort. Also, including in the multivariate cox model 
MGMT promoter methylation status did not show statistical 
significant influence on survival (Table 1).
Figure 1: Extraction of a 4-miRNA signature as independent predictive marker for the overall survival of GBM 
patients in the exploratory cohort. A. Kaplan-Meier overall survival analyses of high-risk and low-risk GBM patients. High-risk 
and low-risk patients were stratified based on the risk factors calculated from the cox-proportional hazard coefficients and the miRNA 
expression levels as measured in the microarray (left panel, 35 patients) or by qRT-PCR analyses (right panel, 19 patients). Hazard ratios 
and p-values were calculated by log-rank test. B. Overall survival (top panel), hierarchical cluster heat map of miRNA array expression 
levels (middle panel), and risk factors calculated on the basis of miRNA expression values and cox-proportional hazard coefficients (bottom 
panel) for all patients. miRNAs hsa-let-7a-5p, hsa-let-7b-5p and hsa-miR-125a-5p in patients of the higher-risk group show a tendency 
towards lower expression and that of hsa-miR-615-5p a tendency towards higher expression. The median risk factor value was used to 
classify high-risk and low-risk patients. C. Distribution of age (left panel) and sex (right panel) in high-risk and low-risk GBM patients. 
Statistical comparison was performed by Student’s t-test or Fisher’s exact test. The patients of the lower-risk group were statistically 
significantly older compared with that of the lower-risk group. The differences in the numbers of male and female patients of the lower- and 
higher-risk groups were not statistically significant.
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Technical validation of signature by qRT-PCR
In order to technically validate the 4-miRNA 
signature and to support potential applicability 
in clinical routine diagnostics, we measured the 
expression of the four miRNAs in a subset of samples 
(n=23), for which residual material was available by 
qRT-PCR. Analogous cox-proportional hazard analysis 
with the qRT-PCR data confirmed the results obtained 
with the miRNA array data. Patients of the high-risk 
group revealed significantly impaired overall survival 
(p-value=0.043) and a hazard-ratio of 3.21 (95% CI 
1.02-10.16) as compared to patients of the low-risk 
group. (Figure 1A).
miRNA-mRNA correlation and pathway 
enrichment analysis
For hsa-let-7b-5p we identified 104 significantly 
correlating genes (53 negative and 51 positive 
correlations), for hsa-miR-125a-5p 112 genes (35 
negative and 77 positive correlations), for hsa-miR-615-
5p 26 genes (10 negative and 16 positive correlations) 
and for hsa-let-7a-5p 412 genes (245 negative and 
167 positive correlations). The overlap between genes 
correlating with expression of the signature miRNAs 
was sparse (Supplementary Figure S1). Heatmaps of 
the top 25 miRNA-mRNA correlations with regard to 
absolute correlation coefficients are depicted in Figure 3. 
Figure 2: Evaluation of the prognostic value of the extracted 4-miRNA signature in an age- and sex-matched subgroup 
of standard-of-care treated patients of the TCGA GBM dataset. A. Age distribution in the exploratory cohort and the TCGA 
GBM cohort before and after age matching. B. Overall survival (top panel), hierarchical cluster heat map of miRNA expression levels 
(middle panel), and risk factors for patients of the age- and sex-matched TCGA GBM cohort. The median risk factor value was used to 
classify high-risk and low-risk patients. miRNAs hsa-let-7a-5p, hsa-let-7b-5p and hsa-miR-125a-5p in patients of the higher-risk group 
show a slight tendency towards lower expression and that of hsa-miR-615-5p a slight tendency towards higher expression. C. Kaplan-
Meier overall survival analyses of high-risk and low-risk standard-of-care treated patients of the age- and sex-matched TCGA GBM cohort. 
Classification of high-risk and low-risk patients was performed on the basis of the risk factors calculated from the cox-proportional hazard 
coefficients (Table 2) and the miRNA expression levels. Hazard ratios and p-values were calculated by log-rank test. D. Distribution of age 
(left panel) and sex (right panel) in high-risk and low-risk patients of the age- and sex-matched TCGA GBM cohort. Student’s t-test and 
Fisher’s exact test were employed for statistical comparison as depicted.
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Interestingly, whereas hsa-let-7b-5p, hsa-miR-125a-5p, 
and hsa-let-7a-5p displayed predominantly negative 
correlations among the top correlations as to be expected, 
hsa-miR-615-5p also showed positive correlations. All 
genes with significant correlations (Pearson correlation 
test, p-value < 0.01) were combined into one list of 
genes (n=654; Supplementary Table S2) and subjected 
to pathway enrichment analysis. In total, 28 statistically 
significant pathways were identified (Supplementary 
Table S3), and the top ten of these (i.e. Transmembrane 
transport of small molecules, Innate Immune System, 
Extracellular matrix organization, Axon guidance, 
Signalling by NGF, Developmental Biology, Neuronal 
System, GPCR downstream signaling, Signaling by 
GPCR and Signaling by Wnt) were considered for 
interpretation of results.
DISCUSSION
GBM patients, who receive surgical resection and 
postoperative radio(chemo)therapy, reveal profound 
differences in terms of overall survival which motivated 
us to search for a miRNA signature that allows the 
identification of patients with specifically poor prognosis 
independently of any other outcome-associated 
parameters. Moreover, we intended to investigate such 
a signature with regard to the molecular mechanisms 
potentially underlying the poor outcome of GBM patients.
Figure 3: Heatmaps of the gene expressions correlating with the 4 miRNAs hsa-let-7b-5p, hsa-miR-125a-5p, hsa-miR-
615-5p and hsa-let-7a-5p the age- and sex-matched TCGA GBM cohort of standard-of-care treated patients. Genes 
whose expression levels statistically significantly correlated (p < 0.01) with the respective miRNA expression levels are shown. Every 
column represents an individual patient. Data are ordered from left to right by increasing miRNA expression.
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To this end, we performed miRNA microarray 
analysis followed by low-complexity miRNA signature 
identification. We could extract a 4-miRNA signature 
which, with high statistical significance, allowed 
differentiating between high- and low-risk GBM patients 
independently of the MGMT methylation status. Technical 
validation by qRT-PCR confirmed the microarray data 
results. Most importantly, the prognostic value of the 
signature could be confirmed by independent validation in 
a large subset of the TCGA study on GBM [25].
At present, the role of individual miRNAs in GBM 
is poorly understood. miRNAs are small non-coding 
regulatory RNAs that reduce stability and/or inhibit 
translation of target mRNAs with full or partial sequence-
complementarity [14]. In this sense, they are important 
post-transcriptional regulators and play essential roles in 
the pathogenesis, development, and progression of cancer 
as well as in the response to therapy [26–28].
It has been shown that GBMs display distinct 
miRNA expression signatures, and several studies have 
linked these miRNA alterations to hallmarks of GBM, 
including proliferation, survival, invasion, angiogenesis, 
and stem cell-like behavior [29]. Moreover, resistance to 
TMZ might be associated with miRNA deregulation [30]. 
In this regard, Ciafre et al. studied the expression of 245 
microRNAs in GBM in comparison to normal brain tissue 
using a microarray technique [31] in comparison to normal 
brain tissue. This approach enabled the identification of 
miRNAs whose expression levels were significantly 
altered in tumor tissue compared to peripheral brain 
tissue of the same patient, including miR-221, which was 
strongly up-regulated in GBM, and a set of brain-enriched 
miRNAs (miR-128, miR-181a, miR-181b, and miR-181c), 
which were down-regulated in GBM [32]. Very recently, 
a number of prognostic miRNA signatures have been 
reported for GBM [33–35, 15, 36, 37, 18–20, 38, 39]. We 
compared these signatures with our signature in terms of 
complexity, independent validation, and the approach used 
for identification of the signature. One important feature 
of molecular signatures is their level of complexity (i.e. 
the number of miRNAs), which should be most optimal 
with regard to prediction performance but at the same time 
should not overfit the data. For data sets with moderate 
dimensionality such as miRNA microarray data sets 
with typically a few hundreds of miRNAs expressed, the 
number of features contained in a signature should be 
of low complexity and in the range of smaller than 10. 
From the above cited studies, only five extracted a miRNA 
signature with low complexity that have been subsequently 
validated in an independent cohort [15, 37, 18–20]. Cheng 
et al. [15] focused on MGMT promoter methylation 
positive tumors only and defined a 5-miRNA signature 
that was validated in an appropriate subset of the so-called 
Chinese Glioma Genome Atlas. In contrast, our signature 
was developed using data from both MGMT promoter 
methylation-positive and -negative tumors. The signatures 
described by Li et al. were developed for each of the five 
molecular GBM subtypes as defined by transcriptomic 
profiling of TCGA GBM cases [37, 40]. Only the signature 
for the ‘mesenchymal‘ subtype consisting of five miRNAs 
was independently validated in a set of GBM tissues [37]. 
Our signature, in contrast, is not limited to this molecular 
subtype only. The small-noncoding RNAs described in 
Manterola et al. [18] allow molecular diagnosis of GBM 
using blood serum samples but the authors did not show 
usability with regard to outcome prediction whilst our 
signature was particularly developed for the purpose 
of predicting survival outcome. In a study by Shou et 
al. [20] three miRNAs were presented that statistically 
significantly allow differentiation into groups of patients 
with favorable and unfavorable prognosis. However, this 
approach was limited to separate and univariate analysis 
for each of the three miRNAs and the study did not include 
an independent validation of the results. The report by 
Sana et al. is most comparable to our study and introduced 
a 6-miRNA-signature which was also validated in the 
TCGA GBM data set [19]. However, contrary to our study 
Sana et al. used different thresholds for the calculated 
risk scores of the discovery and the validation set. Most 
importantly, the thresholds were chosen in such a way that 
they statistically significantly separated the two resulting 
groups of patients [19]. This can be interpreted as a 
technical drawback, and the approach has to be considered 
as a biased one. In strong contrast, we applied the same 
cox-proportional hazard coefficients and the same risk 
score thresholds to all of our three datasets (discovery 
Febit microarray, discovery qRT-PCR and validation 
Agilent microarray). This renders our 4-miRNA-signature, 
in principle, applicable to any other data set regardless of 
the platform the data were generated with.
Comparing our signature with that of the above 
mentioned studies did show no overlapping miRNAs 
of our signature with of the published ones. This can be 
explained by the fact that signature identification is very 
much dependent on the methodology used, the dataset 
with regard to the specific selection criteria of patients 
and the platform that is used for measurements. Since all 
mentioned studies vary with regard to these parameters 
one could not expect overlap of our signature with the 
published ones or overlap between the published ones.
 Besides its prognostic value, it is of major interest 
to understand the impact of the 4-miRNA-signature 
on the biological characteristics of GBM. Our panel of 
miRNAs consists of hsa-let-7a-5p, hsa-let-7b-5p, hsa-
miR-125a-5p and hsa-miR-615-5p. Two miRNAs of 
the signature belong to the let-7 family, which is very 
well known for its tumor suppressor function in various 
cancer entities [41]. The two let-7 miRNAs hsa-let-7a-
5p and hsa-let-7b-5p showed a tendency towards higher 
expression levels in the low-risk compared to the high-
risk group of patients, which is in line with the concept 
of their involvement in tumor suppression. miR-125a-
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5p was described as a tumor suppressor in GBM only 
recently. It is engaged in the repression of target genes 
of the TAZ (transcriptional co-activator with PDZ-
binding motif) transcription factor, including connective 
tissue growth factor (CTGF) and survivin [42]. Our 
analysis revealed a tendency towards higher miR-125a-
5p expression levels in the low-risk compared to the 
high-risk group of patients, again supporting its role in 
tumor suppression. hsa-miR-615-5p was described to act 
as tumor suppressor in pancreatic ductal adenocarcinoma 
[17]. In our analyses, a clear tendency towards higher or 
lower expression levels of hsa-miR-615-5p in the low- and 
high-risk group of patients was not observable. Therefore, 
conclusions concerning its tumorsuppressive role in GBM 
cannot be drawn. Overall, our 4-miRNA-signature reflects 
trends of higher expression levels of tumor suppressive 
miRNAs in low-risk GBMs, supporting the notion that 
these GBMs exhibit a lower degree of malignancy due to 
operational tumor suppressive mechanisms. In order to 
gain insights into the putative functional role of the four 
signature miRNAs, we conducted miRNA-transcriptome 
correlation analyses and obtained 654 genes, whose 
expression levels were positively or negatively correlated 
with that of the miRNAs. We deliberately followed 
this approach to identify direct and indirect regulatory 
effects of the signature miRNAs on the transcriptome. 
An alternative approach would have been to utilize 
miRNA target prediction. This, however, relies strongly 
on the prediction algorithm and the database that are 
used, and databases providing information on in vitro 
validated miRNA targets are still limited with regard to 
the number of miRNAs they provide information on [43]. 
The genes that were identified in our correlation approach 
were subjected to pathway enrichment analyses, which 
disclosed the top ten pathways Transmembrane transport 
of small molecules, Innate Immune System, Extracellular 
matrix organization, Axon guidance, Signalling by 
NGF, Developmental Biology, Neuronal System, GPCR 
downstream signaling, Signaling by GPCR and Signaling 
by Wnt all of which very well known in the context of 
glioblastoma tumorigenesis. These results suggest that our 
4-miRNA signature regulates genes that are well known 
to be involved in the tumorigenesis, progression and 
migration of GBM and may potentially act as druggable 
targets in an alternative treatment approach.
CONCLUSIONS
In the present study, we extracted and validated a 
4-miRNA-signature, which allows to differentiate GBM 
patients undergoing surgical resection and subsequent 
radio(chemo)therapy with favorable and poor prognosis. 
This signature may serve as a potential new marker for 
patient stratification independent of the MGMT methylation 
status. It may furthermore pave the way for personalized 
treatment approaches based on measurements that are 
well feasible in GBM biopsies in the clinical routine. 
Patients with a high-risk score are likely not profiting from 
standard-of-care treatment and therefore the 4-miRNA 
signature could be used to identify patients who require 
therapy intensification. Compared to existing GBM 
miRNA signatures the herein presented signature is of lower 
complexity, was independently validated, and appears to be 
in principle applicable to any data set containing expression 
values of the four signature miRNAs regardless of the 
platform they were generated with.
MATERIALS AND METHODS
For a detailed description of Material and Methods 
sections ’Patient characteristics’, ’miRNA array analysis’, 
’Technical validation of the 4-miRNA signature by qRT-
PCR’ and ’miRNA-mRNA correlation and gene set 
enrichment analysis’ see Supplementary Data.
Patient characteristics
We examined FFPE tissue samples of a non-
selected, retrospective cohort of patients who were 
consecutively treated at the University hospital Frankfurt 
between 1/2009 and 12/2010. Ethics approval (4/09) 
was given by the ethics committee of the medical 
faculty of the Johann-Goethe University (Frankfurt am 
Main, Germany). Only patients who underwent surgical 
resection and post-operative radio(chemo)therapy were 
included into the analyses. Patients underwent resection 
and adjuvant radiotherapy, regularly combined with 
TMZ according to the EORTC/NCIC26981/22981-
NCIC CE3 protocol if no contraindications were 
present (for details see Table 2) [3, 24]. The median 
overall survival time of this patient cohort was 1.28 
years with a median follow-up of 1.99 years (95%-CI, 
634 - 816 days). MGMT promoter methylation status 
was available for all 36 cases (see Table 1). Karnofsky 
performance status (KPS) score and associated recursive 
partitioning analysis (RPA) class had not been collected 
systematically, and no data on the extent of resection 
was available. For independent validation, the miRNA 
expression dataset from an age- and sex-matched subset 
(n=58) of the TCGA GBM cohort (n=357) was used. The 
subset resulted after adjusting the distribution of age of 
Table 2: Cox-proportional hazard coefficients used in 
risk score calculation
miRNA coefficient
hsa-let-7b-5p -0.9669152
hsa-miR-125a-5p -0.2821517
hsa-miR-615-5p 0.3254795
hsa-let-7a-5p 0.5059587
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the whole TCGA GBM dataset to that of our discovery 
cohort (Table 3) and only selecting patients that were 
treated according to standard-of-care.
miRNA array analysis
miRNA analysis was carried out using the Geniom 
Biochip MPEA homo sapiens biochips containing 
1223 miRNA probes (CBC, Heidelberg, Germany). 
FFPE sample preparation, hybridization, washing 
and scanning of arrays was performed as described 
previously [44]. We applied ’winsorized mean’ scaling 
on normalized data with exclusion of 30% of the top 
and bottom values.
TCGA glioblastoma miRNA data set
The validation data set was constructed from 
miRNA microarray profiles of the matched subset of 
patients from the TCGA GBM cohort. Data were generated 
by the University of North Carolina Cancer Genomic 
Characterization Center (CGCC) using the Agilent 8x15K 
Human miRNA-specific microarray platform [22]. For 
the analysis level 3 data were used and in order to allow 
comparability of the data set with the discovery data set 
scaling with ’winsorized mean’ was applied as described 
above.
miRNA signature robust selection
In order to search for a miRNA signature in miRNA 
expression data set of the discovery cohort associated with 
patient survival, the R package rbsurv was used [45]. The 
forward-selection algorithm implemented in the package 
computed the partial likelihood of the Cox model for a 
sequential selection of miRNAs. The best performing 
model was chosen based on the Akaike Information 
Criterion (AIC), which allowed to determine the best 
trade-off between the complexity of a model and its 
goodness of fit.
Calculation of risk scores
The Cox model coefficients (Table 2) were 
multiplied with the scaled expression values of appropriate 
miRNAs and the products were summed up resulting in 
an individual risk score for each patient. The median risk 
score of all patients (0.07811832) was used as a cut-off for 
defining a high-risk (> median risk score) and a low-risk 
group (< median risk score). Subsequently, the log-rank 
test was used to test whether the differences in overall 
survival times between the resulting two groups were 
statistically significant (p-value threshold: 0.05). Further, 
Kaplan-Meier survival curves were plotted for the two 
groups and the hazard ratio was calculated. The influence 
Table 3: Clinical characteristics of discovery cohort
Characteristic Patients (N=36)
Sex
 Male 23 (63.9 %)
 Female 13 (36.1 %)
 Median Age [y] 59 (34-78)
Age Category
< 50 y 13 (36.1 %)
≥ 50 y 23 (63.9 %)
MGMT promoter methylation status
Methylated 18 (50.0 %)
Unmethylated 18 (50.0 %)
Secondary Malignisation
Yes 12 (33.3 %)
No 24 (66.7 %)
Concomitant Temozolomide
Yes 32 (88.9 %)
No 1 (2.8 %)
Unknown 3 (8.3 %)
Median adjuvant TMZ cycles 6 (0−20)
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of the available known risk factors age, sex, and MGMT 
promoter methylation status was assessed univariately and 
by inclusion into the multivariate cox-proportional hazard 
model.
Independent in silico validation of the 4-miRNA 
signature
For each of the 58 included TCGA GBM patients 
(Supplementary Table S1) we calculated a risk score by 
building the sum of the products of the expressions of the 
four miRNAs of the signature and the coxproportional 
hazard coefficients obtained from the initial dataset for 
each of the miRNAs (Table 2).
The patients were assigned to high- and low-risk 
groups by using the same threshold (0.07811832) that 
was defined for the discovery data set. The resulting two 
groups were tested for differential survival outcome using 
log-rank test.
Technical validation of the 4-miRNA signature 
by qRT-PCR
MiScript primer assays (QIAGEN, MD, USA) for 
the four miRNAs of the signature were used for relative 
quantification along with a reference assay for the small 
RNA SNORD61. The relative expression values in 
combination with the cox-proportional hazard coefficients 
were used to calculate a risk score for every patient. The 
patients were dichotomized into a low- and high-risk 
group using the risk score threshold from the discovery 
cohort (0.07811832) and the resulting two groups were 
tested for differences in overall survival using log-rank 
test of the resulting cox-proportinal hazard model.
miRNA-mRNA correlation and gene set 
enrichment analysis
In order to investigate the impact of the four signature 
miRNAs on the transcriptome level we downloaded the 
transcriptome data (level 3) of the cases matching the 
miRNAs data set (n=132) from the TCGA database and 
calculated correlations between the four signature miRNAs 
and expression levels of all genes. Genes that statistically 
significantly correlated with the signature miRNAs were 
subjected to pathway enrichment analysis.
MGMT promoter methylation typing
For the discovery cohort determination of MGMT 
promoter methylation was performed using both 
methylation-specific PCR and sequencing analysis as 
described previously [46, 47].
For the TCGA validation cohort no systematic 
assessment of the MGMT promoter methylation status was 
available. However, in order to determine methylation of 
the MGMT promoter we followed an approach published 
by Bady et al. from methylation array data [48]. The 
resulting MGMT promoter-positive and -negative groups 
were then subsequently tested for association with survival 
univariately and multivariately.
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A genomic copy number signature predicts radiation exposure
in post-Chernobyl breast cancer
Christina M. Wilke 1†, Herbert Braselmann1,2†, Julia Hess1,2, Sergiy V. Klymenko4, Vadim V. Chumak4,
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Breast cancer is the second leading cause of cancer death among women worldwide and besides life style, age and genetic
risk factors, exposure to ionizing radiation is known to increase the risk for breast cancer. Further, DNA copy number altera-
tions (CNAs), which can result from radiation-induced double-strand breaks, are frequently occurring in breast cancer cells. We
set out to identify a signature of CNAs discriminating breast cancers from radiation-exposed and non-exposed female patients.
We analyzed resected breast cancer tissues from 68 exposed female Chernobyl clean-up workers and evacuees and 68
matched non-exposed control patients for CNAs by array comparative genomic hybridization analysis (aCGH). Using a stepwise
forward–backward selection approach a non-complex CNA signature, that is, less than ten features, was identified in the train-
ing data set, which could be subsequently validated in the validation data set (p value<0.05). The signature consisted of
nine copy number regions located on chromosomal bands 7q11.22-11.23, 7q21.3, 16q24.3, 17q21.31, 20p11.23-11.21,
1p21.1, 2q35, 2q35, 6p22.2. The signature was independent of any clinical characteristics of the patients. In all, we identified
a CNA signature that has the potential to allow identification of radiation-associated breast cancer at the individual level.
Ionizing radiation is a known risk factor for the development
of breast cancer.1 An association with increased breast cancer
risk has been reported after exposure to ionizing radiation in
the course of medical treatment, after nuclear reactor acci-
dents or by the Japan atomic bombings.2,3 In particular, for
female breast cancer in Chernobyl clean-up workers, who
participated in recovery operation works in 1986–1987 after
the Chernobyl reactor accident, an almost doubled standard-
ized incidence ratio has been reported when compared to the
national sporadic breast cancer incidence.4,5 Furthermore an
increased breast cancer rate could also be detected among the
population of the most contaminated regions of Ukraine and
Belarus.6 So far only associations with genomic instability,
Her2 and c-myc amplification and higher histological grade
have been described for breast cancers that developed in
atomic bomb survivors in Japan.7,8 Results of breast cancers
that developed in women previously irradiated for Hodgkin
Lymphoma are conflicting with some studies suggesting a
Key words: copy number signature, Chernobyl, breast cancer, ionizing radiation
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higher rate of the basal-like subtype in irradiated women and
others showing a higher rate of Her2 amplification.9,10 How-
ever, no histological or molecular marker has been reported
so far that allows identification of radiation-associated breast
cancers after low-dose exposure. In this study, we aimed to
identify genomic copy number alterations that specifically
allow detection of radiation-associated breast cancers. CNAs
account for 85% of the variation in gene expression and
define key genetic events driving tumorigenesis.11,12 Knowl-
edge of radiation-exposure specific CNAs should therefore
also provide mechanistic insights into radiation-associated
breast carcinogenesis. Breast cancer is a heterogeneous dis-
ease with distinct biological features and clinical behaviour.13
Copy number and gene expression profiling of sporadic
breast cancer has led to the identification of different molecu-
lar subtypes (luminal, Her2, basal-like breast cancer).14
Hence, CNAs represent an important molecular layer in
breast cancer that also bears the potential providing prognos-
tic markers.15 The thyroid is another radiation-sensitive
organ and it has been shown that in papillary thyroid carci-
nomas that developed in patients who were exposed to ioniz-
ing radiation at young age, chromosomal band 7q11.22-11.23
was specifically amplified.16 In this study, a combined for-
ward–backward selection approach was applied on CNA data
in order to identify a CNA-signature with low complexity
that allows the identification of radiation-associated breast
cancers. The approach was applied to a whole genome array
CGH data set on breast cancers from a cohort of female
clean-up workers who were exposed to ionizing radiation
from the Chernobyl reactor accident and non-exposed con-
trols matched for residence, tumor type, age at diagnosis,
TNM classification and histological grading.
Material and Methods
Clinical samples and data
We analyzed formalin-fixed paraffin-embedded (FFPE) breast
cancer tissue samples from 68 female Ukrainian patients that
were exposed to ionizing radiation after the Chernobyl reac-
tor accident in 1986. For comparison, a matched set of 68
breast cancer samples from non-exposed patients from
Ukraine was investigated. The exposed and non-exposed
patients included in this study were matched for residence,
tumor type, age at diagnosis, TNM classification and histo-
logical grading. All tumors were diagnosed as invasive
carcinomas of no special type (NST) and were from female
patients younger than 60 years at the time of diagnosis. The
136 breast cancer cases were randomly split into a training
set (n5 68) and validation set (n5 68), while for each of the
sets half of the cases were exposed and the other half were
non-exposed controls. A genomic copy number signature was
developed from the training set data with subsequent perfor-
mance assessment in the validation set.
Out of the 34 patients from the training set, 27 were regis-
tered as clean-up workers, five patients as evacuees and two
patients were registered as both evacuee and clean-up worker.
Seven out of 68 patients of the training set received neoadju-
vant radiotherapy (1–3 days before surgery). The majority (29
out of 34) of patients from the validation set were registered
as clean-up workers. Three patients were registered as evacuees
and two were registered as both evacuee and clean-up worker.
Seven out of 68 patients of the validation set received neoadju-
vant radiotherapy (1–3 days before surgery). The absorbed
doses of the exposed breast cancer patients were reconstructed
by the RADRUE method, which was adapted specifically for
estimation of breast doses.17 The doses showed a large inter-
individual variability ranging from 0.06 to 582.96 mGy
(median 13.07 mGy) in the clean-up workers and from 5.72 to
36.68 mGy (median 18.40 mGy) in the evacuees.18
HER2 genomic copy number status was detected by fluo-
rescence in situ hybridization as published by Wilke et al.
Progesterone and estrogen receptors, C-kit, cytokeratin 5/6,
p53 and Ki67 antigen expression detection was performed by
immunohistochemical staining according to the previously
described protocol.19
An overview of the clinicopathologic characteristics of the
training and validation sets as well as information about age at
time of exposure, age at time of diagnosis and latency is
shown in Table 1. The patient’s individual data are listed in
Supporting Information, Tables S1 and S2. For testing associa-
tions of exposure status with clinical characteristics of the
patients such as estrogen-receptor status, progesterone-receptor
status, cytokeratin-expression status (positive/negative), C-kit-
expression status (positive/negative), Ki67-expression status
(positive/negative), Her2/neu-status, p53-mutation status,
BRCA1/2-mutation status, pT-status, pN-status and histologi-
cal grading, Fisher’s exact test was used. For testing associa-
tions of exposure status with the age at time of diagnosis,
t test was used. Significance was accepted for p values< 0.05.
What’s new?
Exposure to ionizing radiation during medical procedures or following nuclear accidents can increase breast cancer risk by
inducing DNA double-strand breaks that potentially lead to DNA copy number alterations. In this study, the authors identified
a genomic copy number signature associated with radiation exposure in breast cancers in women who were exposed to ioniz-
ing radiation as Chernobyl clean-up workers or accident evacuees. The signature, composed of nine genomic copy number
regions, enabled the calculation of a breast cancer radiation-exposure risk score, which was independent of clinical character-
istics. The findings cast light on a new approach to radiation-induced breast cancer detection.
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Table 1. Patient characteristics of the Chernobyl training and validation set
Training set Validation set
Characteristics Exposed Not exposed p value1 Exposed Not exposed p value1
Number of patients 34 34 34 34
Tumor type, no. (%) Invasive
carcinoma
of no
special type
34 (100) 34 (100) 11 34 (100) 34 (100) 11
Age at diagnosis,
median (years),
(range (years))
51.50
(37.58–59.67)
49.83
(34.67–59.25)
0.472 48.04
(35.33–59.17)
50.96
(35.58–58.50)
0.552
Age at exposure,
median (years),
(range (years))
33.92
(24.17–45.50)
NA 30.58
(18.50-42.58)
NA
Latency, median
(years), (range
(years))
18.83
(10.00–23.83)
NA 19.92 (9.00–29.58) NA
Estrogen-receptor
status, no. (%)
Positive 21 (62) 20 (59) 11 26 (76) 28 (82) 0.771
Negative 13 (38) 14 (41) 8 (24) 6 (18)
Progesterone-receptor
status, no. (%)
Positive 18 (53) 21 (62) 0.621 25 (74) 25 (74) 11
Negative 16 (47) 13 (38) 9 (26) 9 (26)
C-kit status, no. (%) Positive 4 (12) 2 (6) 0.671 4 (12) 5 (12) 11
Negative 30 (88) 32 (94) 30 (88) 29 (88)
Cytokeratin 5/6
status, no. (%)
Positive 6 (18) 3 (9) 0.481 6 (18) 4 (12) 0.731
Negative 28 (82) 31 (91) 28 (82) 30 (88)
P53 status, no. (%) Positive 18 (53) 14 (41) 0.471 13 (38) 20 (59) 0.151
Negative 16 (47) 20 (59) 21 (62) 14 (41)
Ki-67 status, no. (%) Positive 31 (91) 34 (100) 0.241 30 (88) 30 (88) 11
Negative 3 (9) 0 (0) 4 (12) 4 (12)
BRCA1/2 status,
no. (%)
Positive 4 (12) 4 (12) 11 0 (0) 1 (3) 11
Negative 30 (88) 29 (85) 34 (100) 33 (97)
Not evaluable 0 (0) 1 (3) 0 (0) 0 (0)
Her2 status, no. (%) Positive 4 (12) 7 (21) 0.521 4 (12) 2 (6) 0.431
Negative 27 (79) 27 (79) 29 (85) 32 (94)
Not evaluable 3 (9) 0 (0) 1 (3) 0 (0)
pT stage, no. (%) pT1 13 (38) 15 (44) 0.91 13 (38) 12 (35) 11
pT2 20 (59) 18 (53) 19 (56) 20 (59)
pT3 1 (3) 1 (3) 2 (6) 2 (6)
pN stage, no. (%) pN0 18 (53) 19 (56) 11 17 (50) 17 (50) 11
PN1 14 (41) 15 (44) 17 (50) 17 (50)
pN2 1 (3) 0 (0) 0 (0) 0 (0)
pNx 1 (3) 0 (0) 0 (0) 0 (0)
pM stage, no. (%) M0 34 (100) 34 (100) 11 34 (100) 34 (100) 11
Grade, no. (%) G1 1 (3) 1 (3) 11 3 (9) 3 (9) 11
G2 20 (59) 20 (59) 24 (71) 24 (71)
G3 13 (38) 13 (38) 7 (21) 7 (21)
1The p value was calculated by Fisher’s-exact test.
2The p value was calculated by t test.
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Genomic copy number analysis by array CGH
To characterize genomic copy number alterations in the
post-Chernobyl breast cancer cohorts, array CGH was per-
formed using high-resolution oligonucleotide-based SurePrint
G3 Human 60k CGH microarrays (AMADID 21924, Agilent
Technologies, USA). The workflow is described in the Sup-
porting Information, material and methods part.
Hierarchical cluster analysis of DNA copy number profiles
was performed using correlation distance and method
“Ward.” For testing associations of clusters with exposure
status, estrogen-receptor status, progesterone-receptor status,
cytokeratin-expression status, C-kit-expression status, Ki67-
expression status, Her2/neu-status, p53-mutation status,
BRCA1/2-mutation status, triple negative status, tumor size,
lymph-node status, histological grading, age at exposure,
Fisher’s exact test was used. ANOVA F-test was used for cal-
culating associations of clusters with age at diagnosis, age at
exposure and latency. Significance was accepted for p
values< 0.05.
Generation of CNA signature
To identify a genomic copy number signature that allows the
prediction of radiation exposure we followed a multivariate
logistic regression approach. Logistic regression models the
probabilities P of class membership for each patient (exposed
or non-exposed) directly according to the formula
P5 P(h)5 exp(h)/(11 exp(h)), where h5 ß01 ß1X11. . .
1ßnXn5 log(P/(12 P)) is the logit or logarithmic odds value,
with predictor variables Xi, coefficients ßi and n the number
of variables in the model. The calculated probability P serves
then as risk score for radiation exposure. Tumors with a pre-
diction probability P> 0.5 were classified as radiation associ-
ated. For more details, see James et al.20
Binary copy number alteration states of all altered copy
number regions have been used as variables whilst gains and
losses were treated separately. Thus, for every region gain/no
gain (0/1) and loss/no loss (0/1) were reported. Hence, for
each copy number region gain status and loss status were
treated as independent variables. For the purpose of model fit
and validation, the described training and validation sets
were used. Feature selection was performed by stepwise com-
bined forward–backward selection, using the functions glm
(for generalized linear modelling) and step for Akaike Infor-
mation Criterion (AIC) based selection of the best models
from the R package stats.21 The algorithm of function step
computes the likelihoods of each model fit for a sequential
selection of features, whilst the best performing model was
determined using AIC for the sake of the best trade-off
between bias and variance of the model.20 The negative likeli-
hood, which is a positive value, decreases with increasing
number of features in the model. AIC simply adds twice the
number of features to the negative likelihood, so that it
reaches a minimum, which determines the optimal number
of features. Only CNAs (gains or losses) that occurred at
least 5 times in the training set and with univariate p values
up to 0.25 between exposed and non-exposed tumors (Fish-
er’s exact test) were admitted for the selection algorithm. The
number 5 roughly reflects a standard deviation sqrt(5) (Pois-
son rule) corresponding to a CV< 50%, which makes calcu-
lations more stable. 0.25 is also used as a default entry value
for example in variable selection the SAS procedure PROC
PHREG. Subsequently, the afore-defined risk score, based on
the coefficients defined using the training set, was calculated
for every tumor in the validation set. Finally, a confusion
table was built for the comparison of the true and predicted
exposure states and a p value using one-tailed Fisher’s exact
test was determined.
Fisher’s exact test was also used to test the binary associa-
tions of the risk score with any clinical characteristics of the
patients such as estrogen-receptor status, progesterone-receptor
status, cytokeratin-expression status (positive/negative), C-kit-
expression status (positive/negative), Ki67-expression status
(positive/negative), Her2/neu-status, p53-mutation status,
BRCA1/2-mutation status and intrinsic subtypes. Significance
was accepted for p values< 0.05.
Quantitative PCR (qPCR)
For technical validation of the CNAs detected by aCGH, the
copy number status of genes representative for the copy
number regions included in the CNA-signature, was deter-
mined by genomic copy qPCR. The workflow of the genomic
copy number qPCR is described in the Supporting Informa-
tion, material and methods part.
The calculated copy number state was used as the basis
for further calculations in R. Values smaller than 1.5 were
considered as losses and values >2.5 were considered as
gains. The thresholds were taken from the CopyCaller soft-
ware. As reference assay Life Technologies recommend to use
a gene that is known to exist in two copies in a diploid
genome and is being unaffected in all of the experimental
samples. It was not possible to extract a gene showing no
CNA in the whole data set. From the most commonly used
reference genes, the RNaseP gene showed the lowest number
of CNAs over all experimental samples. Therefore, we
decided to use copy number reference assay for this gene as
reference. To make results comparable between qPCR and
aCGH, we also corrected the aCGH copy number states with
that of the appropriate locus covering the RNaseP gene. The
copy number state as determined by array CGH and qPCR
were summarized in a confusion table and subjected to Fish-
er’s exact test. p values <0.05 indicated confirmation of the
array CGH results by qPCR.
Dose–response analysis
Logistic-regression analysis was performed in order to test
for relation between radiation dose and the occurrence of sig-
nature CNAs. The workflow is described in the Supporting
Information, material and methods part.
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Results
This study aimed at the identification of radiation-associated
DNA copy number changes in a cohort of breast cancers
from post-Chernobyl clean-up workers and evacuees from
highly contaminated territories. For this purpose, copy num-
ber profiles of exposed and non-exposed control cases were
generated and a radiation-exposure CNA-signature was
established.
Hierarchical clusters reveal association with radiation
exposure
High-resolution aCGH profiles of 136 breast cancer samples
were generated in order to characterize genomic copy num-
ber patterns of radiation-associated breast cancer. Supporting
Information, Figure S1 shows all genomic copy number pro-
files after unsupervised hierarchical clustering with annotated
parameters exposure status, estrogen-receptor status,
progesterone-receptor status, cytokeratin-expression status,
C-kit-expression status, Ki67-expression status, Her2/neu-sta-
tus, p53-mutation status, BRCA1/2-mutation status, triple
negative status, tumor size, lymph-node status and histologi-
cal grading. The two main clusters C1 and C2 of the hierar-
chical cluster analysis consisted of 33 and 103 cases,
respectively, the subclusters of C2 consisted of 36 cases
(C2.1) and 67 cases (C2.2), respectively, and the sub-sub
clusters of C2.2 consisted of 22 cases (C2.2.1) and 45 cases
(C2.2.2), respectively. In general DNA losses and gains
occurred more frequently in cluster C1 compared to clusters
C2.1, C2.2.1 and C2.2.2. Furthermore, C2.2.1 in general
showed a lower number of aberrations compared to clusters
C1, C2.1 and C2.2.2. From all tested parameters exposure
status (p5 0.019), histological grading (p5 0.03), estrogen-
receptor status (p5 0.04), cytokeratin-expression status
(p5 0.04), Her2/neu-status (p5 0.01), BRCA1/2-mutation
status (p5 0.04), age at diagnosis (F-test, degrees of numera-
tor dn5 3, degrees of denominator dd5 132, p5 0.03) and
tumor size (p5 0.02) were differentially distributed across
C1, C2.1, C2.2.1 and C2.2.2 (Supporting Information, Table
S3). With regard to exposure status all clusters showed equal
distributions except cluster C2.1, which contained signifi-
cantly more non-exposed than exposed cases (26 out of 36,
72%). Further, no association of exposure status with age at
diagnosis or other clinical characteristics of the patients was
detected (Table 1). Large tumors (pT2 and pT3) were associ-
ated with clusters C1, C2.1 and C2.2.2 (76 out of 83, 92%).
Within clusters C2.2.1 and C2.2.2 significantly less G3
tumors (12 out of 40, 30%) were included. In addition aCGH
profiles from estrogen-receptor negative cases were underrep-
resented in clusters C2.2.1 and C2.2.2 (13 out of 41, 32%).
Cases with Her2/neu-status positive and Cytokeratin 5/6-
expression positive were associated with clusters C1, C2.1
and C2.2.2 (Cytokeratin 5/6-expression positive: 19 out of 19,
100%, Her2/neu-status positive 17 out of 17, 100%). Cases
with a BRCA1/2-mutation were enriched in cluster C2.1 (6
out of 9, 67%).
Moreover, patients of cluster C2.1 were significantly youn-
ger at age of diagnosis (mean: 47.08 years) compared to cases
of cluster C1 (mean: 50.79 years), cluster C2.2.1 (mean: 51.66
years) and cluster C2.2.2 (mean: 50.04 years).
Identification of a nine-genomic CNA-signature predicting
radiation exposure
In the first step, univariate testing was used as a preselection
step for selection of highly discriminating copy number
changes. Admitted for the selection algorithm were only
gains or losses that occurred at least five times in the training
set and that showed univariate p values <0.25 (see Material
and Methods and Supporting Information, Table S4). This
resulted in 144 out of 910 CNA regions. In a next step, the
most discriminating features (i.e., CNA regions) were selected
by stepwise combined forward and backward selection and
the optimal number of features was determined by Akaike
Information Criterion (AIC, see Material and Methods) to
avoid overfitting. This approach revealed a CNA-signature
composed of nine altered genomic copy number regions
located on chromosomal bands 7q11.22–11.23 (7:70899666–
72726548), 7q21.3 (7:97597612–97749420), 16q24.3 (16:894
72538–90111178), 17q21.31 (17:44210733–44231916), 20p11.
23–11.21 (20:20226791–24223097), 1p21.1 (1:105300245–10
5546898), 2q35 (2:220499593–220503940), 2q35 (2:219083470
–220474362), 6p22.2 (6:26033303–26234636) in the Cherno-
byl training set. The parameter values of the features are
shown in Table 2. Further, as explained in Material and
Methods, the model, defined by the calculated parameters,
was evaluated in the validation set. For every tumor, the
probability P was calculated as a risk score according to the
model formula. The score values P appeared to be strongly
clustered. 22 values were <1.0 3 1027, 11 times 0.833, 33
times >(1–1027) and two values 0.355 and 0.667. After
rounding to a few decimal digits, 5 uniquely different values
remained. Tumors were then predicted as exposed if P> 0.5
or as non-exposed if P< 0.5. The results of the prediction
performance assessment of the CNA-signature on the valida-
tion set are shown in Figure 1. Of the 68 cases, 45 were pre-
dicted to be exposed and 23 non-exposed (predicted positive
and predicted negative, right and left side in the three panels
of Figure 1, respectively). From the lower panel in Figure 1
performance parameters can be read. The 45 positive pre-
dicted split into 27 true and 18 false positives, the 23 negative
predicted into 16 true and 7 false negatives. We found a sig-
nificant binary association of the risk score with radiation
exposure status, which means that among the positive pre-
dicted cases we found an enrichment of exposed cases
(PPV5 27/435 0.60, lower panel, right side) compared to
exposed cases on the left side (12NPV5 7/235 0.304, lower
panel, right side, one-tailed Fisher’s-exact test, p value5 0.0
2). Under the given conditions (34 exposed, 34 non-exposed),
this is equivalent to say that the true positive rate
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(sensitivity5 27/345 0.794) is higher than false positive rate
(12 specificity5 18/345 0.529). The overall prediction error
is 0.368. The foregoing analysis could be done with any other
cutoff level of the probability score, yielding for each cutoff a
pair of specificity and sensitivity values. These are shown in
the ROC curve, Figure 2. Due to the discrete distribution of
the rounded scores, the ROC contains only 4 points. One of
these points, corresponding to a level of about P5 0.70
(between scores to avoid boundary ambiguities) shows a
slightly better specificity (0.50) and prediction error (0.353),
PPV5 0.614. However, this is in good agreement with the
level of P5 0.50 which corresponds to the smallest expected
prediction error bases on theoretical probabilistic consider-
ations. The AUC (area under the curve) amounted to 0.617.
Technical validation of the nine-CNA-signature by qPCR
The copy number status of the nine signature CNAs, which
was initially determined by array CGH, was technically vali-
dated by qPCR (p< 0.05) (Table 2 and Supporting Informa-
tion, Figure S2). For this purpose, aliquots of the same
genomic DNA samples that were used in array CGH analysis
were analyzed by qPCR. All nine representative genes/regions
from the copy number regions of the CNA-signature showed
similar copy number changes compared to array CGH, con-
firming the initial finding (p< 0.05).
Association of the nine-CNA-signature with clinical and
histological data
The risk score derived from the CNA-signature (7q11.22–
11.23, 7q21.3, 16q24.3, 17q21.31, 20p11.23–11.21, 1p21.1,
2q35, 2q35, 6p22.2) was not associated with any clinical char-
acteristics of the patients such as estrogen-receptor status,
progesterone-receptor status, cytokeratin-expression status
(positive/negative), C-kit-expression status (positive/negative),
Ki67-expression status (positive/negative), Her2/neu-status,
p53-mutation status, BRCA1/2-mutation status and intrinsic
subtypes in the Chernobyl training or the Chernobyl valida-
tion set. This suggests an independent association of the dis-
covered nine-CNA-signature with radiation exposure of
patients.
Dose–response analysis
No statistically significant association of the occurrence of
each of the nine signature CNAs with reconstructed radiation
dose was detected. Moreover, no significant influence of
radiation-dose on the occurrence of each of the nine signa-
ture CNAs could be found in logistic-regression analysis.
Discussion
In this study, we identified a genomic copy number signature
that predicts radiation exposure in post-Chernobyl breast
cancer. Previous studies reported that even at low doses, ion-
ising radiation alters gene expression as a result of induced
CNAs and thus is capable of driving the process of carcino-
genesis.22 In young patients who were exposed to radiation atTa
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very young age, copy number gain of the chromosomal band
7q11.22–11.23 has been identified as a marker of radiation
exposure in papillary thyroid carcinomas.16 As for thyroid
cancer, ionizing radiation is also known to be a risk factor
for the development of breast cancer; however, radiation-
specific markers in these tumors are yet undiscovered.1,4–6
Initial studies on gene alterations in breast cancers from the
Atomic bomb survivors in Japan revealed a higher frequency
of Her2 and c-myc oncogene amplifications as well as a
higher histological grading in these radiation-associated
tumors.7,8 However, we did not detect an association of Her2
and c-myc amplification and high histological grade with
breast cancer of patients from the exposed group in our
study (Table 1). This could be due to the fact that patients in
our study were exposed to different radiation conditions
compared to those the Atomic bomb survivors were exposed
to. Clean-up workers of the Chernobyl accident were exposed
to more heterogenous conditions in contrast to the rather
homogenous conditions the Atomic bomb survivors were
exposed to. In addition, women in our study were younger at
time of diagnosis (under 60 years old). Furthermore, exposed
and non-exposed samples were matched for histological grad-
ing in the present study. For the identification of radiation-
specific copy number changes, we used an exploratory
approach on whole genome profiling of genomic copy num-
ber alterations of resected breast cancer tissues from exposed
and matched non-exposed patients.
So far, CNAs are very well described in sporadic breast
cancer while frequently observed CNAs include gain of chro-
mosomal bands 1q, 3q, 4p, 8q, 11q, 17q and 20q and losses
of chromosomal bands 1p, 8p, 11p, 13q, 16q, 17p, 19p and
22q.15,23–25
Figure 1. Heatmap of the 9-CNA-signature of 68 breast cancer patients of the validation set composed of 34 exposed and 34 non-exposed
cases. Copy number gains are represented by green color, losses by red color (top panel). The middle panel shows the risk score on the
probability scale calculated according to the formular described in Material and Methods. Samples (columns) are sorted in ascending order
of the risk score. Cases with probabilities 0.5 are predicted as exposed, otherwise as non-exposed (middle panel, right and left side,
respectively). Given exposure status is shown in the lower panel, thus on the right orange cases mark true positives, blue cases mark false
positives. On the left side orange cases mark false negatives, blue cases mark true negatives.
Figure 2. ROC curve calculated by applying a logistic regression
model fitted on the training set and evaluated on the validation
set. Each point (circles) corresponds to a probability cutoff level
decreasing from left to right, given by the steps visualized in Figure
1. Points are connected by straight lines.
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All these CNAs are in good agreement with CNA-profiles
of this study, which substantiates the plausibility of our
results. Similar findings have been observed in breast cancers
associated with exposure to ionizing radiation in the course
of medical treatment.10 Other cytogenetic studies on breast
cancer have identified CNAs that are associated with clinical
parameters and overall survival.15,24–26 Of special interest is
an association of histological grading and estrogen-receptor
status with specific DNA copy number patterns derived from
primary breast cancers.24 These estrogen-receptor and histo-
logical grading specific patterns, such as gain of 1q and loss
of 16q which are associated with lower histological grading
and estrogen-positive tumors, could also be confirmed in our
study after unsupervised clustering of array-CGH profiles
(Supporting Information, Figure S1). Overall, unsupervised
hierarchical clustering separated the breast cancer CNA pro-
files into four main clusters that correlate with histological
grading, estrogen-receptor status, Her2/neu-status, BRCA1/2-
mutation status, cytokeratin-expression status, age at diagno-
sis and tumor size (Supporting Information, Figure S1 and
Table S3). In addition, the profiles of exposed and non-
exposed cases were differentially distributed between observed
clusters suggesting a radiation-exposure-specific signal within
the genomic copy number profiling data. However,
delineation of copy number alterations determining the clus-
tering is not trivial and might not result in radiation-
exposure specific copy number alterations since an influence
of the other cluster-associated parameters is likely. However,
these findings from the unsupervised cluster analysis moti-
vated us to develop a low-complex CNA-signature predicting
radiation exposure. From mRNA and miRNA expression
data, signatures have been already generated predicting clini-
cal outcome or estrogen-, progesteron-receptor-status and
Her2-status in sporadic breast cancer but there is no such
prediction rule at the genomic copy number level.27,28 Com-
pared to results from association testing, prediction models
come with the advantage that they provide both biological
mechanistic insights and, moreover, bare the potential of
being used as diagnostic or prognostic tools. In the context
of radiation-associated breast cancer a prediction rule could
allow identification of breast cancer tissues that developed
after exposure of patients to ionizing radiation. In order to
generate such a prediction rule we deployed stepwise com-
bined forward–backward selection in combination with mul-
tivariate logistic regression. Signature modeling approaches
using copy number alterations were applied earlier by Pro-
nold et al. and by Sung et al. who applied other statistical
approaches.29,30 Pronold et al. used nearest shrunken
Table 3. Cancer-related candidate genes and miRNAs located in the chromosomal regions of the nine-CNA-signature predicting radiation
exposure in breast cancer
Chromosomal
location Start of region1,2 End of region1,2
Cancer-related candidate genes
and miRNAs Type of aberration
7q21.3 97597612 97749420 OCM2, LMTK2 Gain
6p22.2 26033303 26234636 HIST1H1C, HIST1H1T, HIST1H1E,
HIST1H1D,
HIST1H2AB, HIST1H2AC,
HIST1H2AD,
HIST1H2BB, HIST1H2BC,
HIST1H2BD, HIST1H2BE,
HIST1H2BF, HIST1H2BG,
HIST1H4C, HIST1H4D, HIST1H4E
HFE
Loss
17q21.31 44210733 44231916 KANSL1 Gain
2q35 219083470 220474362 ARPC2, TMBIM1, GPBAR1, AAMP,
PNKD, SLC11A1, USP37, TTLL4
RQCD1, CYP27A1, WNT6,
WNT10A, IHH, NHEJ1, ATG9A,
PTPRN, STK36,
hsa-miR-26b-5p, hsa-miR-375
Loss
1p21.1 105300245 105546898 No tumor-related candidate gene Loss
16q24.3 89472538 90111178 ANKRD11, SPG7, RPL13, CPNE7,
DPEP1, CHMP1A, CDK10,
FANCA, MC1R, TUBB3, C16orf3
Gain
20p11.23-11.21 20226791 24223097 INSM1, RALGAPA2, PAX1, XRN2,
NKX2-2, FOXA2, SSTR4, CD93
Gain
7q11.22-11.23 70899666 72726548 CALN1, STAG3L3, SBDSP1 Gain
2q35 220499593 220503940 SLC4A3 Loss
1Number of clones determined by CGH regions start5 position of first, end5 position of last clone region identifier according to CGH regions.
2According to annotation GRCh37.
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centroids applied to sums of log2-ratios within common
copy number variation segments to predict human ancestry
of healthy individuals.29 Sung et al. applied a 1-norm support
vector machine (SVM) to binary copy number alteration data
for a binary classification of histological subtypes of endome-
trial cancer.30 In our study, logistic regression for a binary
classification of radiation exposure status was chosen for two
reasons: First, called copy number data should preferentially
represent raw or segmented log2-ratios because of the reduc-
tion of noise, interpretability and downstream analysis
according to Van Wieringen et al.31 Second, logistic regres-
sion allows to provide a risk score on the individual level
which is directly associated to the class probabilities.32 Our
approach resulted in a CNA-signature predicting radiation
exposure in breast cancer that is composed of nine genomic
copy number regions located on chromosomal bands
7q11.22–11.23, 7q21.3, 16q24.3, 17q21.31, 20p11.23–11.21,
1p21.1, 2q35, 2q35 and 6p22.2 (Figure 1 and Table 2). The
signature allowed calculating a breast cancer radiation expo-
sure risk score on the probability scale (Figure 1), which was
statistically not associated with any clinical characteristics.
This suggests the signature being an independent prognosti-
cator of radiation exposure of patients. At this point one lim-
itation factor is, that we do not have data on lifestyle factors
such as obesity (in postmenopausal women) and alcohol con-
sumption, which are known to increase the risk for develop-
ing a breast cancer.33 Therefore, we cannot address any
potential influence of these in our analysis. Moreover,
although having information on the smoking status of
patients, we considered working out potential influence of
smoking as not meaningful since most of the patients were
non-smokers.34
Furthermore, no dose–response or statistical association of
the occurrence of CNAs of the signature regions could be
detected. This might be due to another limitation, which is
that dose estimates by RADRUE were only available for a
subset of patients. In addition, an important fact is the uncer-
tainty of dose estimation. The intrinsic uncertainty is mostly
influenced by the uncertainty of dose rates. Another impor-
tant component is the ‘human factor uncertainty,’ which
includes intentional or unintentional mistakes of recollection
and description of the clean-up activities.35 In case of the
female clean-up workers included in this study, this factor is
less pronounced due to the relative simplicity of individual
histories and their operation away from highly heterogeneous
dose rate fields. Furthermore, a small proportion of patients
received very small irradiation doses (0.06 mGy) according to
the RADRUE dose estimation. Although it is possible that
such low doses have no biological effects the samples were
not excluded since we aimed at the identification of a robust
CNA signature for which we preferred a heterogeneous data
set over a homogeneous one. A further limitation point of
this study is, that some of the patients received neoadjuvant
radiotherapy one to three days prior surgery. However, it is
unlikely that over this short period clonal expansion of cells
harboring the same CNAs occurs. Therefore, we would not
expect detectable CNAs that developed in the course of the
neoadjuvant radiotherapy treatment.
However, like many statistical methods, the application of
the signature as a classifier has its own limitations. The best
performance values calculated on the validation set were a
sensitivity of about 80% (0.794) and an NPV (negative pre-
dictive value) of 70% (0.70, given a prevalence of 0.50, that
is, 34 exposed and 34 non-exposed). The PPV (positive pre-
dictive value) was 61.7% (0.617). Often, in diagnostic prac-
tice, one tries to improve the PPV by increasing the cutoff
level of the risk score at the cost of sensitivity. This assumes
a continuous relationship between the score and the PPV.
Using the highest discriminating probability cutoff level in
the data (P  0.9) yields a PPV of 19/335 0.576 (Figure 1).
Modeled probabilities higher than 0.9 were clustered close to
1.0. They correspond to linear score values h larger than 20.0
up to 300.0. From a post hoc logistic regression of exposure
status (lower panel in Figure 1) with the linear score values h
as independent variable, a smoothed estimate of the PPV
could be achieved, approaching values up to 0.74; however,
this continuous dependency was not significant (results not
shown). Fisher’s exact test showed a significant binary associ-
ation between exposure status and the risk score, using a
probability of 0.5 as decision cutoff. The optimal cutoff (0.7)
determined by ROC analysis (Figure 2) appeared to be
slightly better (one case different); however, from Bayesian
decision theoretic considerations 0.5 is the cutoff with the
smallest expected prediction error. A continuous association
between a risk score given by a signature of CNA and expo-
sure status can also not be expected, because CNA are binary
features. This is one reason for the discrete appearing proba-
bility scores (middle panel in Figure 1 and ROC curve Figure
2). Many of the signature patterns (heatmap, Figure 1) have
frequency 1 and one cannot interpolate between different
combinations of CNA. On the other hand, dosimetric uncer-
tainties may add to the noise seen in the lower panel of
Figure 1. Also and most importantly, it cannot be expected
to predict a complex biological process such as tumorigenesis
with only one parameter such as the signature risk score. The
ability to partly explain the variance of tumorigenesis with a
prediction model is scientifically important.
To get insights into the potential functional impact of the
nine-CNA-signature we extracted all tumor-associated genes
and miRNAs that are mapped to the signature regions (Table
3 and Supporting Information, Table S5). Interestingly, one
region of the CNA-signature overlaps largely with the chro-
mosomal band 7q11.22–11.23 which was gained in the
majority of patients that have been classified as exposed.
7q11.22–11.23 has been reported to be exclusively gained in
papillary thyroid carcinomas of patients who were exposed to
ionizing radiation at very young age in aftermath of the
Chernobyl reactor accident.16 This finding suggests that gain
of the chromosomal band 7q11.22–11.23 could be a radiation
marker of low doses of ionizing radiation, independent of the
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tumor type. Another region of the signature, which is located
on chromosomal band 16q24.3 and overexpression of the
gene FANCA, which is located in this region, predicts
reduced clinical outcome of radiotherapy-treated patients
with head and neck squamous cell carcinoma (HNSCC).36,37
FANCA is a key regulator of the Fanconi anemia (FA)/breast
cancer (BRCA) pathway and controls homology-directed
DNA repair.38 Besides FANCA, many of the genes located
within the copy number regions of the signature are known
to be involved in DNA-damage response and repair (Sup-
porting Information, Table S5). A very prominent gene in
this context is the non-homologous end-joining factor 1 gene
(NHEJ1), which is located on chromosomal band 2q35.
NHEJ1 is required for the non-homologous end-joining path-
way of DNA repair.39 In addition, members of the Histone
H1, H2A, H2b and H4 family, all of which located in the
region of the CNA-signature that covers chromosomal band
6p22.2, were also known to be involved in these processes.40
These findings point to chromosomal instability as a major
consequence of deregulated DNA repair processes, which is a
well-known feature of cells exposed to ionizing radiation.41
Interestingly, copy number loss of the signature region on
2q35 contains miRNA hsa-miRNA-26b-5p, which recently
was published as a breast cancer radiation marker.19 Hsa-
miRNA-26b-5p expression was significantly reduced in cases
showing the loss, indicating, that its expression is mainly
determined by the copy number of the underlying miRNA
gene (Supporting Information, Figure S3).
In summary, our study presents a novel approach to pre-
dict the radiation exposure status of breast cancer patients
using a genomic copy number signature composed of nine
genomic copy number regions. The identified CNA-signature
may allow the detection of radiation-induced breast cancers
and could serve as a diagnostic marker for radiation exposure
in breast cancer. In further studies, an integration of copy
number data with transcriptome data would be desirable to
in-depth investigate if radiation-induced breast cancers repre-
sent a potential new molecular subtype.
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Expression of miRNA-26b-5p and its target TRPS1 is associated
with radiation exposure in post-Chernobyl breast cancer
Christina M. Wilke 1, Julia Hess1,2, Sergiy V. Klymenko4, Vadim V. Chumak4, Liubov M. Zakhartseva5,
Elena V. Bakhanova4, Annette Feuchtinger6, Axel K. Walch6, Martin Selmansberger1, Herbert Braselmann1,2,
Ludmila Schneider1,2, Adriana Pitea1,7, Julia Steinhilber8, Falko Fend8, Hans C. B€osm€uller8, Horst Zitzelsberger1,2,3 and
Kristian Unger1,2
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Ionizing radiation is a well-recognized risk factor for the development of breast cancer. However, it is unknown whether
radiation-specific molecular oncogenic mechanisms exist. We investigated post-Chernobyl breast cancers from radiation-
exposed female clean-up workers and nonexposed controls for molecular changes. Radiation-associated alterations identified
in the discovery cohort (n538) were subsequently validated in a second cohort (n539). Increased expression of hsa-miR-
26b-5p was associated with radiation exposure in both of the cohorts. Moreover, downregulation of the TRPS1 protein, which
is a transcriptional target of hsa-miR-26b-5p, was associated with radiation exposure. As TRPS1 overexpression is common in
sporadic breast cancer, its observed downregulation in radiation-associated breast cancer warrants clarification of the specific
functional role of TRPS1 in the radiation context. For this purpose, the impact of TRPS1 on the transcriptome was character-
ized in two radiation-transformed breast cell culture models after siRNA-knockdown. Deregulated genes upon TRPS1 knock-
down were associated with DNA-repair, cell cycle, mitosis, cell migration, angiogenesis and EMT pathways. Furthermore, we
identified the interaction partners of TRPS1 from the transcriptomic correlation networks derived from gene expression data
on radiation-transformed breast cell culture models and sporadic breast cancer tissues provided by the TCGA database. The
genes correlating with TRPS1 in the radiation-transformed breast cell lines were primarily linked to DNA damage response and
chromosome segregation, while the transcriptional interaction partners in the sporadic breast cancers were mostly associated
with apoptosis. Thus, upregulation of hsa-miR-26b-5p and downregulation of TRPS1 in radiation-associated breast cancer tis-
sue samples suggests these molecules representing radiation markers in breast cancer.
Breast cancer is one of the most common cancers in women
worldwide. Besides risk factors such as age and lifestyle, it is
well-recognized that breast cancer risk increases with expo-
sure to ionizing radiation. Patients with preceding
radiotherapy for the treatment of Hodgkin lymphoma exhibit
an increased risk to develop breast cancer as a secondary
tumor. In the Japanese atomic bomb survivors cohort, a simi-
lar finding has been reported for women who were exposed
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fluoride; qRT-PCR: quantitative real-time reverse transcription polymerase chain reaction; SDS-PAGE: sodium dodecyl sulfate polyacryl-
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to ionizing radiation during adolescence.1 Also in the after-
math of the Chernobyl accident in 1986, a significant
increase of the breast carcinoma rate (standardized incidence
ratio 190.6%) in female clean-up workers was noticed in
comparison to sporadic breast cancer rates in Ukraine.2,3 To
date, despite this epidemiologic evidence, the knowledge
about radiation-specific mechanisms of breast carcinogenesis
after low-dose exposure is sparse.
In contrast to environmental exposures of patients from
this study, aberrant expressions of miRNAs after exposure to
therapeutic doses of ionizing radiation have already been
reported.4 miRNAs are 19–25 nucleotides long, noncoding,
highly conserved RNA molecules, that are known to play an
important role in the regulation of gene expression at the
post-transcriptional level. Numerous studies have shown a
deregulation of miRNAs in tumors, thereby demonstrating
that miRNAs are involved in the process of carcinogenesis
and act as oncogenes or as tumor suppressors.5 Breast
cancer-specific miRNA profiles have been observed for differ-
ent breast cancer subtypes, enabling a classification into dif-
ferent molecular subtypes.6 However, the role of miRNAs in
radiation-associated breast cancer has not been investigated
so far. Therefore, our study intended to investigate the
miRNA profiles of breast cancers from a cohort of female
clean-up workers who were exposed to ionizing radiation
from the Chernobyl reactor accident and nonexposed con-
trols matched for residence, tumor type, age at diagnosis,
TNM classification and grading. We explored if among miR-
NAs that are known to play a role in sporadic breast cancer
there are specifically radiation-associated ones. We discovered
that expression of hsa-miR-26b-5p was increased in
radiation-associated breast cancers compared to nonexposed
controls. Further, we showed that expression of one of the
hsa-miR-26b-5p target proteins TRPS1 was significantly
decreased in radiation-exposed cases. TRPS1 is a GATA-type
transcription factor and consists of nine zinc-finger domains,
including a single GATA-type DNA-binding domain. Either
mutation or deletion of this gene causes a disease called tri-
chorhinophalangeal syndrome. Previous studies have shown
that TRPS1 is expressed in several human malignant tumors
and implied an important function in tumor growth, cell
cycle, angiogenesis, apoptosis, cell proliferation, migration
and metastasis.7–13
In this study, we were able to identify for the first time
one miRNA and one of its target proteins to be significantly
associated with radiation-associated breast cancer.
Material and Methods
Patients tumor tissues and clinical data
Formalin-fixed paraffin-embedded (FFPE) breast cancer tis-
sue samples (n5 76) from 38 female Ukrainian patients that
were exposed to radiation after the Chernobyl reactor acci-
dent and a matched set of 38 breast cancer samples from
nonexposed patients from Ukraine were collected (discovery
set). The vast majority (34 out of 38) of patients have been
exposed as clean-up workers after the accident for which an
elevated breast cancer incidence has been reported.2,3 Four
patients were exposed as evacuees after the accident. The
mean age at time of exposure was 33 years (range 18–45
years), the mean age at time of diagnosis was 49 years (range
33–59 years), and the mean latency of tumors was 17 years.
None of the patients from the discovery set received neoadju-
vant radio(chemo)therapy (Table 1).
A validation cohort consisting of FFPE breast cancer tis-
sue samples, 39 from post-Chernobyl clean-up workers and
39 matched nonexposed Ukrainian control cases, was estab-
lished. The mean age at time of exposure was 33 years (range
23–48 years) and the mean age at diagnosis 51 years (range
35–59 years) and the mean latency was 18 years. Out of 78
patients of the validation cohort, 18 received a neoadjuvant
radio(chemo)therapy (Table 1).
The so-called RADRUE method, which was adapted specifi-
cally for estimation of breast doses, was used for reconstruction
of the absorbed doses of the exposed breast cancer patients.14
Information about the absorbed doses were only available for a
subset of the exposed breast cancer patients (n5 54). The
absorbed doses showed a large interindividual variability
between patients ranging from 0.06 to 929 mGy (median 8.53
mGy) in the clean-up workers and from 5.72 to 36.85 mGy
(median 18.68 mGy) in the evacuees (unpublished data).
In both cohorts, all patients were younger than 60 years at
the time of diagnosis. Exposed patients and nonexposed con-
trols for this case–case study were frequency matched for resi-
dence, tumor subtype, age at diagnosis, TNM-classification and
histological grading. The majority of tumors was diagnosed as
invasive carcinoma of no special type (NST; discovery cohort:
What’s new?
While ionizing radiation is an established risk factor for breast cancer, little is known about mechanisms of radiation-specific
breast carcinogenesis related to low-dose exposure. Here, investigation of molecular changes in breast cancers from female
post-Chernobyl clean-up workers exposed to radiation revealed two radiation-specific molecular markers: increased expression
of hsa-miR-26b-5p and downregulation of its target TRPS1. In human radiation-transformed breast cells, TRPS1 knockdown
was found to be associated with enrichment of DNA repair, cell cycle, mitosis, angiogenesis, migration and EMT pathways.
Further investigation of specific markers could facilitate the identification of radiation-induced breast cancer and potentially
provide a basis for individualized therapy.
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95%, validation cohort: 90%) and invasive lobular carcinoma
(ILC; discovery cohort: 2.5%, validation cohort: 8%). Two cases
were diagnosed as intracystic papillary breast carcinoma and
another two as breast carcinomas with medullary features.
Immunohistochemical staining for estrogen and progesterone
receptors, C-kit, Cytokeratin 5/6, TP53 and Ki67 antigen expres-
sion and HER2 gene status determination by fluorescence
in situ hybridization (FISH) is described in the Supporting
Information, Material and Methods part.
Information of all clinicopathologic characteristics of the
discovery and validation cohort is presented in Supporting
Information, Tables S1 and S2.
Total RNA including the small RNA fraction was isolated
using the Qiagen RNeasy FFPE Kit (Qiagen, Hilden, Germany).
Table 1. Patient characteristics of the Chernobyl discovery and validation cohort
Chernobyl Discovery Cohort Chernobyl Validation Cohort
Characteristics Exposed Not exposed p value1 Exposed Not exposed p value1
Number of patients 38 38 39 39
Tumor type, no. (%) invasive carcinoma
of no special type
36 (95) 36 (95) 1 35 (90) 35 (90) 1
lobular 1 (3) 1 (3) 3 (8) 3 (8)
intracystic 0 (0) 0 (0) 1 (3) 1 (3)
medullar 1 (3) 1 (3) 0 (0) 0 (0)
Estrogen-receptor status, no. (%) positive 24 (63) 24 (63) 1 28 (72) 30 (77) 0.8
negative 14 (37) 14 (37) 11 (28) 9 (23)
Progesteron-receptor status, no. (%) positive 22 (58) 26 (68) 0.48 26 (67) 29 (74) 0.62
negative 16 (42) 12 (32) 13 (33) 10 (26)
C-kit status, no. (%) positive 7 (18) 6 (16) 1 2 (5) 3 (8) 1
negative 31 (82) 32 (84) 37 (95) 36 (92)
Cytokeratin 5/6 status, no. (%) positive 7 (18) 7 (18) 1 6 (15) 1 (3) 0.11
negative 31 (82) 31 (82) 33 (85) 38 (97)
P53 status, no. (%) positive 13 (34) 15 (39) 0.81 24 (62) 22 (56) 0.82
negative 25 (66) 23 (61) 15 (38) 17 (44)
Ki-67 status, no. (%) positive 31 (82) 32 (84) 1 39 (100) 39 (100) 1
negative 7 (18) 6 (16) 0 (0) 0 (0)
BRCA1/2 status, no. (%) positive 2 (5) 3 (8) 0.67 4 (10) 3 (8) 1
negative 36 (95) 34 (89) 35 (90) 36 (92)
not eveluable 0 (0) 1 (3) 0 (0) 0 (0)
Her2 status, no. (%) positive 2 (5) 4 (11) 0.67 6 (15) 8 (21) 0.77
negative 36 (95) 34 (89) 29 (74) 31 (79)
not eveluable 0 (0) 0 (0) 4 (10) 0 (0)
pT stage, no. (%) pT1 21 (55) 20 (53) 0.88 11 (28) 12 (31) 0.85
pT2 14 (37) 16 (42) 27 (69) 25 (64)
pT3 3 (8) 2 (5) 1 (3) 2 (5)
pN stage, no. (%) pN0 24 (63) 24 (63) 1 16 (41) 17 (44) 1
PN1 13 (34) 14 (37) 18 (46) 19 (49)
pN2 1 (3) 0 (0) 3 (8) 3 (8)
pN3 0 (0) 0 (0) 1 (3) 0 (0)
pNx 0 (0) 0 (0) 1 (3) 0 (0)
pM stage, no. (%) M0 38 (100) 38 (100) 1 39 (100) 39 (100) 1
Grade, no. (%) G1 1 (3) 1 (3) 1 2 (5) 2 (5) 1
G2 24 (63) 24 (63) 26 (67) 26 (67)
G3 13 (34) 13 (34) 11 (28) 11 (28)
1The p values were calculated by Fisher’s-exact test.
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Small RNA (miRNA) integrity was analyzed by qRT-PCR of
the small noncoding RNA RNU24 using TaqMan chemistry
(Life technologies, Carlsbad, CA). Samples with Ct values <35
were considered suitable for analysis.
Fisher’s exact test was used to test associations of the expo-
sure status with any clinical characteristics of the patients such
as estrogen-receptor status, progesterone-receptor status,
cytokeratin-expression status (positive/negative), C-kit-
expression status (positive/negative), Ki67-expression status
(positive/negative), Her2/neu-status, p53-mutation status,
BRCA1/2-mutation status, pT-status, pN-status and grading.
Significance was accepted for p< 0.05.
Quantitative real-time RT-PCR (qRT-PCR)
Reverse transcription of miRNAs was performed using the
MicroRNA Reverse Transcription Kit and microRNA-specific
stem-loop primers according to the manufacturer’s protocol
(Life Technologies). TaqMan MicroRNA assays (Life Technol-
ogies) for the following miRNAs were used: hsa-miR-222-3p
(477982_mir), hsa-miR-221-3p (477981_mir), hsa-miR-372-3p
(478071_mir), hsa-miR-26b-5p (478418_mir), hsa-miR-302d-3p
(478237_mir), hsa-miR-124-3p (477879_mir), hsa-miR-1–3p
(477820_mir) and hsa-miR-99b-5p (478343_mir). For endoge-
nous normalization, the assays for RNU44 (001094) and
RNU48 (001006) were used. qRT-PCR reactions (20 ml) were
carried out in triplicates using the ViiA 7 Real Time PCR Sys-
tem in combination with the ViiA 7 Software v.1.2.2 following
the manufacturer’s protocol (Life Technologies). Relative
expressions were calculated using the DDCt method. The par-
tial differential test considering intertumor heterogeneity was
used to test for statistical significant differences of miRNA
expressions between exposed and nonexposed samples and
possible associations of miRNA expression with clinicopatho-
logical data.15
TRPS1 (Hs00232645_m1) TaqMan gene expression assay
(LifeTechnologies) was used to validate the TRPS1-
knockdown and to determine the TRPS1-knockdown efficacy
in B42-11 and B42-16 cells at gene expression level.
For technical validation of the gene expression microarray
data, qRT-PCR was performed for randomly selected genes
(n5 12) detected by gene expression microarray in B42-11
and B42-16 cells: ANXA1 (Hs00167549_m1), APRT
(Hs00975725_m1), BBC3 (Hs00248075_m1), BMP2 (Hs010
55564_m1), CLNS1A (Hs00818054_m1), DTL (Hs00978
565_m1), DUSP6 (Hs00169257_m1), F2R (Hs00169258_m1),
PLK2 (Hs01573405_g1), RFC5 (Hs00738859_m1), TRPS1
(Hs00232645_m1) and TUBB3 (Hs00801390_s1). For endog-
enous normalization, the assays for ACTB (Hs99999903_m1)
and B2M (Hs99999907_m1) were used. RNA was reverse
transcribed using the QuantiTect Reverse Transcription Kit
(Qiagen). qRT-PCR reactions (10 ml) and calculations of rela-
tive expressions were carried out as described above. For
technical validation of the gene expression microarray data,
Pearson correlation analyses of expression determined by
qRT-PCR with that determined by microarray were
performed. Validation was considered successful for correla-
tion coefficients >0.5 and p values <0.05.
Immunohistochemistry
The expression of the TRPS1 protein in both tumor cohorts
was measured by immunohistochemical staining (IHC) of
FFPE tumor sections with a primary antibody against
TRPS1 (Abcam: ab111439, Cambridge, UK). The antibody
was selected from Abcam with information about antibody
specificity and staining patterns.9 The primary antibody was
used in a dilution of 1:100 and Discovery-Universal (Roche,
Ventana, Tucson, AZ) as a secondary antibody. IHC stain-
ing was performed with the automated staining instrument
Discovery XT (Roche, Ventana) system using peroxidase-
DAB-(diaminobenzidine)-MAP chemistry (Roche, Ventana)
for signal detection. The stained tissue sections were fixed
in an ethanol series and coated by a coverslip. All stained
slides were scanned at 203 objective magnification using
the Leica SCN400 digital slide scanning system (Leica,
Houston, TX).
Digital image analysis
The evaluation of the immunohistochemical staining was per-
formed using the digital image analysis platform Definien-
sTissueStudio 3.5 (Definiens AG, Munich, Germany). For
this purpose, the digital slide images were imported into the
image analysis software. In the first step regions of interest,
that is tumor area, were manually defined. A specific rule set
was then created to detect and quantify the TRPS1-stained
nuclei within the annotated tissue areas. The quantified
parameters were the amount and the mean brown intensity
of TRPS1-positive nuclei per annotated tissue area. The aver-
aged TRPS1 staining intensities were tested for significant dif-
ferences between exposed and nonexposed samples and
possible associations of TRPS1 staining intensities with clini-
copathological data using partial differential testing, which
considers intertumor heterogeneity.15 p values <0.05 were
considered statistically significant.
B42-11 and B42-16 cell lines and spectral karyotyping
(SKY)
Human B42-11 and B42-16 radiation transformed breast cells
were grown in mammary epithelial growth medium (MEGM)
as published previously.16 The B42-11 and B42-16 cell lines
were authenticated by STR-typing and spectral karyotyping
(SKY). Metaphase chromosome spreads were prepared and
hybridized as described earlier.17 SKY image analysis was
performed with a SpectraCube system and SkyView imaging
software (Applied Spectral Imaging).
RNA interference
The B42-11 and B42-16 cells were seeded into six-well plates
and were transfected at 70–90% confluency in triplicates with
a nonsense scrambled control (Ambion, Carlsbad, CA; Nega-
tive control #1) or two specific siRNAs against TRPS1
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(Ambion, silencer select siRNA 1: ID: s14428 and siRNA 2:
ID: s14427). SiRNA transfections were performed using Lipo-
fectamine RNAiMAX (Life Technologies) according to the
manufacturer’s instructions. 7.5 ml lipofectamine and 3.75 ml
of TRPS1 siRNA were used per sample resulting in a siRNA
concentration of 75 pmol per well. After 24, 48, 72 and
96 hrs, cells were harvested for total RNA isolation using the
Qiagen RNeasy Mini Kit (Qiagen). In addition, protein
lysates were generated 48 and 72 hrs after transfection to ver-
ify TRPS1-knockdown efficacy by Western blot analysis.
Western blot analysis
Western blot analysis with an antibody against TRPS1
(Abcam: ab111439) was performed to monitor the TRPS1
knockdown at protein level. RIPA-buffer (150 mM NaCl, 1%
NP-40, 10 mM MDOC, 0.1% SDS, 50 mM Tris pH 8.0 sup-
plemented with protease, phosphatase and HDAC inhibitors)
was used for protein extraction which was performed on ice.
Twenty-five micrograms of total protein was used for each
Western blot analysis. The proteins were separated on a 10%
SDS-PAGE. PVDF-membranes were cut and blocked with
8% skim milk buffer after immunoblotting followed by incu-
bation over night at 48C with primary antibodies (rabbit
polyclonal anti-TRPS1, Abcam: ab111439; 1:2000; mouse
monoclonal anti-ß-Actin, Sigma: A5441; 1:10000) diluted in
Roti-Block (Roth). After four washing steps with TBST-buffer
(5 min each), the PVDF-membranes were incubated for 2
hrs with a secondary antibody (anti-rabbit IgG, Jackson
ImmunoResearch; 1:50000, anti-mouse IgG Jackson Immu-
noResearch; 1:50000), diluted in 8% skim milk buffer. Blots
were developed with Amersham ECL Select Western Blotting
Detection Reagent (GE Healthcare, Little Chalfont, United
Kingdom). Chemiluminescence was detected and images
were acquired with a FluorChem HD2 documentation system
from Alpha Innotech in combination with the AlphaView
software (Biozym, Oldendorf, Germany).
Microarray-based gene expression analysis
To investigate the effect of TRPS1-knockdown on the tran-
scriptome, mRNA microarray expression profiling of biological
triplicates of cells after TRPS1-knockdown, a nonsense scram-
bled control and the B42-11 and B42-16 untreated cell lines 48
hrs after transfection was performed using G3 Human Gene
Expression 8x60k v2 microarrays (AMADID 72363, Agilent
Technologies, Santa Clara, CA). RNA quality was assessed
prior to expression analysis using an Agilent 2100 Bioanalyzer
(Agilent Technologies). The obtained RNA integrity numbers
(RINs) ranged from 6.7 to 9.7. The analysis was performed
according to the manufacturer’s instructions using 50 ng of
total RNA. Microarrays were scanned using a G2505C Sure
Scan Microarray Scanner (Agilent Technologies) followed by
raw data extraction with the Feature Extraction 10.7 software
(Agilent Technologies). Data quality assessment, preprocessing
and normalization were conducted in R using the Bioconduc-
tor AgiMicroRNA package.18 Statistical analyses were
performed using functions from the Bioconductor limma pack-
age for the identification of significantly differentially expressed
genes after TRPS1-knockdown (siRNA 1 and siRNA 2 taken
together) compared to the nonsense scrambled control.19 A
cutoff for FDR-adjusted p values of 0.05 and minimum abso-
lute log2-fold change of 0.5 was applied. Significantly deregu-
lated genes after TRPS1 knockdown were subjected to pathway
enrichment analysis using the Cytoscape Reactome Functional
Interaction (FI) plugin (version 2016) within the Cytoscape
network visualization software (version 3.5.1).20,21 For pathway
enrichment analysis, only network modules containing more
than three genes were considered. The top 50 pathways with
an FDR-adjusted p values <0.05 were considered for further
interpretation.
TRPS1-centered correlation network
To explore potential direct and indirect interaction partners of
TRPS1 at the transcriptome level, we generated gene correla-
tion networks from the microarray gene expression data on
B42-11 and B42-16 untransfected, scrambled-siRNA trans-
fected and TRPS1-downregulated cells and from global mRNA
expression data on sporadic breast cancers of the publicly
available The Cancer Genome Atlas (TCGA) breast cancer
dataset.22,23 The latter of which were matched to the breast
cancer post-Chernobyl cohort for the parameters tumor type,
hormone receptor status, age, TNM-classification, grading,
BRCA1/2- and Her2-status. For both data sets, correlation
(Pearson) of the TRPS1 expression vector and all other genes
was determined and a correlation test was applied. The result-
ing p values were corrected for multiple-testing error deter-
mining the Benjamini–Hochberg FDR.24 A cutoff for FDR-
adjusted p values of 0.05 was applied. The top 100 correlating
genes were selected and subjected to GO-term and pathway
enrichment analysis using the ClueGo plugin (version 2.3.2,
2016) of the Cytoscape network analysis software (version
3.0.2).21,25 The top 50 pathways with an FDR-adjusted p value
<0.05 were considered for further interpretation.
Results
Selection of candidate miRNAs
We explored the literature by PubMed research and identified
the following miRNAs to be most frequently published as
being associated with breast cancer and radiation exposure:
hsa-miR-26b-5p, hsa-miR-99b-5p, hsa-miR-221-3p and hsa-
miR-222-3p.13,26–29 Commonly regulated target genes of these
miRNAs were identified using MiRTarBase (version 4.0, 2014)
and revealed the gene TRPS1 (The trichorhinophalangeal syn-
drome 1).30 According to MiRTarBase (version 4.0, 2014),
TRPS1 is regulated by additional four miRNAs: hsa-miR-124-
3p, hsa-miR-302d-3p, hsa-miR-1–3p and hsa-miR-372-3p. We
selected these eight TRPS1-regulating miRNAs and the target
protein TRPS1 for further analysis in the discovery and valida-
tion cohorts.
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Increased hsa-miR-26b-5p expression is associated with
radiation exposure
The analysis of the selected miRNAs was performed by qRT-
PCR and subsequent partial differential testing between the
exposed and nonexposed tumor sets. Hsa-miR-221-3p
(FC5 1.87, partial differential test p5 0.006), hsa-miR-222-3p
(FC5 1.39, partial differential test p5 0.03) and hsa-miR-26b-
5p (FC5 1.97, partial differential test p value5 0.01) were sig-
nificantly upregulated in the exposed compared to the nonex-
posed tumor set of the discovery cohort. The other miRNAs
did not show statistically significant deregulation between
exposed cases and controls. From the three miRNAs that were
found to be significantly associated with radiation exposure in
the discovery cohort, upregulation of hsa-miR-26b-5p could be
confirmed in the exposed cases of the validation cohort
(FC5 1.3, partial differential test p5 0.02, Figs. 1a and 1b).
Hsa-miR-26b-5p expression was not associated with estrogen-
receptor status, progesterone-receptor status, cytokeratin-
expression (positive/negative), C-kit-expression (positive/nega-
tive), Ki67-expression (positive/negative), Her2/neu-status,
TP53-status and BRCA1/2-mutation status in the discovery or
the validation cohort. Moreover, no dose–response effect was
observed for hsa-miR-26b-5p (data not shown). We also tested
if the exposure status was associated with any clinical
characteristics of the patients, whereby no significant associa-
tion between exposure status and any of the clinical character-
istics could be detected (Table 1).
Decreased TRPS1 protein expression is associated with
radiation exposure
The expression of the TRPS1 protein, which was identified as
a target of the literature-derived candidate miRNAs, was deter-
mined by immunohistochemical staining of serial FFPE tissue
sections and subsequently tested for association with radiation
exposure. After software-based quantification of staining inten-
sities a significant downregulation of TRPS1 protein expression
in breast cancer tissues from exposed patients was detected
(partial differential test p5 0.028). This finding was confirmed
in the validation cohort (partial differential test p5 0.027).
Visualization of these results can be found in Figures 2 and 3a
and 3b. Furthemore, no dose–response effect was observed for
TRPS1 (data not shown).
Association of TRPS1 expression with clinical and
histological data
For all tumor samples of the discovery and validation cohorts,
an association of the TRPS1 protein expression with other
clinical parameters was tested (partial differential test). TRPS1
Figure 1. (a) The expression levels of all eight TRPS1-regulating miRNAs were analyzed in the Chernobyl discovery cohort by qRT-PCR. Hsa-miR-
222-3p, hsa-miR-221-3p and hsa-miR-26b-5p showed a significant differential expression between exposed and nonexposed samples. The
expression levels of these three microRNAs were also tested in the Chernobyl validation cohort. The expression of hsa-miR-26b-5p was associ-
ated with exposure to ionizing radiation in the validation cohort. (b) Violin plots displaying the expressions of hsa-miR-26b-5p, hsa-miR-221-3p
and hsa-miR-222-3p in the Chernobyl discovery cohort and hsa-miR-26b-5p in the Chernobyl validation cohort measured by qRT-PCR (2DCT val-
ues) are shown (right panel). The nonexposed control group is labeled in light blue and the exposed group in purple. The middle dark line repre-
sents the median of expression values. The vertical black line represents the interquartile. [Color figure can be viewed at wileyonlinelibrary.com]
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protein expression was not associated with estrogen-receptor
status, progesterone-receptor status, cytokeratin-expression
(positive/negative), C-kit-expression (positive/negative), Ki67-
expression (positive/negative), Her2/neu-status, TP53-status
and BRCA1/2-mutation status in the discovery and the valida-
tion cohort, suggesting an independent association of TRPS1
downregulation with radiation exposure of patients.
Characterization of the B42-11 and B42-16 cell lines
SKY analysis revealed the following karyotype for B42-16
resulting from evaluation of 15 metaphases: 47,XX,der
(4)t(4;12)(p31;?),i(8)(q10),1der(8)t(8;10)(q21;?),der(10)t(8;10;12)
(?;p12;q23;?),der(12)t(8;10:12)(?;?;q22) and for B42-11:47,XX,
1i(8)(q10),der(7)t(7;10)(q11.1;11.2). A representative metaphase
for each is shown in Supporting Information, Figure S1.
TRPS1 knockdown in B42-11 and B42-16 cells
To characterize the impact of TRPS1 on the transcriptome in
radiation-transformed breast cells, siRNA-knockdown of
TRPS1 was performed in the radiation-transformed breast
cell lines B42-11 and B42-16. The knockdown reached a
maximum after 48 hrs (Fig. 4 and Supporting Information,
Fig. S2); therefore, this timepoint was chosen for differential
expression analysis between TRPS1-knockdown and scram-
bled control of B42-11 and B42-16 cells. The analysis
revealed 281 significantly differentially expressed microarray
probes (144 downregulated and 137 upregulated) relating to
267 different genes (Supporting Information, Table S3). Ran-
domly selected genes (n5 12) detected by gene expression
microarray in B42-11 and B42-16 cells were chosen for tech-
nical validation of the microarray data. Correlation analysis
of expression of the genes selected for validation determined
by qRT-PCR and mRNA microarray showed strong correla-
tion for ten out of 12 analyzed genes (Supporting Informa-
tion, Table S4). Furthermore, pathway enrichment analysis
was conducted based on the Reactome network, resulting in
nine modules containing the 267 significantly deregulated
genes after TRPS1 knockdown. Significantly enriched path-
ways involving DNA-repair, cell cycle, mitosis, cell migration,
angiogenesis and EMT were detected (Supporting
Figure 2. Digital image analysis of immunohistochemically stained FFPE tumor sections from non-exposed and exposed breast cancer sam-
ples using an antibody against TRPS1. (a/b) Two representative immunohistochemically stained breast carcinoma cases are shown for non-
exposed (a) and exposed (b) cases. Image details of Aa and Ba (black frames) are shown in Ab and Bb. Detection and quantification of
TRPS1-stained nuclei was performed using the digital image software Definiens. Nuclei of tumor cells, for which the staining intensities
were calculated based on the algorithm, are labeled in yellow (Ac, Bc). [Color figure can be viewed at wileyonlinelibrary.com]
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Information, Table S5). Downregulated genes were mainly
involved in DNA-repair, cell cycle and mitosis while upregu-
lated genes mostly showed up in cell migration, angiogenesis
and EMT pathways (Supporting Information, Table S5).
TRPS1-centered correlation network
To explore putative direct and indirect interaction partners of
TRPS1 in the sporadic and radiation-associated context at
the transcriptome level, two TRPS1-centered correlation net-
works were generated and subsequently analyzed for involved
pathways. To examine the role of TRPS1 in sporadic breast
cancer, we deployed the RNAseq-derived global gene expres-
sion data set on breast cancer from the The Cancer Genome
Atlas (TCGA) dataset.22,23 From the 1106 available cases, a
subset that matched our radiation-associated breast cancer
cohort (n5 382) was used. In total, 12,106 genes showed a
statistical significant correlation with TRPS1 expression in
sporadic breast cancers of the publicly available TCGA data-
set and 1,270 genes in the B42-11 and B42-16 cells
(FDR< 0.05) (Supporting Information, Table S6).
From both correlation networks, we selected the top 100
correlating genes with regard to FDR (Figs. 5a and 5b and Sup-
porting Information, Table S6). GO and pathway enrichment
analysis including the top 100 correlating genes of the sporadic
breast cancer correlation network revealed mainly significant
enrichment of apoptosis related pathways such as TRADD:-
TRAF2:RIP1 complex binds FADD and RIPK1 is
deubiquitinated. The radiation-associated cell lines B42-11 and
B42-16 showed mainly significant enrichment of GO terms
related to the process of chromosome segregation and DNA
repair.
Discussion
Radiation-specific markers have already been reported in
young patients suffering from papillary thyroid carcinomas in
the aftermath of the Chernobyl accident.31 Although ionizing
radiation is also known to be a risk factor for the develop-
ment of breast cancer, radiation-specific markers in these
tumors are still unknown.2,3,32 This study aimed for the dis-
covery of radiation-specific changes of miRNA and protein
expressions in breast cancer samples from Ukrainian clean-
up workers, who were exposed to ionizing radiation from the
Chernobyl accident by comparison with nonexposed Ukrai-
nian control cases matched for age and clinical parameters.
From the published literature, we identified four miRNAs
(hsa-miR-26b-5p, hsa-miR-99b-5p, hsa-miR-221-3p and hsa-
miR-222-3p) that were associated with breast cancer and radi-
ation exposure.13,26–29 The TRPS1 gene was recognized as a
common target gene that is regulated by additional four miR-
NAs (hsa-miR-124-3p, hsa-miR-302d-3p, hsa-miR-1-3p and
hsa-miR-372-3p).30 The eight TRPS1-regulating miRNAs in
total along with the TRPS1 protein were investigated on two
independent post-Chernobyl breast cancer cohorts from clean-
up workers. Consistently, a significant upregulation of hsa-
miR-26b-5p in exposed compared to matched nonexposed
patients became apparent in both cohorts and thus, an associa-
tion of hsa-miR-26b-5p with radiation exposure could be vali-
dated independently (Fig. 1). Hsa-miR-26b-5p plays a pivotal
role in sporadic breast cancer.29 In sporadic breast cancer,
decreased hsa-miR-26b-5p expression was reported, and could
be confirmed in our sporadic breast cancer control cases. Hsa-
miR-26b-5p obviously plays a tumor-suppressive role by the
promotion of apoptosis and the suppression of cell growth.29,33
An opposed observation in post-Chernobyl cases points to a
radiation-specific deregulation of hsa-miR-26b-5p and renders
the question whether TRPS1 is also affected. Surprisingly, also
the TRPS1 expression was significantly downregulated in both
exposed breast cancer cohorts compared to the nonexposed
cohorts. As this finding was confirmed in two independent
cohorts, it suggests an important role of TRPS1 in radiation-
associated breast cancer (Figs. 2 and 3). To our knowledge
TRPS1 and hsa-miR-26b-5p alterations have not been investi-
gated in radiation-associated breast cancers so far. In sporadic
breast cancer, an upregulated TRPS1 expression was previously
reported which is in line with our findings in the sporadic
subset of control cases.34 In sporadic breast cancer TRPS1 is
linked to the stimulation of cell proliferation and angiogenesis
and the promotion of cell cycle progression.7,10,12 Furthermore,
TRPS1 overexpression was proposed as a prognostic marker in
early stage breast cancer due to an association with improved
overall survival and disease-free survival in these tumors.35
Moreover, TRPS1 expression was found to correlate with ER,
Figure 3. Significantly increased TRPS1 protein expression repre-
sented by the marker staining intensity was observed in breast
cancer tissues from the nonexposed groups (light blue) compared
to the exposed groups (purple) in the discovery (a, p50.028) and
validation cohorts (b, p50.027). p values were calculated using
the partial differential test considering intertumor heterogeneity.
[Color figure can be viewed at wileyonlinelibrary.com]
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PgR, Ki67, GATA-3 and Her2 expression, which we could not
confirm in our data.36,37 At the same time, TRPS1 acts as a
negative regulator of EMT and thus could reduce the meta-
static potential of breast cancers by suppressing transcription-
ally the processes of migration and invasion.11,13 Taken
together the published data on TRPS1 overexpression in spo-
radic breast cancer and its impact on tumor progression sug-
gests in turn a more aggressive tumor behavior in radiation-
associated breast cancers with downregulated TRPS1.
To clarify the functional consequences of TRPS1 downre-
gulation in the radiation-associated context, we performed
siRNA-knockdown experiments in radiation transformed
breast cells B42-11 and B42-16. A time-course analysis of
TRPS1 expression after siRNA-transfection (Supporting
Information, Fig. S2) showed a downregulation of TRPS1
compared to the scrambled control at the mRNA and protein
levels (Fig. 4). The major goal of this knockdown experiment
was to establish a gene-correlation network in radiation-
associated B42-11 and B42-16 cells based on global transcrip-
tomic data for functional insights. A pathway enrichment
analysis of differentially expressed genes revealed a significant
enrichment of pathways related to DNA-repair, cell cycle,
mitosis, cell migration, angiogenesis and EMT (Supporting
Information, Table S5). This is in good agreement with the
expectations from the published data as discussed above.
However, a novel finding of this study is the effect of TRPS1
downregulation on DNA-repair pathways in radiation-
associated B42-11 and B42-16 cells pointing to radiation-
induced effects in these cells. Furthermore, gene-expression-
microarray data could be technically validated by qRT-PCR
(Supporting Information, Table S4).
The gene interaction network of TRPS1 from global tran-
scriptomic data of the TRPS1-knockdown in B42-11 and B42-
16 cells was compared to a TRPS1-centered correlation net-
work based on global mRNA expression data from matched
sporadic breast cancers of the publicly available TCGA dataset
(Figs. 5a and 5b and Supporting Information, Table S6). The
main difference between both networks was a significant
enrichment of apoptosis-related processes in sporadic tumors,
while a link to DNA repair, chromosome segregation and
genomic instability became apparent in the radiation trans-
formed cell lines B42-11 and B42-16 (Supporting Information,
Table S7). The involvement of TRPS1 in chromosome segrega-
tion has already been described in chondrocytes.38 Many of
the top ten genes interacting with TRPS1 are known to be
involved in fundamental carcinogenic processes such as DNA
repair and cell migration. For example, GPR64 and LYAR
(TRPS1-interaction partners in B42-11 and B42-16 cells show-
ing a positive correlation with TRPS1) are known to be
involved in the process of migration. GPR64 is known to be
involved in the adhesion and migration of breast cancer cells
through mechanisms including a noncanonical NFkB path-
way.39 Furthermore, it was reported that transcription factor
LYAR promote tumor cell migration and invasion by
Figure 4. (a/c) Levels of TRPS1-mRNA-expression in untransfected (cont), scrambled-siRNA transfected (scr) and TRPS1-siRNA transfected
B42-11 and B42-16 cells 48 hrs after transfection. (b/d): Western Blot images show levels of TRPS1-protein expression in untransfected
(cont), scrambled-siRNA transfected (scr) and TRPS1-siRNA transfected B42-11 and B42-16 cells 48 hrs after transfection.
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upregulating galectin-1 gene expression in colorectal cancer.40
Another interesting network link was RFC5 (activated by
TRPS1 in B42-11 and B42-16) as it appeared in many (10 out
of 14) pathways related to DNA repair and cell cycle/mitosis
from the differential expression analysis and is among the top
five genes correlating with TRPS1. The RFC5 gene belongs to
the replication factor C family and was described to reflect the
hallmark of cancer “genomic instability.”41 It was already
reported that RFC5 recognize DNA damage and is involved in
pathways related to the process of mismatch repair.42,43 Fur-
thermore, an aberrant expression of this gene was already
observed in several tumor entities.42,44,45
This suggests deregulation of cellular processes involved in
radiation-induced damage response. In all, there are several
hints that TRPS1 plays a specific role in DNA repair, chromo-
some segregation and genomic instability which is a well-
established phenotype after irradiation and in radiation-
associated carcinogenesis.46 A link of TRPS1-interaction part-
ners to DNA repair and chromosome segregation is not obvi-
ous from the TRPS1-centered correlation network derived
from the sporadic breast cancer TCGA dataset suggesting this
being a specific effect of TRPS1 deregulation in radiation-
associated breast cancer. Moreover, most of the top ten
TRPS1-interaction partners derived from the sporadic dataset
are known to be involved in apoptosis, cell migration and cell
cycle which is in agreement with the published literature on
TRPS1 in sporadic breast cancer and prostate cancer.47–49
It was already shown in MCF7 breast cancer cells that
TRPS1 functions as a transcription activator of FOXA1 and
negatively regulates the expression of ZEB2.11,13 An interac-
tion of FOXA1 with TRPS1 was also detected in the correla-
tion network of the sporadic TCGA breast cancer dataset
(FOXA1, Pearson correlation5 0.17, FDR5 0.02). The weak
but significant correlation could be due to the fact that the
TRPS1-interaction network for sporadic breast cancer in this
study was developed from mRNA expressions of tumor tis-
sues in contrast to proteomics data from in vitro models as
published by Huang et al.11 The negative association of
TRPS1 with ZEB2, however, was not detected in our data. It
is interesting to note that there is no common gene between
the correlation networks of B42-11 and B42-16 cells and of
the sporadic TCGA dataset which again points to specific
radiation-associated functions of TRPS1.
In conclusion, this study reveals radiation markers in
breast carcinogenesis consisting of an upregulated hsa-miR-
26b-5p and a downregulation of the validated target protein
TRPS1. Both markers could be validated in independent
tumor cohorts of radiation-associated post-Chernobyl breast
cancers, suggesting an important role in radiation-induced
carcinogenesis. Moreover, we could identify interaction
partners of TRPS1 in TRPS1-knockdown models that point
to a functional role of TRPS1 in radiation-associated breast
carcinogenesis in DNA damage response and tumor
progression.
Figure 5. TRPS1-centered correlation networks consisting of the top 100 correlating genes with an FDR <0.05. The expression of genes
labeled with dark grey circles showed negative correlation with TRPS1 expression and that of genes labeled with light grey circles showed
positive correlation with TRPS1 expression. (a) TRPS1-centered correlation network based on global mRNA expression data from matched
sporadic breast cancers of the publicly available TCGA dataset. (b) TRPS1-centered correlation network based on microarray gene expres-
sion data from B42-11 and B42-16 untransfected, scrambled-siRNA transfected and TRPS1-downregulated cells.
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Abstract
Gene expression time-course experiments allow to study the dynamics of transcriptomic
changes in cells exposed to different stimuli. However, most approaches for the reconstruc-
tion of gene association networks (GANs) do not propose prior-selection approaches tai-
lored to time-course transcriptome data. Here, we present a workflow for the identification of
GANs from time-course data using prior selection of genes differentially expressed over
time identified by natural cubic spline regression modeling (NCSRM). The workflow com-
prises three major steps: 1) the identification of differentially expressed genes from time-
course expression data by employing NCSRM, 2) the use of regularized dynamic partial
correlation as implemented in GeneNet to infer GANs from differentially expressed genes
and 3) the identification and functional characterization of the key nodes in the recon-
structed networks. The approach was applied on a time-resolved transcriptome data set of
radiation-perturbed cell culture models of non-tumor cells with normal and increased radia-
tion sensitivity. NCSRM detected significantly more genes than another commonly used
method for time-course transcriptome analysis (BETR). While most genes detected with
BETR were also detected with NCSRM the false-detection rate of NCSRM was low (3%).
The GANs reconstructed from genes detected with NCSRM showed a better overlap with
the interactome network Reactome compared to GANs derived from BETR detected genes.
After exposure to 1 Gy the normal sensitive cells showed only sparse response compared
to cells with increased sensitivity, which exhibited a strong response mainly of genes related
to the senescence pathway. After exposure to 10 Gy the response of the normal sensitive
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cells was mainly associated with senescence and that of cells with increased sensitivity
with apoptosis. We discuss these results in a clinical context and underline the impact of
senescence-associated pathways in acute radiation response of normal cells. The workflow
of this novel approach is implemented in the open-source Bioconductor R-package
splineTimeR.
Introduction
In general terms, the expression of genes can be studied from a static or temporal point of view.
Static microarray experiments allow measuring gene expression responses only at one single
time point. Therefore, data obtained from those experiments can be considered as more or less
randomly taken snapshots of the molecular phenotype of a cell. However, biological processes
are dynamic and thus, the expression of a gene is a function of time [1]. To be able to under-
stand and model the dynamic behavior and association of genes, it is important to study gene
expression patterns over time.
However, compared to static microarray data, the analysis of time-course data introduces a
number of new challenges. First, the experimental costs for the generation of data as well as the
computational cost increases with the increase in the number of introduced time points. Sec-
ond, hidden correlation caused by co-expression of genes makes the data linearly dependent
[2]. Finally, one has to be aware of additional correlations existing between neighboring time
points clearly revealed in published gene expression profiles [3].
Several different algorithms have been suggested to analyze gene time-course microarray
data with regard to differential expression in two or more biological groups (e.g. exposed to
radiation vs. non-exposed) [4–7]. Nevertheless solitary identification of differentially expressed
genes does not help to determine the molecular mechanisms in the investigated biological
groups. Therefore, it is not only important to know differentially expressed genes per se, but
also how those genes interact and regulate each other in order to determine specifically deregu-
lated molecular networks.
Currently, many different algorithms including cluster analysis [8–13] and supervised clas-
sification [14–16] are used to identify relationships between genes. However, both of these
methods suffer from serious limitations. First, the timing information of the measurements is
not incorporated and, therefore, the intrinsic temporal structure of the time-course data is
neglected. Second, the available standard clustering and classification methods are not designed
to measure statistical significance of the results based on a statistical hypothesis test. By nature
of these methods, clusters or classes of genes with similar expression patterns will always be
identified but they do not provide a measure of how reliable this information is. For this reason,
we preferred usage of a dynamic network modeling approach that allows delineation of rela-
tionships between genes along with providing statistical significance for these relationships.
The aim of the present study was to identify and compare signaling pathways involved in the
radiation responses of normal cells differing in their radiation sensitivity that could be used to mod-
ulate cell sensitivity to ionizing radiation. For this, we propose an approach that combines the detec-
tion of genes differentially expressed over time based on statistics determined by natural cubic spline
regression (NCSRM) [17] followed by dynamic gene association network (GAN) reconstruction
based on a regularized dynamic partial correlation as implemented in the GeneNet R-package [18].
Most exploratory gene expression studies focus only on the identification of differentially
expressed genes by treating them as independent events and do not seek to study the interplay
of identified genes. This makes it difficult to tell which genes are part of the interaction network
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causal of the studied phenotype and which are the most “important” with regard to the context
of the investigation. The herein present approach combines the identification of differentially
expressed genes and reconstruction of possible associations between them. Further analysis of
identified GANs then allows hypothesizing which genes may play a crucial role in the investi-
gated processes. This should markedly increase the likelihood to find meaningful results from
an initial observation and help to understand the underlying molecular mechanisms. We
applied our workflow on time-course transcriptome data of two normal and well-characterized
lymphoblastoid cell lines with normal (20037–200) and increased radiation sensitivity (4060–
200), in order to identify molecular mechanisms and potential key players responsible for dif-
ferent radiation responses [19, 20]. Our exploratory approach provides novel and informative
insights in the biology of radiation sensitivity of non-tumor cells after exposure to ionizing
radiation with regard to the identified signaling pathways and their key drivers. Moreover, we
could demonstrate that spline regression in differential gene expression analysis for the pur-
pose of prior selection in gene-association network reconstruction outperforms another com-
monly used existing approach for time-course gene expression analysis.
Results
The schematic workflow of the presented novel approach for time-course gene expression data
analysis is presented in Fig 1.
Identification of ionizing radiation-responsive genes using NCSRM
method
A fraction of the probes was removed due to low expression levels, with not detectable signal
intensities as described in [21]. Table 1 shows the number of probes remained after quality filter-
ing from the total number of 25220 unique probes representing HGNC annotated genes. Differ-
ential analysis was performed relative to the corresponding sham irradiated cells as a reference.
In general, more genes were detected as differentially expressed in the cells with increased radia-
tion sensitivity compared to cells with normal radiation sensitivity after each dose of gamma irra-
diation (Table 1). The most prominent difference was observed when comparing the responses
after 1 Gy irradiation. In the cells with increased radiation sensitivity 2335 genes showed differen-
tial expression compared to only seven genes in cells with normal radiation sensitivity. We
observed the same trend after irradiation with 10 Gy where the cells with increased sensitivity
showed 6019 and the normal sensitive cells 3892 differentially expressed genes.
Pathway enrichment analysis of NCSRM identified genes
Pathway enrichment analysis was performed on differentially expressed genes to identify over-
represented biological pathways. The analysis on genes identified with NCSRM revealed 634
and 964 significantly enriched pathways for the cells with increased radiation sensitivity after 1
Gy and 10 Gy irradiation dose, respectively and 758 pathways for the normal sensitive cell line
after 10 Gy irradiation. For the seven differentially expressed genes (i.e. FDXR, BBC3, VWCE,
PHLDA3, SCARF2, HIST1H4C, PCNA) of the cell line with normal radiation sensitivity after
1 Gy dose of irradiation we did not find any significantly enriched pathways. A summary of the
pathway enrichment results can be found in S2 Table.
Gene association network reconstruction
None of the edge probabilities calculated for the seven differentially expressed genes in the cell
line with normal radiation sensitivity after 1 Gy irradiation exceeded the considered
Spline Regression and Network Reconstruction for Time-Course Expression Data
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significance threshold and hence no network was obtained. For the remaining conditions we
were able to obtain association networks as presented in Table 2. Obtained networks are pro-
vided as igraph R-objects in the supplementary data (S1 File). The graph densities for all result-
ing networks were in the same range as the density of the Reactome interaction network
(Table 2).
Identification and functional characterization of the most important
genes in the reconstructed association networks
The combined topological centrality measure was used to characterize the biological impor-
tance of nodes (genes) in the reconstructed association networks. The 5% of the highest ranked
genes listed in supplementary S3 Table were mapped to Reactome pathways in order to further
evaluate their biological roles. The top 10 most relevant pathways according to the FDR values
are shown in Table 3. For the cell line with increased radiation sensitivity after irradiation with
1 Gy and for the normal sensitive cell line after 10 Gy the induction of pathways associated
with senescence response was detected. For the cell line with increased radiation sensitivity
after 10 Gy of irradiation we mostly observed pathways associated with apoptosis. All pathways
are listed in supplementary S4 Table.
False detected differentially expressed genes between technical replicates
In order to assess the false positive rate, the spline regression based differential analyses between
technical replicates of each treatment conditions and cell lines were performed. Here, we can
state that the null-hypothesis of no differential expression is true for all genes. Then the q-level
of 0.05 for Benjamini-Hochberg method controls also the FWER at alpha-level equal to 0.05
(type I error) [22]. For all compared technical replicates not more than 3% rejections of null
hypothesis were detected, which is in good accordance to the expected or nominal type I error.
Evaluation of spline regression model in comparison to BETRmethod
Table 1 compares the numbers of differentially expressed genes obtained from both methods
applied on the same gene expression data set and FDR thresholds. For almost all treatment
conditions the BETRmethod detected less differentially expressed genes in comparison to
Fig 1. Schematic workflow of the analysis of gene expression time-course data. Samples were collected 0.25, 0.5, 1, 2, 4, 8 and 24 hours after
sham or actual irradiation. Transcriptional profiling was performed using Agilent gene expression microarrays and comprises three major steps: the
identification of differentially expressed genes from time-course expression data by employing a natural cubic spline regression model; the use of
regularized dynamic partial correlation method to infer gene associations networks from differentially expressed genes and the topological identification
and functional characterization of the key nodes in the reconstructed networks.
doi:10.1371/journal.pone.0160791.g001
Table 1. Number of detected and differentially expressed genes for each dose and cell lines for NCSRM and BETRmethods.
cell line and applied radiation dose increased sensitivity (1
Gy vs 0 Gy)
Normal sensitivity (1
Gy vs 0 Gy)
increased sensitivity (10
Gy vs 0 Gy)
Normal sensitivity (10
Gy vs 0 Gy)
total number of detected probes after
preprocessing
10388 11311 10330 11446
differentially expressed genes detected with
NCSRM
2335 7 6019 3892
differentially expressed genes detected with
BETR
923 12 3889 1256
intersection of differentially expressed genes
resulting from both methods
855 4 3875 1233
doi:10.1371/journal.pone.0160791.t001
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NCSRM. Only for the normal cell line after irradiation with 1 Gy BETR identified 12 genes
whereas NCSRM identified only 7 genes. As a consequence of the lower numbers of detected dif-
ferentially expressed genes with BETR, the obtained networks are smaller than those obtained
after spline regression. The detailed comparison results including numbers of detected differen-
tially expressed genes and the sizes of reconstructed association networks are presented in the
Table 2. The lists of differentially expressed genes obtained with the two methods are shown in
supplementary S1 Table. The top 10 pathways to which the 5% of the most important genes in
the reconstructed association networks where mapped to are shown in Table 3. With NCSRM
we were not only able to detect almost all genes that were detected also by BETR (Table 1), but
also an additional set of genes resulting in almost twice the number of genes compared to BETR.
Nevertheless, the top 5% hub genes of the networks derived from the differentially expressed
genes defined by BETR were associated with similar biological processes as those from the spline
differential expression analysis derived networks. The numbers and names of overlapping hub
genes in the GANs are presented in Table 4 and in supplementary S3 Table, respectively.
Evaluation of reconstructed networks
The evaluation of the two networks derived after 1 Gy irradiation of the cell line with increased
sensitivity showed that the network reconstructed with the differentially expressed genes deter-
mined using BETR did not contain significantly more common edges than random networks
(p = 0.529), whereas the network reconstructed with the differentially expressed genes deter-
mined by NCSRM did (p = 0.048). The networks derived after 10 Gy irradiation of the cell line
with increased sensitivity and 10 Gy irradiation of the normal sensitive cell line contained sig-
nificantly more edges that were common with the Reactome network compared to random
networks for both methods.
Discussion
The success of tumor radiation therapy predominantly depends on the total applied radiation
dose, but also on the tolerance of the tumor surrounding normal tissues to radiation. Toxicity
Table 2. Number of genes subjected to GAN reconstruction and properties of resulted GANs.
method NCSRM BETR
cell line and
applied radiation
dose
Increased
sensitivity (1
Gy)
normal
sensitivity (1
Gy)
Increased
sensitivity (10
Gy)
normal
sensitivity (10
Gy)
Increased
sensitivity (1
Gy)
normal
sensitivity (1
Gy)
Increased
sensitivity (10
Gy)
normal
sensitivity (10
Gy)
number of genes
taken for network
reconstruction
2335 7 6019 3892 923 12 3889 1256
number of nodes
remained in the
network
1140 - 3483 2735 336 - 2299 773
number of edges in
the network
12198 - 114629 84695 3268 - 126378 16862
network density 0.00939 - 0.00945 0.01133 0.02903 - 0.02392 0.02826
density of the
Reactome
interaction network
0.00536
Gene association network reconstructions were performed using the GeneNet method [18]. Association between two genes was considered as significant if
posterior edge probability was equal or greater than 0.95. Densities of the reconstructed networks were compared with the density of the Reactome
interaction network in order to assess their complexity.
doi:10.1371/journal.pone.0160791.t002
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towards radiation, which greatly varies on an individual level due to inherited susceptibility, is
one of the most important limiting factors for dose escalation in radiooncology treatment [23,
24]. To account for radiation sensitivity of normal tissue in personalized treatment approaches
the underlying molecular mechanisms need to be thoroughly understood in order to identify
Table 3. Comparison of NCSRM and BETRmethodswith respect to the top 10 pathways after mapping of 5% highest ranked genes from the recon-
structed gene association networks.
with NCSRMmethod with BETRmethod
increased sensitivity
(1 Gy)
increased sensitivity (10
Gy)
normal sensitivity (10
Gy)
increased sensitivity (1
Gy)
increased sensitivity (10
Gy)
normal sensitivity
(10 Gy)
Signal Transduction Signal Transduction Generic Transcription
Pathway
DNA Damage/Telomere
Stress Induced
Senescencea
Activation of BH3-only
proteinsb
DNA Damage/
Telomere Stress
Induced
Senescencea
Cellular Senescencea Activation of BH3-only
proteinsb
DNA Damage/
Telomere Stress
Induced Senescencea
Senescence-Associated
Secretory Phenotype
(SASP)a
Activation of PUMA and
translocation to
mitochondriab
Generic
Transcription
Pathway
DNA Damage/
Telomere Stress
Induced Senescencea
Activation of PUMA and
translocation to
mitochondriab
Immune System Signal Transduction Cytokine Signaling in
Immune system
Cellular
Senescencea
Formation of
Senescence-
Associated
Heterochromatin Foci
(SAHF)a
Fatty acid, triacylglycerol,
and ketone body
metabolism
Gene Expression Activated PKN1
stimulates transcription
of AR (androgen
receptor) regulated
genes KLK2 and KLK3
Immune System Gene Expression
Cellular responses to
stress
Metabolism Inositol phosphate
metabolism
Cell Cycle Checkpoints Intrinsic Pathway for
Apoptosisb
Meiotic
recombination
RAF-independent
MAPK1/3 activation
Metabolism of proteins IRF3-mediated
induction of type I IFN
Cellular Senescencea Signal Transduction Signal Transduction
Signaling by ERBB4 PPARA activates gene
expression
Cellular Senescencea DNAmethylation Gene Expression Cell Cycle
DAP12 interactions Regulation of lipid
metabolism by
Peroxisome proliferator-
activated receptor alpha
(PPARalpha)
Formation of
Senescence-
Associated
Heterochromatin Foci
(SAHF)a
Packaging Of Telomere
Ends
BH3-only proteins
associate with and
inactivate anti-apoptotic
BCL-2 membersb
Transcriptional
activation of cell
cycle inhibitor p21
PRC2 methylates
histones and DNA
Activation of gene
expression by SREBF
(SREBP)
STING mediated
induction of host
immune responses
RNA Polymerase I
Promoter Opening
Activation of the mRNA
upon binding of the cap-
binding complex and
eIFs, and subsequent
binding to 43S
Transcriptional
activation of p53
responsive genes
Apoptotic execution
phaseb
BH3-only proteins
associate with and
inactivate anti-apoptotic
BCL-2 membersb
Metabolism SIRT1 negatively
regulates rRNA
Expression
Endosomal/Vacuolar
pathway
Senescence-
Associated
Secretory
Phenotype (SASP)a
aPathways associated with senescence responses.
bPathways associated with apoptotic processes.
doi:10.1371/journal.pone.0160791.t003
Table 4. Comparison of hub genes in networks resulting from different methods.
cell line and applied radiation dose increased sensitivity (1 Gy) increased sensitivity (10 Gy) Normal sensitivity (10 Gy)
5% hub genes in the NCSRM resulting network in numbers 57 174 137
5% hub genes in the BETR resulting network in numbers 17 115 39
number of common hub genes resulting from both methods 9 111 31
doi:10.1371/journal.pone.0160791.t004
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molecular targets for the modulation of radiation sensitivity and molecular markers for the
stratification of patients with different intrinsic radiation sensitivity. In the present study we
identified significantly differentially expressed genes over time between the radiation-treated
group and the control group to be used as prior genes for GAN reconstruction. Two doses of
gamma irradiation were used to characterize the differences in radiation response of the two
lymphoblastoid cell lines with known differences in radiation sensitivity. The dose of 10 Gy
was selected following the fact that the same dose has been applied in a previous research proj-
ect examining the radiation sensitivity of the same lymphoblastoid cell lines analyzed in the
study at hand [20]. The dose of 1 Gy reflects the dose that is delivered as part of the so called
“low-dose bath” to the tumor-surrounding tissue during the radiotherapy of the tumors [25].
Here, we conducted time-resolved transcriptome analysis of radiation-perturbed cell culture
models of non-tumor cells with normal and with increased radiation sensitivity in order to
work out the molecular phenotype of radiation sensitivity in normal cells. Moreover, we pres-
ent an innovative approach for the identification of GANs from time-course perturbation tran-
scriptome data. The approach comprises three major steps: 1) the identification of
differentially expressed genes from time-course gene expression data by employing a natural
cubic spline regression model (NCSRM); 2) the use of a regularized dynamic partial correlation
method to infer gene associations network from differentially expressed genes; 3) the identifi-
cation and functional characterization of the key nodes (hubs) in the reconstructed gene
dependency network (Fig 1).
Our proposed method for the detection of differentially expressed genes over time is based
on NCSRM with a small number of basis functions. A relatively low number of basis functions
generally results in a good fit of data and, at the same time, reduces the complexity of the fitted
models. Treating time in the model as a continuous variable, a non-linear behavior of gene
expressions was approximated by spline curves fitted to the experimental time-course data.
Considering temporal changes in gene expression as continuous curves and not as single time
points greatly decreases the dimensionality of the data and thereby decreases computational
cost. In addition, the proposed NCRSM does not require identical sampling time points for the
compared treatment conditions. Furthermore, no biological replicates are needed. Therefore,
the method is applicable to data generated according to a tailored time-course differential
expression study design and to data that were not specifically generated for time-course differ-
ential expression analysis, e.g. existing/previously generated data from clinical samples. Thus,
the adaption of the method to differential expression analysis comprises the potential to reana-
lyze existing data, address new questions in silico and thereby potentially add new or additional
value to existing data. Incomplete time-course data, e.g. due to the exclusion of samples for
technical reasons, that often create major problems for the estimation of the model, are also
suitable for fitting the spline regression model as long as enough data points remain in the data
set. This is especially valuable when data on certain time points, derived from a very limited
sample source, have been excluded from a time-course data set and cannot be repeatedly
generated.
Since gene expression is not only dynamic in the treatment group but also in the control
group, the inclusion of the time-course control data greatly improves the ability to detect truly
differentially expressed genes, as the gene expression values are not referred to a single time
point with static gene expression levels only. Comparing a treatment group to time point zero
does not provide a proper control over the entire time-course, although it is widely practiced
[26–28]. The proposed workflow is implemented in an open-source R-package splineTimeR
and is available through Bioconductor (https://www.bioconductor.org).
Amongst a panel, the two lymphoblastoid cell lines that were different with regard to radia-
tion sensitivity after irradiation with 10 Gy [20], also responded differently with regard to the
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quantity of differentially expressed genes. Interestingly, cells with normal radiation sensitivity
barely responded to 1 Gy irradiation at the transcriptome level. Only seven genes (FDXR,
BBC3, VWCE, PHLDA3, SCARF2, HIST1H4C, PCNA) were identified as differentially
expressed, whereas for the cell line with increased sensitivity 2335 differentially expressed
genes were detected after exposure to the same dose. A similar behavior was observed for those
two cell lines after irradiation with 10 Gy. We detected 6019 and 3892 genes as differentially
expressed in the sensitive and normal cell lines, respectively (Table 2). Those results are in a
good agreement with the previous proteomic study where more differentially expressed pro-
teins were detected for the same sensitive cell line compare to the cell line with normal radia-
tion sensitivity 24 hours after irradiation with 10 Gy [29]. Thus, for both applied doses, the
radiation sensitive cells exhibited much more pronounced transcriptional response compared
to the cells with normal radiation sensitivity and thereby underlines the expected radiation
response of those two cell lines.
Concerning qualitative differences in the transcriptomic response of normal sensitive cells
and cells with increased sensitivity after treatment with 1 Gy and 10 Gy pathway enrichment
analysis was performed. Differentially expressed genes identified for all considered treatment
conditions except for the normal sensitive cells after exposure to 1 Gy radiation showed statisti-
cally significant enrichment of pathways. Most of which were in agreement with known radia-
tion responses such as DNA repair, cell cycle regulation, oxidative stress response or pathways
related to apoptosis (S2 Table) [30–32]. Therefore, the pathway enrichment analysis results
suggest plausibility of generated data and, more importantly, underline the meaningfulness of
our suggested approach based on cubic spline regression for differential gene expression analy-
sis of time-course data. However, differential expression analysis alone followed by pathway
enrichment analysis does not provide any mechanistic insights. For this reason we performed
GAN reconstruction using identified differentially expressed genes. Based on the assumption
that the expression levels of functionally related genes are highly correlated, partial correlation
was used for GAN reconstruction. In simple correlation, the strength of the linear relationship
between two genes is measured, without taking into account that those genes may be actually
influenced by other genes. Partial correlation eliminates the influence of other genes when one
particular relationship between pair of genes is considered. Network reconstruction was per-
formed separately for the cell line with increased radiation sensitivity after 1 Gy and 10 Gy and
for the cell line with normal radiation sensitivity after 10 Gy of radiation dose. Due to the
sparseness of the set of genes differentially expressed after irradiation of the normal-sensitive
cell line with 1 Gy, no GAN was obtained.
Subsequently, we identified the network hubs (i.e. most important genes) of the GANs by
combining three network centrality measures: degree, closeness and shortest path betweenness
[33]. Combining different centrality measures is a widely used approach to identify nodes that
are likely to control the network [34]. Also, this approach allows identification of nodes that
are connected to the central nodes at the same time which can be informative for the interpre-
tation of the whole GAN or single modules making up the network [33, 34].
Identification of key pathways associated with radiation sensitivity
In order to get functional insights into the reconstructed GANs the 5% top important nodes
were identified after a ranking with the combined centrality measure and mapped to the path-
ways from the interactome database Reactome [35]. The obtained results revealed different
pathways considered as the most important in cells with different radiation sensitivity after dif-
ferent doses of ionizing radiation. For the radiation sensitive cell line 4060–200 and 1 Gy irradi-
ation, we mainly detected pathways associated with senescence (Table 3).
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A different outcome was observed after irradiation with 10 Gy. For the radiation sensitive
cells three out of the ten top pathways were linked to apoptotic processes with the genes BBC3,
BCL2, TP53 as key players, whereas for the normal sensitive cell line we mainly observed the
induction of senescence related pathways. This indicates that different doses are necessary to
induce a similar response in the two cell lines. The activation of senescence genes is a damage
response mechanism, which stably arrests proliferating cells and protects them from apoptotic
cell death [36]. Together with the senescence pathway we observed increased levels of chemo-
kine, cytokine and interleukin genes that are known to activate an immune response and signal
transduction pathways in response to irradiation.
Although the senescence-associated pathways were not seen as the most important ones for
the treatment condition 10 Gy/increased sensitivity, they were significantly enriched in the
GANs of the three conditions 1 Gy/increased sensitivity, 10 Gy/ increased sensitivity and 10
Gy/normal sensitivity. All differentially expressed genes that related to senescence-associated
pathways are shown in supplementary S5 Table. The observation that cells with increased radi-
ation sensitivity compared to cells with normal sensitivity, become senescent after exposure to
doses in the range of 1 Gy, rises the question whether this has a positive or negative influence on
the tumor therapy. On the one hand side, senescent cell may secret the so-called SASP (“senes-
cence-associated secretory phenotype“) factors, including growth factors, chemokines and cyto-
kines, which participate in intercellular signaling leading to the attraction of immune cells to the
tumor location that, in turn, eliminate the tumor cells and, thereby, positively contribute to the
tumor therapy [37, 38]. On the other hand side, senescent cells and the SASP are reported to pro-
mote proliferation, survival, invasion and migration of neighboring cells by the release of pro-
inflammatory cytokines leading to sustained inflammation [36]. In this way senescence cells can
damage their local environment and stimulate angiogenesis and tumor progression [39, 40].
Besides, there are some evidences that the induction of senescence in surrounding normal tissue
may lead to an increased radio-tolerance or even radioresistance of the tumor and is, therefore,
not desirable and negatively influences the tumor radiotherapy [41]. Thus, it might be beneficial
to block senescence in order to prevent the radio-hyposensibilization of tumor cells. Therefore,
we suggest a detailed investigation of the consequences of senescent non-tumor cells with the
aim to improve the radiotherapy of tumors in radiosensitive patients.
Identification of senescence associated genes involved in cell radiation
responses
CDKN1A gene was identified as one of the most important key players linked to the identified
senescence associated pathways for both 1 Gy/sensitive and 10 Gy/normal treatment condi-
tions. For both conditions the expression of the CDKN1A was up-regulated for all considered
time points. CDKN1A is a well-known damage response gene for which aberrant transcrip-
tional response has been associated with abnormal sensitivity to ionizing radiation [42, 43].
The study by Badie et al. (2008) has shown that a subgroup of breast cancer patients, who
developed severe reactions to radiation therapy, could be identified by aberrant overexpression
of CDKN1 in peripheral blood lymphocytes [43].
LMNB1 is another genes we identified as a response hub gene after irradiation of sensitive
cell line with 1 Gy radiation dose that is associated with senescence. Although the LMNB1 gene
was not identified as hub gene in the GAN of the 10 Gy/normal treatment condition, it was still
differentially expressed. For both treatment conditions we observed significant downregulation
of this gene 24 hours after irradiation. Shah et al (2013) has suggested that downregulation of
LMNB1 in senescence is a key trigger of chromatin changes affecting gene expression [44]. In
fact also in our data we observed strong downregulation of a group of histone genes associated
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with senescence (S5 Table) for the treatment conditions 1 Gy/increased sensitivity and 10 Gy/
normal sensitivity. Furthermore, Lee et al. (2012) has shown that histone protein modification
may have an impact on the radiation sensitivity of a tissue [45]. Moreover, evidence has been
provided that mutation of LMNA can cause increased sensitivity to ionizing radiation [46],
however, to our knowledge there are no data showing the role of LMNB gene in the context of
radiation sensitivity.
Another potential therapeutic candidate associated with senescence that was identified for
the 10 Gy/normal sensitivity treatment condition was MRE11A for which cell culture data sug-
gest that treatment of cells with Mre11 siRNA increases radiation sensitivity and reduces heat-
induced radiosensitization [47, 48]. However, the clinical applicability of MRE11, has not been
confirmed [49].
Assessment of the false positive rate and validation of the NCSRM
method
The spline regression based differential analyses between technical replicates were performed
in order to estimate the extent of random fluctuations of gene expression values. The detected
3% rejections of the overall null hypothesis of no differential gene expression are in accordance
with the alpha-level of 5% of the familywise error rate (FWER) and can be considered as false
positives. On the other hand, it shows that type I error, due to technical variation, is covered by
the model and test assumptions (moderated F-test, [50]) so that it was not necessary to include
an extra parameter for technical replicates into the model.
In order to validate the previously mentioned biological results using NCSRM, we per-
formed the differential expression analysis with another established method for time-course
data analysis called BETR (Bayesian Estimation of Temporal Regulation) [6]. The number of
genes detected by BETR was considerably lower compared to NCRSM (Table 1), however the
majority of which were also detected with NCSRM (S1 Table). This is in line with the calcula-
tions on the false positive rates that have been conducted on the simulated data presented in
the BETR study. In an analysis of the simulated data set, 65% of truly differentially expressed
genes have been identified after accepting a false positive rate of 5% [6]. This means that a sub-
stantial proportion of differentially expressed genes remained undetected, which is likely to be
also the case for the herein analyzed data with BETR. Although the numbers of differentially
expressed genes and genes remained in the reconstructed networks greatly differ (Table 1), the
qualitative results are well comparable (Table 3). For all treatment conditions where for which
we were able to reconstruct GANs, we observed a great overlap of pathways where the 5% of
hub genes were mapped to (Table 3). The detection of a higher number of differentially
expressed genes with NCSRM resulted in larger GANs with additional information compared
to the smaller GANs that were reconstructed on the basis of genes detected with BETR. This is
underlined by the results of the conducted evaluation of GANs. Except one network based on
the differentially expressed genes using BETR, all investigated networks consist significantly
more common edges with the Reactome reference network compared to random networks
with identical network topology and genes. This shows that the additionally detected genes
with NCSRM add additional information rather than adding false positives or noise to the set
of differentially expressed genes. Moreover the spline regression method is much more flexible
and allows for more freedom during the data collection process. As already mentioned,
NCSRM does not require the same sampling time for treated and control groups and can easily
deal with incomplete data, whereas BETR method is not able to overcome or bypass those limi-
tations. Thus, NCSRM is very robust against the frequently occurring shortcomings in study
design and subsequent data generation occurring in life sciences.
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Conclusion
Prospectively, we suggest and plan a detailed in silico and in vitro analysis of the interactions in
the proposed gene association networks in order to add meaningful knowledge to the mecha-
nism of radiosensitivity at the experimental level. This novel knowledge has the potential to
improve cancer radiation therapy by preventing or lowering the acute responses of normal
cells resulting from radiation therapy. The results add novel information to the understanding
of mechanisms that are involved in the radiation response of human cells, with the potential to
improve tumor radiotherapy. Besides, the presented workflow is not limited to presented study
only, but may be applied in other special fields with different biological questions to be
addressed.
The software is provided as R-package “splineTimeR” and freely available via the Biocon-
ductor project at http://www.bioconductor.org.
Material and Methods
Cell culture
Experiments were conducted with two monoclonal lymphoblastoid Epstein-Barr virus-immor-
talized cell lines (LCL) obtained from young lung cancer patients of the LUCY study (LUng
Cancer in Young) that differ in radiosensitivity, as tested with Trypan Blue and WST-1 assays
[19, 20]. The non-cancer cell lines LCL 4060–200 with increased radiation sensitivity and LCL
20037–200 with normal radiation sensitivity were cultured at 37°C/5% CO2 in RPMI 1640
medium (Biochrom) supplemented with 10% fetal calf serum (FCS; PAA). Mycoplasma con-
tamination was routinely tested using luminescence-based assays (MycoAlert, Lonza).
Irradiation and sample preparation
The cells were seeded in 75 cm2 flasks at a concentration of 0.5 x 106 cells/ml in a total volume
of 60 ml. Exponentially growing cells were irradiated with sham, 1 Gy and 10 Gy of gamma-
irradiation (137Cs-source HWM-D 2000, Markdorf, Germany) at a dose rate of 0.49 Gy/min.
Samples were collected 0.25, 0.5, 1, 2, 4, 8 and 24 hours after sham or actual irradiation.
Between the time of collection cells were kept in the incubator. Collected cells were washed
with PBS and frozen at -80°C. Total RNA was isolated from frozen cell pellets obtained from
two independent experiments using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen)
including an DNase digestion step, according to the manufacturer's protocol. The concentra-
tion of RNA was quantified with a Qubit 2.0 Fluorometer (Life Technologies), and integrity
was determined using a Bioanalyzer 2100 (Agilent Technologies). RNA samples with a RNA
integrity number (RIN) greater than 7 indicated sufficient quality to be used in subsequent
RNA microarray analysis.
Gene expression profiling
Transcriptional profiling was performed using SurePrint G3 Human Gene Expression 8x60k
V2 microarrays (Agilent Technologies, AMADID 39494) according to the manufacturer’s pro-
tocol. 75 ng of total RNA was used in labeling using the Low Input Quick Amp Labeling Kit
(one-color, Agilent Technologies). Raw gene expression data were extracted as text files with
the Feature Extraction software 11.0.1.1 (Agilent Technologies). The expression microarray
data were uploaded to ArrayExpress (www.ebi.ac.uk/arrayexpress/) and the data set is available
under the accession number E-MTAB-4829. All data analysis was conducted using the R statis-
tical platform (version 3.2.2, www.r-project.org) [51]. Data quality assessment, filtering, pre-
processing, normalization, batch correction based on nucleic acid labeling batches and data
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analyses were carried out with the Bioconductor R-packages limma, Agi4x44PreProcess and the
ComBat function of the sva R-package [4, 21, 52]. All quality control, filtering, preprocessing and
normalization thresholds were set to the same values as suggested in Agi4x44PreProcess R-pack-
age user guide [21]. Only HGNC annotated genes were used in the analysis. For multiple micro-
array probes representing the same gene the optimal probe was selected according to the
Megablast score of probe sequences against the human reference sequence (http://www.ncbi.
nlm.nih.gov/refseq/) [53]. If the resulted score was equal for two or more probes, the probe with
the lowest differential gene expression FDR value was kept for further analyses since only one
expression value per gene was allowed in subsequent GAN reconstruction analysis.
Spline regression model for two-way experimental design
A natural cubic spline regression model (NCSRM) with three degrees of freedom for an experi-
mental two-way design with one treatment factor and time as a continuous variable was fitted
to the experimental time-course data. The mathematical model is defined by the following eq
(1):
y ¼ yðt; xÞ
¼ b0 þ b1B1ðt  t0Þ þ b2B2ðt  t0Þ þ . . .þ bmBmðt  t0Þ þ xðd0 þ d1B1ðt  t0Þ þ d2B2ðt
 t0Þ þ . . .þ dmBmðt  t0ÞÞ
where b0, b1, . . ., bm are the spline coefficients in the control group and d0, d1, . . ., dm are differ-
ential spline coefficients between the control and the irradiated group. B1(t-t0), B2(t-t0), . . .,
Bm(t-t0) are the spline base functions and t0 is the time of the first measurement. For x = 0,
y = ycontrol and for x = 1, y = yirradiated. For three degrees of freedom (df = 3), m = 3.
Depending on the number of degrees of freedom, two boundary knots and df-1 interior knots
are specified. The interior knots were chosen at values corresponding to equally sized quantiles of
the sampling time from both compared groups. For example, for df = 3 interior knots correspond
to the 0.33- and 0.66-quantiles. The spline function is cubic on each defined by knots intervals,
continuous at each knot and has continuous derivatives of first and second orders.
Time-course differential gene expression analysis
The time-course differential gene expression analyses were conducted between irradiated and
control cells (sham-irradiated). Analyses were performed on the normalized gene expression
data using NCSRMwith three degrees of freedom. The splines were fitted to the real time-course
expression data for each gene separately according to eq (1). The example of spline regression
model fitted to the measured time-course data for one selected gene is shown on the Fig 2.
Time dependent differential expression of a gene between the irradiated and corresponding
control cells was determined by the application of empirical Bayes moderated F-statistics [50]
on the differential coefficients values in eq (1). In order to account for the multiple-testing
error, corresponding p-values were adjusted by the Benjamini-Hochberg method for false dis-
covery [22]. Genes with an adjusted p-value (FDR, false discovery rate) lower than 0.05 were
considered as differentially expressed and associated with radiation response.
Assessment of the false positive rate of the NCSRM
Additionally, in order to assess the false positive rate (statistical type I error, also called familywise
error rate or FWER) we applied differential gene expression analysis using NCSRM between two
technical replicates for all treatment groups. Because only two technical replicates were generated
for each time point and treatment, we could not use the same approach to assess the technical vari-
ability for the BETRmethod, as it requires at least two replicates in each compared groups.
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Gene association network reconstruction from prior selected
differentially expressed genes
Differentially expressed genes were subjected to gene association network reconstruction from
time-course data using a regularized dynamic partial correlation method [54]. Pairwise rela-
tionships between genes over time were inferred based on a dynamic Bayesian network model
with shrinkage estimation of covariance matrices as implemented in the GeneNet R-package
available from CRAN [18]. Analyses were conducted with a posterior probability of 0.95 for
each potential edge. Edge directions were not considered. In order to assess the complexity of
the resulting networks, the density of each network was compared to the density of the Reac-
tome functional interaction network [35, 55].
Identification of important nodes in the network
Graph topological analyses based on centrality measures were applied in order to determine
the importance of each node in the reconstructed association networks [56]. Three most
Fig 2. Example of fitted spline regression models. The plot shows spline regression models fitted to the
measured time-course expression data of an arbitrary chosen gene (BBC3). The blue line represents the fitted
model for the control (0 Gy) and read line that for the irradiated group (1 Gy). Blue and red dots represent the
measured expression levels of the biological replicates. Vertical lines represent the endpoints and interior knots
correspond to the 0.33- and 0.66-quantiles.
doi:10.1371/journal.pone.0160791.g002
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commonly used centrality measures: degree, shortest path betweenness and closeness were
combined into one cumulative centrality measure [34]. For each gene the three centrality val-
ues where ranked. The consensus centrality measure for each node was defined as the mean of
the three independent centrality ranks. Combining centrality measures supports the identifica-
tion of the nodes that are central themselves and also connected to direct central nodes, which
demonstrates strategic positions for controlling the network.
Pathway enrichment analysis
The Reactome pathway database was used to conduct the pathway enrichment analysis in
order to further investigate the functions of the selected sets of differentially expressed genes
[35]. Statistical significance of enriched pathways was determined by one-sided Fisher's exact
test. The resulting p-values were adjusted for FDR using the Benjamini-Hochberg method.
Pathways with FDR<0.05 were considered statistically significant and pathways were ranked
according to ascending FDRs.
Evaluation of NCSRM approach
Since we decided to use the set of genes that appeared to be differentially expressed we assessed
the performance of the herein used NCSRM approach in comparison to the BETR approach
implemented in the R/Bioconductor package betr [6]. BETR is a well-established algorithm
that has been previously compared to limma, MB-statistic and EDGE methods and showed the
best performance [6]. The results of spline and BETR methods were compared using the same
initial microarray gene expression data set. The probabilities of each gene to be differentially
expressed obtained with BETR method, were transformed to p-values as described in the origi-
nal paper. Genes were considered significantly differentially expressed if the Benjamini-Hoch-
berg adjusted p-value was lower than 0.05 (FDR<0.05). This transformation allowed us to
compare the outcomes of both methods based on the FDR values for differential expression.
The resulting differentially expressed genes using BETR were analyzed and subjected to net-
work reconstruction as described above for the differentially expressed genes obtained using
NCSRM. Outcomes of both obtained association networks were compared to each other and to
the a priori known biological network provided by the Reactome database [35].
Evaluation of reconstructed gene association networks
In order to assess the quality of the de novo reconstructed gene association networks (GANs),
we developed a novel method that compares the interactions in the reconstructed network to
the experimentally validated interactions present in the Reactome interaction network. For this
purpose we used the Reactome reference network, consisting of protein-protein interaction
pairs stored in the Reactome database (http://www.reactome.org/pages/download-data/). For
the comparison, sub-networks of reconstructed networks consisting only of genes overlapping
with the Reactome network were built. The number of common edges between these two sub-
networks was determined and referred to the total number of edges in the reconstructed net-
work (percentage of common edges in the reconstructed network). Further, a permutation test
was performed to assess whether the number of common edges in the reconstructed network
was significantly higher than in randomized networks with the same genes. Random networks
were generated by permutation of the node names in the network, while preserving the recon-
structed sub-network topology. After each permutation (n = 1000) the number of common
edges with the reference Reactome sub-network was determined. The reconstructed network
was considered significantly better than random, if more than 90% of the random sub-net-
works contained lower numbers of edges common with the Reactome network than the
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reconstructed sub-network (p-value< 0.1). All networks reconstructed with the genes deter-
mined as differentially expressed from the herein presented spline regression method and the
BETR method were evaluated.
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Abstract
Copy number aberrations (CNAs) are known to strongly affect oncogenes and tumour suppressor genes. Given the critical
role CNAs play in cancer research, it is essential to accurately identify CNAs from tumour genomes. One particular
challenge in finding CNAs is the effect of confounding variables. To address this issue, we assessed how commonly used
CNA identification algorithms perform on SNP 6.0 genotyping data in the presence of confounding variables. We simulated
realistic synthetic data with varying levels of three confounding variables—the tumour purity, the length of a copy number
region and the CNA burden (the percentage of CNAs present in a profiled genome)—and evaluated the performance of
OncoSNP, ASCAT, GenoCNA, GISTIC and CGHcall. Furthermore, we implemented and assessed CGHcall*, an adjusted version
of CGHcall accounting for high CNA burden. Our analysis on synthetic data indicates that tumour purity and the CNA
burden strongly influence the performance of all the algorithms. No algorithm can correctly find lost and gained genomic
regions across all tumour purities. The length of CNA regions influenced the performance of ASCAT, CGHcall and GISTIC.
OncoSNP, GenoCNA and CGHcall* showed little sensitivity. Overall, CGHcall* and OncoSNP showed reasonable performance,
particularly in samples with high tumour purity. Our analysis on the HapMap data revealed a good overlap between
CGHcall, CGHcall* and GenoCNA results and experimentally validated data. Our exploratory analysis on the TCGA HNSCC
data revealed plausible results of CGHcall, CGHcall* and GISTIC in consensus HNSCC CNA regions. Code is available at
https://github.com/adspit/PASCAL.
Key words: copy number calling algorithm; performance assessment; cancer genomics; copy number aberrations
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Introduction
Copy number aberrations (CNAs) are present in all known
cancer genomes [1–3]. Unlike copy number variations (CNVs)
which occur naturally and originate in germline cells [4–6],
CNAs accumulate somatically, emerge after many selection
events and have been associated with development and
progression of human disease, especially with carcinogenesis:
Bardeesy et al. showed that the deletion of the tumour supressor
gene SMAD4 plays a critical role in progression and tumour
biology of pancreatic cancer [7], Witkiewicz et al. showed that
amplification of the gene MYC is uniquely associated with poor
outcome in pancreatic ductal adenocarcinoma [8], Leucci et al.
showed that the long non-coding RNA (lncRNA) gene SAMMSON
is consistently co-gained with MITF in more than 90% of human
melanomas [9], while Wells et al. showed that deletion of the
gene PTGHD1 in the thalamic reticular nucleus only leads to
attention deficiency and hyperactivity [10]. Identifying CNAs that
are affecting oncogenes or tumour suppressor genes provides
knowledge required for the development of new targeted cancer
therapies or patient stratification. It is thus of great importance
to accurately estimate CNAs from tumour genomes. However,
one particular challenge in the accurate estimation of cancer-
related CNAs is the presence of confounding variables such as
tumour purity and length of CNAs.
The tumour purity represents the ratio between cancerous
cells and all the cells present in a tumour sample—comprising
both of cancerous and non-cancerous cells. The mixture of can-
cerous and non-cancerous cells affects the expected allelic frac-
tion between germline and somatic variants and thus influences
the accuracy of CNA calling [11]. In simple terms, the higher the
non-tumour cell content within the assessed tissue sample, the
lower the sensitivity of the copy number calling algorithm gets.
Previous studies have shown that the length of a CNA region, i.e.
the number of covered base pairs by a genomic region, affects the
sensitivity of CNA calling, with longer CNA regions being easier
to find [12, 13].
Within this study we focus on algorithms that call CNAs from
single-nucleotide polymorphism (SNP) arrays. Nowadays, SNP
arrays typically comprise approximately 1.8 million probes and
return allele-specific signals at each marker of genetic variation.
Affymetrix SNP 6.0 data also come with the great advantage that
they can be used for both genotype and copy number analysis.
Another advantage of this technology is that it allows us to
characterise both copy number changes and allelic imbalances
of a sample. To achieve this, the signals resulting from the
array genotyping need to be processed and analysed by specific
methods. Although numerous methods have been proposed,
reliably uncovering cancer-associated CNAs from SNP array data
still represents a challenge [3, 14, 15]. One difficulty is that CNA
calling algorithms fail to address the effect of known biological
confounding variables [16, 17], i.e. the tumour purity of the anal-
ysed tissue and the length of underlying CNA regions. GenoCN
represents a statistical framework that simultaneously searches
for CNAs and CNVs while taking into account the tumour purity
but does not account for a chromosomal background that is not
diploid [18]. OncoSNP represents a unified Bayesian framework
based on a cancer-specific statistical model that classifies SNP
array signals into 21 states and accounts for tumour purity, poly-
ploidy and intra-tumour heterogeneity [19]. ASCAT focuses on
analysing allele-specific copy numbers in solid tumour initially
but requires a threshold-based, model-free segmentation of the
SNPs into regions of equal copy number [6]. Another method
that is used for finding cancer–related CNAs is CGHcall. CGHcall
makes use of breakpoint information from segmentation across
all samples and includes information as tumour purity for find-
ing CNAs [20].
The Cancer Genome Atlas (https://cancergenome.nih.gov)
(TCGA) is one of the largest resources providing molecular
omics data on multiple levels. TCGA covers various cancer
types and aims to improve general knowledge about cancer
development and treatment. The commonly used method to
estimate copy number states from SNP genotyping data in
TCGA studies is GISTIC 2.0 (GISTIC) [21]. GISTIC was designed
to primarily estimate significant relative CNAs across a set
of patients and not on single patient level. GISTIC eliminates
common chromosome arm-level events which are not cancer-
specific and focuses on focal events. However, GISTIC does not
address the effect of confounding variables on the resulting CNA
regions.
Within this study we assessed the performance of the fol-
lowing common-used CNA calling algorithms on Affymetrix SNP
6.0 array data: OncoSNP [19], ASCAT [6], CGHcall [20], genoCNA
[18] and GISTIC [21]. All algorithms are commonly used for
estimating copy number states in tumour samples and, except
for GISTIC, correct for tumour purity, intra-tumour heterogeneity
and tumour cell ploidy (ASCAT and OncoSNP). Unlike previous
studies that evaluated CNV detection—and not cancer-specific
CNAs—for an SNP platform [13, 22] or used a model with 24
parameters for which it is difficult to find a combination that
provides realistic data [23, 24], we focused on five different
algorithms designed to specifically find CNAs and, moreover,
evaluated them on synthetic data derived from Affymetrix SNP
6.0 data. Our contribution consists of
• a pipeline that uses realistic Affymetrix SNP 6.0 array-like
synthetic DNA copy number profiles for evaluating the per-
formance of OncoSNP, ASCAT, CGHcall, genoCNA and GIS-
TIC CNA calling algorithms, under the influence of tumour
purity, length of CNA and CNA burden (the percentage of
CNAs present in the profiled genome, [25])
• the implementation of an adjusted version of the CGHcall
algorithm that allows the estimation of CNAs in highly
variant genomes.
We applied our pipeline on two real data sets derived from
patient samples: a cohort of 522 head and neck squamous
cell carcinoma (HNSCC) samples from TCGA [26] and a
set of 81 Haplotype Map samples [4]. The pipelines con-
sist of R, Python and shell scripts and can be accessed
at https://github.com/adspit/PASCAL. Finally, we provide an
appropriate framework to compare CNAs calling algorithms
with the aim of finding the algorithm that classifies genomic
regions correctly independent of tumour purity, length of a CNA
region and CNA burden. Moreover, we developed an improved
version of CGHcall that we refer to as CGHcall* and included it
in our comparison.
Methods and materials
Preliminaries
The data resulting from Affymetrix SNP 6.0 arrays experiments
comprised of fluorescence intensity values of hybridised A and
B allele probes for each genetic marker on the array [27]. We
obtained and used the following measures from the data:
(i) the log R ratio (LRR) – a log2-transformed value of the total
intensity for allele A and allele B for more than 1.8 million
markers of genetic variation.
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(ii) the B allele frequency (BAF) – the ratio of bases genotyped
as variant allele (B allele). BAF ranged from 0 to 1, where
0 represented the AA/A− genotype, 0.5 represented the
heterozygous AB genotype and 1 represented the BB/B−
genotype [28].
Realistic synthetic data
We used the jointseg R package [24] to generate realistic
Affymetrix SNP 6.0 array-like synthetic tumour data consisting
of 400 samples. Each sample comprised of 1.844.399 markers
of genetic variation. Jointseg was built to generate realistic
synthetic DNA copy number profiles. The framework resamples
signals corresponding to genomic regions with manually
annotated copy number states from the publicly available lung
cancer NCI-H1395 SNP microarray data [24, 29]. We generated
100 samples with each of the following tumour purity levels:
30, 50, 70 and 100%. The tumour purity levels corresponded to
the experimental settings of the [29] study. We randomly placed
between 1 and 8 breakpoints within each sample. A breakpoint
represented a loci where one of the two parental copy number
changed. For the resulting regions we sampled the copy number
states from a predefined set of copy number states: (0,1), (0,2),
(1,1), (1,2), (1,3), (2,2) and (3,2), where (0,1) represented the loss of
a single copy, (0,2) and (1,1) represented normal and (1,2), (1,3),
(2,2) and (3,2) represented the gain of one, two or three copies.
Haplotype Map data
We started the analysis with 98 Affymetrix 6.0 SNP array profiles
of healthy patients from the publicly available Haplotype Map
(HapMap) repository: ftp://ftp.ncbi.nlm.nih.gov/hapmap/ [4]. We
preprocessed the data with the Aroma Affymetrix Power Tools
package [30] and the PennCNV-Affy pipeline [31]. In the prepro-
cessing step, we performed quantile normalisation and gener-
ated genotype calls from the Affymetrix spot intensity readout
files (CEL format) as output by the Affymetrix microarray scan-
ner files using the Birdseed algorithm [32]. Next, we extracted
allele-specific signals, and we calculated the canonical cluster-
ing parameters for each marker of genetic variation. We then
calculated probe-wise LRR and BAF for each patient sample. Fur-
ther, we split the signal file into individual files for each patient.
We then selected 81 patients that were further experimentally
profiled by Redon et al. [4].
HNSCC data
We used Level 1 Affymetrix SNP 6.0 array data generated by the
TCGA research network (http://cancergenome.nih.gov/) consist-
ing of 522 samples collected from patients suffering from HNSCC
[26]. We preprocessed the tumour and normal matched raw
HNSCC CEL files with the Affymetrix Power Tools package [30]
and the PennCNV-Affy pipeline [31] as described in the previous
section.
Genomic copy number calling algorithms
We selected five CNA calling algorithms for comparison: CGH-
Call (release 3.6), OncoSNP (version 2.1), ASCAT (version 2.4),
genoCNA and GISTIC (version 2.0).
OncoSNP
OncoSNP was built upon a statistical model that classifies SNP
array signals—both LRR and BAF, from cancer genomes into 21
states covering different combinations of allele loss and ampli-
fication. The model includes effects of polyploidy, tumour purity
and intra-tumour heterogeneity [19]. We applied OncoSNP on the
synthetic data with the arguments specific for Affymetrix SNP
array, together with the predefined number of training states
and tumour states. We used the intratumour mode and set
the tumour purity paramater to 30, 50, 70 and 100% . For the
HapMap data, we used the same parameter settings, except for
the tumour purity which was set to 0.
ASCAT
ASCAT was designed to perform allele-specific CNA analysis
in tumour samples. The algorithm corrects for the effects of
tumour purity and tumour aneuploidy and infers copy num-
ber classes, loss of heterozygosity and homozygous deletions.
ASCAT estimates the number of copies for both alleles at all
SNP marker positions together with the tumour purity of each
sample [6].
We preprocessed the synthetic data and generated the
ASCAT-format input tumour LRR and BAF files. Afterwards,
we generated corresponding germline genotypes with the
ascat.predictGermlineGenotypes R function with the platform
parameters set to ‘AffySNP6’. Finally, we segmented the data
with the ASPCF segmentation algorithm and applied the ASCAT
copy number calling function. Next, we applied the same steps
to the HapMap data.
GenoCNA
GenoCN was built as a statistical framework that simultaneously
searches for CNAs and CNVs while inferring the tumour
purity. In this study we used the genoCNA component,
which was specifically designed for CNA finding. Applying
genoCNA required the following information for each of the
genetic markers: name, chromosome, position and population
frequency (PFB). We used the genetic marker information as
provided by the Affymetrix PFB file corresponding to the human
genome assembly hg18. Each input file contained LRR, BAF and
PFB values for each genetic marker. We selected the output
format 2 which returned the most likely copy number and
genotype state of all the genetic markers.
GISTIC
GISTIC was designed to find regions of the genome that are
significantly amplified or deleted across a set of samples. The
significance measure is based on the amplitude of the CNA,
on how frequently the CNA occurs across samples and a user-
defined threshold for the discovery rate. GISTIC required as input
a segmentation file, a reference genome file and the LRR signals.
GISTIC does not use the BAF signals. For all data sets we used
the hg18 reference genome and segmentation files obtained by
applying circular binary segmentation—further referred to as
CBS [33]. For the TCGA HNSCC analysis we used the GISTIC
results provided by TCGA as level 3 data.
CGHcall
CGHcall was originally designed for array Comparative Genomic
Hybridization (aCGH) data. The algorithm uses breakpoint
information from CBS [33] and classifies raw log2-ratios between
reference and tumour DNA into five discrete states: double
loss-homozygous (biallelic) deletion, loss-hemizygous deletion
(loss of one of the alleles), normal-two copies, gain-three to four
copies and amplification–more than four copies [20]. We log-
transformed the total copy numbers and we applied the CGHcall
D
ow
nloaded from
 https://academ
ic.oup.com
/bib/advance-article-abstract/doi/10.1093/bib/bby096/5139664 by guest on 23 O
ctober 2018
4 Pitea et al.
pipeline on resulting signals with adjustment for tumour purity.
For the HNSCC TCGA data set, we implemented a Python script
to calculate log2-ratios between tumour and normal matched
patient samples. As the HapMap cohort included only healthy
patients, we calculated log2-ratios between each LRR signal and
the mean LRR signal of the 81 selected samples.
CGHcall*
We developed an adjusted version of CGHcall to prevent shifts
of the baseline level after global normalisation: CGHcall*. We
adjusted the normalisation and post-segmentation normalisa-
tion for samples in which the CNA burden exceeded 50% of
the sample profile, by considering only the signals included in
the [-0.1, 0.1] interval (see Section 3.1). We applied the CGHcall*
pipeline on the synthetic data and on the HapMap as described
in the previous section for CGHcall. Further, we applied CGHcall*
on the log2-ratios between tumour and normal matched TCGA
HNSCC samples. When running CGHcall and CGHcall* on the
TCGA HNSCC data, we set the tumour purity parameter to the
consensus measurement of TCGA HNSCC estimations derived
by Aran et al. [34]. For samples with missing derived consensus
measurement estimations, we used the immunohistochemistry
measurements as tumour purity values.
Performance analysis of genomic copy number calling
algorithms
For evaluating the performance of the selected algorithms, we
collapsed the resulting calls to three states: loss, normal and
gain. For CGHcall, CGHcall* and GISTIC the double loss and loss
were collapsed to loss, while the gain and amplification were
collapsed to gain. For OncoSNP we collapsed the homozygous
and the hemizygous deletion states to loss, and all the states
that were defined by more than two copies were considered
gain. For ASCAT and genoCNA, the probes with less than two
copies were defined as lost, while the probes with more than two
copies were defined as gained. We calculated the sample-wise
confusion matrix, precision, recall and balanced F-score [35] as
follows:
precisionc =
TP
TP + FP
(1)
recallc = TPTP + FN (2)
Fc = 2 · precisionc · recallcprecisionc + recallc
, (3)
where c represented the class: loss, normal or gain. True positives
(TP) represent the number of probes that were classified correctly
for each class c, while false positives (FP) are the probes classified
incorrectly as class c. False negatives (FN) represent the number
of probes that belong to class c but were classified as belong-
ing to another class. To test for statistically significant shifts
between F-score distributions of the algorithms, we performed
non-parametric pairwise comparison Wilcoxon tests [36]. We
adjusted the resulting P-values for multiple testing error through
Bonferroni correction [37].
Next, we assessed the performance of the CNA calling
algorithms on the Affymetrix SNP 6.0 HapMap samples with
matched experimentally genomic copy number validated
results. Finally, we analysed the results of the CNA calling
algorithms on the TCGA HNSCC Affymetrix SNP 6.0 samples in
HNSCC consensus regions with focus on the Cyclin D1 (CCND1)
and the cyclin dependent kinase inhibitor 2A (CDKN2A) genes.
Results and discussion
Characterising molecular phenotypes in cancer research
requires the accurate identification of DNA copy number
changes. Although genomics increasingly deploys genome
sequencing, there is still a wealth of cost-effective SNP array
data available. Thus, making use of these data is important and
requires best possible analysis approaches that, among other
features, are able to correct for cancer-specific confounding
variables such as tumour purity and a wide range of CNA
lengths. To benchmark commonly used CNA calling approaches
in the presence of such confounding variables, we developed an
evaluation pipeline.
To evaluate the CNA algorithms, tumour samples with known
true states are required. Since the true copy number states for
real cancer data are unknown and experimental validation on
genome-wide level is not feasible (the human genome size is
about 3.0 × 109 bp and is affected by CNVs), we assessed the
performance of the algorithms using synthetic data mimicking
Affymetrix SNP 6.0 array experiments (see Methods for details).
To make the samples as similar as possible to the real Affymetrix
SNP 6.0 array samples, we simulated data for 1.844.399 markers
of genetic variation—number of probes comparable to the one
present on an Affymetrix SNP 6.0 array. Subsequently, we eval-
uated the performance of OncoSNP, ASCAT, GenoCNA, CGHcall
and GISTIC at SNP level resolution.
When conducting a benchmarking study, in addition to real-
istic synthetic data, we need to use an appropriate measure for
the performance of copy number calling algorithms. In general,
to show how prediction algorithms perform, receiver operating
characteristics (ROC) curves are commonly used [38]. However,
when the distribution of the classes is imbalanced, as in our case
(Figure S1), ROC curves can present an over-optimistic view on
how an algorithm performs, while the recall and the precision
have been shown to give a more informative view [39, 40]. Since
the F-score represents the balance between the precision and the
recall of an algorithm, we selected it as an appropriate criteria
and used it to evaluate the performance of the copy number
algorithms for each class. The F-score allowed us to determine
the algorithm that classified correctly genomic regions inde-
pendently of the CNA type. This is of great importance, since
for a putative future use in personalised medicine, classifying
correctly regions overlapping oncogenes or tumour suppressor
genes may affect the diagnosis and, thus, the treatment of a
patient.
We were interested whether the investigated algorithms can
classify precisely the LRR and the BAF signals on probe level
into three classes: loss, normal and gain. Therefore, we split the
multi-class classification problem into three binary classification
problems.
An improved algorithm for copy number calling from
Affymetrix SNP 6.0 data: CGHcall*
During manual inspection of the CGHcall pipeline we observed
that the normalised signals before and after segmentation in the
synthetic samples with more 50% non-normal states covering
the sample profiles were incorrectly shifted (either to -1, either
to 1). This led to defining an incorrect baseline level in these
samples and thus, calling the wrong copy number state. Since
cases in which more than half of the genotyped probes are in
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Figure 1. Performance of CNA calling algorithms on synthetic data. We evaluated the performance of six algorithms which are colour-coded as it follows: OncoSNP, coral
red; ASCAT, light green; CGHcall, purple; CGHcall*, cyan; GenoCNA, pale pink brown; and GISTIC, yellow. (A). The y-axis represents the F-score and x-axis represents
the tumour purity level in %. The three facets represent the different classes: loss, normal and gain. Each boxplot consists of F-scores for 100 synthetic samples. The
total number of genetic markers covered by the synthetic signal was approximately 1:8 bp. (B). Heatmap of mean F-scores for different lengths of copy number regions.
(C). Heatmap of mean F-scores for samples with CNA burden ratio < 0.5 versus samples with CNA burden ratio > 0.5.
a non-normal state have already been reported in a pan-cancer
study on somatic genomic CNAs [14], we set up to correct for the
CNA burden effect.
The problem arose from the LRR levels being normalised to
the median level over a sample. If more than half of the genome
is changed in one direction (loss or gain), CGHcall is unable to
correctly estimate the baseline level and assigns the 0 level to
what is actually lost or gained. We observed the same behaviour
when we applied the post-segmentation normalisation, which
assigns the baseline segment to a segment that is either lost
or gained. To correct for this effect, we selected three different
intervals as constrains for the LRR signals, [-0.1, 0.1], [-0.05,
0.05] and [-0.2, 0.2], and analysed how the performance of the
algorithm changes in samples with 100% tumour purity. The
resulting F-scores suggested that the LRR signals within the [-0.1,
0.1] interval provided the optimal mean for normalisation and
post-segmentation normalisation (Figure S2). As a result, we pro-
posed a solution in which, instead of performing normalisation
and post-segmentation normalisation based on all LRR signals,
we limit ourselves to LRR signals that fall in the [-0.1, 0.1] interval.
Tumour purity showed strong influence on
performance
We first analysed how different tumour purities influenced the
performance of the algorithms on synthetic data. We compared
the algorithms based on their F-score distributions (Figure 1A).
We first showed how the six algorithms (OncoSNP, red; ASCAT,
neon green; GISTIC, yellow; CGHcall, purple; CGhcall*, cyan; and
GenoCNA, pale orange) identified losses at tumour purity levels
(depicted on the x-axis) varying from 30 to 100% (Figure 1A, left
panel). OncoSNP was not able to identify losses in samples with
tumour purity < 100% (mean F-score = 0.03). ASCAT, GISTIC,
CGHcall and CGHcall* showed poor performance when calling
losses independent of the tumour purity level (mean ASCAT F-
score = 0.26, mean GISTIC F-score = 0.34, mean CGHcall F-score
= 0.39, mean CGHcall* F-score = 0.51). GenoCNA showed good
performance for correctly calling losses in samples with tumour
purities > 50% (mean F-score = 0.68). Thus, the performance
of CGHcall* and GenoCNA for calling losses increased with the
tumour purity.
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OncoSNP showed increasing performance for calling normal
states as the tumour purity level increased (Figure 1A, middle
panel). This may be caused by the log2 ratios being pushed
towards the 0 baseline in the presence of normal DNA. Moreover,
since the normal state represented the majority class, the
improved F-score for OncoSNP when calling normal states
suggested that the algorithm may not be able to tackle the
imbalance of the classes—represented by the copy number
states. ASCAT was unable to classify correctly normal states
independent of the tumour puritity. GISTIC, CGHcall and
GenoCNA showed poor performance when trying to classify
normal states (mean GISTIC F-score = 0.28, mean CGHcall F-
score = 0.29, mean GenoCNA F-score = 0.35). CGHcall* showed
overall good performance in correctly finding the normal state
when compared to the other three algorithms in samples with
tumour purity 100% (mean F-score = 0.70, Figure 1A, middle
panel).
Next, we compared how the algorithms performed when
trying to identify gains (Figure 1A, right panel). OncoSNP showed
good performance when the tumour purity was > 50%. This
suggests that OncoSNP is not able to correct the effect of tumour
contamination > 50% on the signals in gained genomic regions.
The performance of all algorithms for calling gains increased as
the tumour purity increased. ASCAT was the only algorithm able
to correctly call gains in samples with tumour purities > 30%
(mean F-score = 0.76). Overall, our adjusted version of CGHcall–
CGHcall* showed improved performance with regard to all copy
number states and all tumour purities when compared to CGH-
call. GISTIC and CGHcall showed comparable results. This can be
explained by the fact that both algorithms use CBS segmentation
results and do not make use of the BAF. Our analysis suggested
that OncoSNP and CGHcall* handled calling CNAs better than
the other algorithms in samples with high tumour purities. The
main message of this analysis is that tumour purity strongly
influences the results of the CNA calling algorithms.This is an
important information to be considered in designing a CNA
study, since samples with tumour purities markedly below 50%
should not be included in the analysis or at least, profiles result-
ing from such samples should be handled with care.
The effect of copy number region length
Next, we aimed to understand how the length of a copy number
region influenced the performance of the calling algorithms. For
this purpose, we examined the difference between the mean F-
scores of samples with region lengths of ≤ 105probes (short),
between 105 and 106 probes (medium) and region lengths > 106
(long) (Figure 1B). In order to eliminate the effect of reduced
tumour purity, we selected only samples with 100% tumour
purity. The region length was equal to the number of genetic
markers with the same copy number state within a chromoso-
mal segment. One chromosomal segment covered from 3 kilo
base pairs (kbp) to 1.8 million base pairs (Mbp).
We observed that OncoSNP, GenoCNA and CGHcall* showed
little sensitivity to the length of copy number regions. While
CGHcall* and OncoSNP performed well for all three states,
GenoCNA had difficulty in correctly identifying normal genomic
regions. ASCAT performed worse in samples that included short-
and medium-length CNA regions than in samples containing
long CNA regions. GISTIC was not able to correctly find lost
or amplified genomic regions independent of the length. We
observed the same behaviour for CGHcall. One reason that may
lay at the core of this problem is the fact that both CGHcall and
GISTIC use the CBS algorithm. In all, OncoSNP and CGHcall*
showed consistency and performed well for all three copy
number states across the investigated ranges of copy number
region lengths.
The effect of CNA burden
Since we observed that the percentage of aberrated regions in a
tumour sample—CNA burden—affected the normalisation of the
log2 ratios in the CGHcall pipeline, we investigated whether we
observe a similar effect when applying the other copy number
calling algorithms.
We therefore grouped the synthetic data into samples with
CNA burden > 50% and samples with CNA burden < 50% and
calculated the mean F-scores statewise (Figure 1C). We observed
that both CGHcall and GISTIC performed poorly for samples with
CNA burden > 50%. ASCAT also showed decreased performance
for the same scenario, but only for the normal state. The perfor-
mance of CGHcall* increased in samples with CNA burden > 50%
when compared to CGHcall, confirming that we corrected the
inaccuracy from CGHcall, especially for predicting normal and
gained genomic regions. OncoSNP and CGHcall* were again the
best performing algorithms included in this study.
Performance of the copy number calling algorithms on
SNP 6.0 array profiles of healthy patients (HapMap)
To assess how OncoSNP, ASCAT, CGHcall, CGHcall*, GenoCNA
and GISTIC perform on real data, we would need a gold stan-
dard. Due to the size of human genome – 3.0 × 109 bp, we
lack a complete Affymetrix SNP 6.0 array gold standard. Since
the HapMap project subsequently experimentally validated the
CNAs determined from Affymetrix SNP 6.0 data, we defined the
copy number profiles annotated by Redon et al. [4] as our ‘gold
standard’. OncoSNP, ASCAT, CGHcall, CGHcall* and genoCNA
returned predictions for over 14.500 regions that overlapped the
‘gold standard’. When analysing the F-scores of the algorithms
corresponding to 81 profiles with matched annotated copy num-
ber profiles (Figure 2), we first observed that OncoSNP, ASCAT,
CGHcall, CGHcall* and genoCNA performed well for the normal
class (mean F-score = 0.91). Unlike the other algorithms, GISTIC
returned predictions for only 381 regions overlapping the ‘gold
standard’ and performed poorly for all the classes (mean F-score
Figure 2. Distribution of F-scores for OncoSNP, ASCAT, CGHcall, CGHcall*,
GenoCNA and GISTIC in 81 healthy HapMap subjects.
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= 0.10). OncoSNP could not identify any germline alterations.
ASCAT showed a poor performance for identifying gains and
losses (mean F-score = 0.20). CGHcall showed a mean F-score
of 0.67 for identifying losses, but performed poorly for identify-
ing gains (mean F-score = 0.25). CGHcall* showed a significant
improvement only for the normal class compared to the other
algorithms. GenoCNA performed best for identifying losses and
gains, mean F-score = 0.50. ASCAT, just as OncoSNP and GISTIC,
was implemented to find somatic CNAs in cancer samples and
was not designed to find germline alterations in the first place.
We hypothesise that this might be the reason why OncoSNP,
ASCAT and GISTIC perform poorly on healthy patient data.
We are aware that tumour data tailored genomic copy num-
ber algorithms are designed to consider CNAs deriving from
tumour cell populations. However, HapMap data were gener-
ated from blood cells. The genomic copy number changes to be
expected from these samples are germline. Therefore, all cells
analysed should contain the same alterations. We assume that
it would be ‘easier’ for a tumour data tailored algorithm to pick
up copy number changes. The genomic copy number changes
present in the HapMap samples were comprehensively experi-
mentally validated. Thereby, HapMap provides added value since
the ‘gold standard’ with regard to genomic copy number is
known for these samples and allowed us to calculate the per-
formance of the CNA calling algorithms on real data. Based on
the resulting F-scores, genoCNA, CGHcall and CGHcall* were the
best performing algorithms.
CNAs in HNSCC
To test the plausability of CNA calling results in tumour samples,
we explored the concordance between raw LRR signals from
TCGA HNSCC samples and the CNA calls of the six algorithms.
Additionally, we compared the results with the HNSCC-specific
CNA regions defined in Gollin et. al [41]. We focused on two genes:
one known to be amplified in HNSCC–CCND1 and one that is
known to be lost in HNSCC–CDKN2A (Figures 3 and 4).
Figure 3. CCND1: Concordance between raw data and algorithm calls in TCGA HNSCC. The heatmap columns represent patients clustered by raw LRR signals. The
rows represent the Affymetrix SNP 6.0 probes that overlap the CCND1 region. For CGhcall*, CGHcall, GenoCNA, ASCAT and OncoSNP we also include the neighbouring
probe sets of the overlapping region. The lower bar represents the tumour purity of each sample.
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Figure 4. CDKN2A: Concordance between raw data and algorithm calls in TCGA HNSCC. The heatmap columns represent patients clustered by raw LRR signals in the
probes overlapping the CDKN2A genomic region. The rows represent the Affymetrix SNP 6.0 probes that overlap the CDKN2A region. For CGhcall, CGHcall, GenoCNA,
ASCAT and OncoSNP we also include the neighbouring probe sets of the overlapping region. The lower bar represents the tumour purity of each sample.
The data presented in Figures 3 and 4 show that genomic
regions with high LRR values overlapping the CCND1 and
CDKN2A genes are called as gained, while genomic regions
with low LRR values overlapping the CCND1 and CDKN2A genes
are called as lost. The frequencies of CCND1 gains called by
CGHcall, CGHcall*, OncoSNP and GISTIC are comparable to
the frequencies of CCND1 gains reported from CGH data in
Gollin et. al [41], 32%; CGHcall, 26.5%; CGHcall*, 24.9%; OncoSNP,
44%; and GISTIC, 43%. CGHcall, CGHcall*, OncoSNP and GISTIC
showed a good overlap in frequencies of CDKN2A losses:
CGHcall, 39.8%; CGHcall*, 35.4%; and GISTIC, 59%. The tumour
purity ranged from 27.9 to 97.7%. Most of the samples present
tumour purity > 60%. These results indicate that in a realistic
tumour purity range the algorithms that best performed on
synthetic data CGHcall* and OncoSNP showed plausible results
in the TCGA HNSCC data as well.
Concluding remarks
Within our study we addressed the problem of evaluating the
performance of commonly used copy number calling algorithms
in the presence of cancer-specific confounding variables. Since
we lacked a complete Affymetrix SNP 6.0 array gold standard,
we provided a pipeline to evaluate CNA calling algorithms on
Affymetrix SNP 6.0 array-like synthetic data. The analysis on
the synthetic data revealed that the performance of the CNA
calling algorithms is strongly influenced by tumour purity. CGH-
call, GISTIC and ASCAT showed high sensitivity to the length
of the genomic segments. The CNA burden strongly influenced
the performance of ASCAT, GISTIC and CGHcall. We proposed
CGHcall*, an adjusted version of CGHcall, in which we correct
for the effect of the CNA burden and we showed that indeed the
performance of CGHcall* in samples with a CNA burden higher
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than 50%. However, the scope of our paper was to benchmark
commonly used CNA calling algorithms, and not to develop a
new algorithm.
We further evaluated how the algorithms performed on a real
data set comprising of 81 healthy patients HapMap samples that
were subsequently experimentally validated. CGHcall and CGH-
call* were able to detect germline alterations, unlike OncoSNP
and ASCAT. Finally, we examined how comparable were the
results of the CNA calling algorithms with the annotated CNAs
in CCND1 and CDKN2A, when evaluated on the TCGA HNSCC
data set. The results indicated that CGHcall, CGHcall* and GISTIC
return comparable calls to what has been reported so far.
In conclusion, we provided a benchmarking pipeline for CNA
calling algorithms from Affymetrix SNP 6.0 array tumour profiles
together with CGHcall*—an adjusted version of CGHcall for find-
ing CNAs in highly variant genomes.
Key Points
• CNAs are tumour-specific DNA changes that play an
important role in cancer research.
• The accurate identification of CNAs is affected by bio-
logical confounding variables like tumour purity, the
length of a chromosomal segment and the percentage
of CNAs present in a genome.
• Within this benchmarking study we provide a pipeline
through which we evaluated the performance of six
CNA calling algorithms (OncoSNP, ASCAT, CGHcall,
CGHcall*, GenoCNA and GISTIC) in the presence of
biological confounding variables.
• We provide an adjusted version of CGHcall–CGHcall*
that accounts for a high CNA burden.
• We identify tumour purity and CNA burden to signifi-
cantly influence the performance of all the CNA calling
algorithms.
Supplementary Data
Supplementary data are available online at https://academic.
oup.com/bib.
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